<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17191267</PMID><DateCompleted><Year>2007</Year><Month>05</Month><Day>02</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-6222</ISSN><JournalIssue CitedMedium="Print"><Volume>22</Volume><Issue>1</Issue><PubDate><Year>2007</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Human psychopharmacology</Title><ISOAbbreviation>Hum Psychopharmacol</ISOAbbreviation></Journal><ArticleTitle>Possible predictors of response to clonazepam augmentation therapy in patients with protracted depression.</ArticleTitle><Pagination><MedlinePgn>27-31</MedlinePgn></Pagination><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Clonazepam has been shown to be an effective supplementary treatment for depression. Thus, it would be useful to determine which patient characteristics are associated with response to clonazepam.</AbstractText><AbstractText Label="AIMS" NlmCategory="OBJECTIVE">The purpose of this study was to examine the possible predictors of response to clonazepam in the treatment of depression.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">A retrospective cohort analysis was carried out in 120 patients with protracted depression who were being treated with clonazepam.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A variety of clinical factors, including age, gender, type of depression, frequency of episodes, family history; and daily dose of clonazepam, were analyzed as possible predictors of response to clonazepam. A Weibull regression analysis showed that the factors that best predicted improvement with clonazepam augmentation were negative family history of psychiatric illness (e(coef) = 0.378), daily clonazepam dose of 2.5-4.0 mg (e(coef) = 0.160), and unipolar depression (e(coef) = 0.147).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These factors should be considered when clonazepam augmentation therapy is selected for protracted depression.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Morishita</LastName><ForeName>Shigeru</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Depression Prevention Medical Center, Kyoto Jujo Rehabilitation Hospital, Kyoto, Japan. s.morishita31@r9.dion.ne.jp</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arita</LastName><ForeName>Seizaburo</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Hum Psychopharmacol</MedlineTA><NlmUniqueID>8702539</NlmUniqueID><ISSNLinking>0885-6222</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018757">GABA Modulators</NameOfSubstance></Chemical><Chemical><RegistryNumber>5PE9FDE8GB</RegistryNumber><NameOfSubstance UI="D002998">Clonazepam</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002908" MajorTopicYN="N">Chronic Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002998" MajorTopicYN="N">Clonazepam</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018757" MajorTopicYN="N">GABA Modulators</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007564" MajorTopicYN="N" Type="Geographic">Japan</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010555" MajorTopicYN="N">Personality Inventory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>12</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>5</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>12</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17191267</ArticleId><ArticleId IdType="doi">10.1002/hup.818</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23302184</PMID><DateCompleted><Year>2013</Year><Month>09</Month><Day>18</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1469-8978</ISSN><JournalIssue CitedMedium="Internet"><Volume>43</Volume><Issue>4</Issue><PubDate><Year>2013</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Psychological medicine</Title><ISOAbbreviation>Psychol Med</ISOAbbreviation></Journal><ArticleTitle>Letter to the Editor: Shopping frenzy induced by naltrexone--a paradoxical effect in bipolar disorder?</ArticleTitle><Pagination><MedlinePgn>895</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1017/S0033291712003005</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Losekam</LastName><ForeName>Stefanie</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Kluge</LastName><ForeName>Ina</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Nittel</LastName><ForeName>Karin Silvia</ForeName><Initials>KS</Initials></Author><Author ValidYN="Y"><LastName>Kircher</LastName><ForeName>Tilo</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Konrad</LastName><ForeName>Carsten</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>01</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Psychol Med</MedlineTA><NlmUniqueID>1254142</NlmUniqueID><ISSNLinking>0033-2917</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009292">Narcotic Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>5S6W795CQM</RegistryNumber><NameOfSubstance UI="D009271">Naltrexone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003192" MajorTopicYN="N">Compulsive Behavior</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009271" MajorTopicYN="N">Naltrexone</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009292" MajorTopicYN="N">Narcotic Antagonists</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>1</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>1</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>9</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23302184</ArticleId><ArticleId IdType="pii">S0033291712003005</ArticleId><ArticleId IdType="doi">10.1017/S0033291712003005</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18792087</PMID><DateCompleted><Year>2009</Year><Month>02</Month><Day>23</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1049-8931</ISSN><JournalIssue CitedMedium="Print"><Volume>17</Volume><Issue>4</Issue><PubDate><Year>2008</Year></PubDate></JournalIssue><Title>International journal of methods in psychiatric research</Title><ISOAbbreviation>Int J Methods Psychiatr Res</ISOAbbreviation></Journal><ArticleTitle>Development of the Bipolar Inventory of Symptoms Scale: concurrent validity, discriminant validity and retest reliability.</ArticleTitle><Pagination><MedlinePgn>198-209</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/mpr.262</ELocationID><Abstract><AbstractText>Scales used in studies of bipolar disorder have generally been standardized with major depressive or hospitalized manic patients. A clinician rated scale based on a semi-structured interview for persons with bipolar disorder, with comprehensive coverage of bipolar symptomatology, is needed. We report concurrent, divergent and convergent psychometric reliability, discriminant validity and relationship to a measure of overall function for a new psychometric rating instrument. A primarily outpatient sample of 224 subjects was assessed using the Bipolar Inventory of Symptoms Scale (BISS). The BISS total score and depression and mania subscales were compared to the Young Mania Rating Scale (YMRS), the Montgomery Asberg Depression Rating Scale (MADRS) and the Global Assessment of Functioning Scale (GAF). Clinical mood states were also compared using the BISS. The BISS scores demonstrated good concurrent validity, with estimates (Pearson correlations) ranging from 0.74 to 0.94 for YMRS and MADRS and test-retest reliability from 0.95 to 0.98. BISS concurrent validity with the GAF was significant for four clinical states, but not mixed states. The BISS discriminated primary bipolar mood states as well as subjects recovered for eight weeks compared to healthy controls. In conclusion, the BISS is a reliable and valid instrument broadly applicable in clinical research to assess the comprehensive domains of bipolar disorder. Future directions include factor analysis and sensitivity to change from treatment studies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gonzalez</LastName><ForeName>Jodi M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, UT Health Science Center, San Antonio, TX 78229, USA. gonzalezjm1@uthscsa.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bowden</LastName><ForeName>Charles L</ForeName><Initials>CL</Initials></Author><Author ValidYN="Y"><LastName>Katz</LastName><ForeName>Martin M</ForeName><Initials>MM</Initials></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Vivek</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Prihoda</LastName><ForeName>Thomas J</ForeName><Initials>TJ</Initials></Author><Author ValidYN="Y"><LastName>Dahl</LastName><ForeName>Martha</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D023361">Validation Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Int J Methods Psychiatr Res</MedlineTA><NlmUniqueID>9111433</NlmUniqueID><ISSNLinking>1049-8931</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004185" MajorTopicYN="N">Disability Evaluation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007406" MajorTopicYN="Y">Interview, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010552" MajorTopicYN="N">Personality Assessment</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012016" MajorTopicYN="N">Reference Values</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>9</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>2</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>9</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18792087</ArticleId><ArticleId IdType="doi">10.1002/mpr.262</ArticleId><ArticleId IdType="pmc">PMC6878587</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57</Citation><ArticleIdList><ArticleId IdType="pubmed">9881538</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2004 Jun 30;127(1-2):137-45</Citation><ArticleIdList><ArticleId IdType="pubmed">15261712</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2005 Oct;7(5):456-64</Citation><ArticleIdList><ArticleId IdType="pubmed">16176439</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1978 Nov;133:429-35</Citation><ArticleIdList><ArticleId IdType="pubmed">728692</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2004 Dec;161(12):2163-77</Citation><ArticleIdList><ArticleId IdType="pubmed">15569884</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2007 Sep;116(3):189-94</Citation><ArticleIdList><ArticleId IdType="pubmed">17655560</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2007 Aug;164(8):1242-9</Citation><ArticleIdList><ArticleId IdType="pubmed">17671288</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 1990 May;51 Suppl:31-4; discussion 50-3</Citation><ArticleIdList><ArticleId IdType="pubmed">1970815</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychobiology. 2006;54(3):152-9</Citation><ArticleIdList><ArticleId IdType="pubmed">17230032</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2006 Nov;67(11):1721-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17196051</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand Suppl. 2004;(422):39-45</Citation><ArticleIdList><ArticleId IdType="pubmed">15330937</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2000 Aug;177:149-55</Citation><ArticleIdList><ArticleId IdType="pubmed">11026955</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopathology. 2004 Sep-Oct;37(5):207-12</Citation><ArticleIdList><ArticleId IdType="pubmed">15353886</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2006 Dec;189:515-9</Citation><ArticleIdList><ArticleId IdType="pubmed">17139035</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2006 Apr;67(4):584-93</Citation><ArticleIdList><ArticleId IdType="pubmed">16669723</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychopharmacol. 2006 Dec;26(6):600-9</Citation><ArticleIdList><ArticleId IdType="pubmed">17110817</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Clin Psychopharmacol. 2004 May;19(3):157-60</Citation><ArticleIdList><ArticleId IdType="pubmed">15107658</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1998 Jan;55(1):27-32</Citation><ArticleIdList><ArticleId IdType="pubmed">9435757</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2005 Jun;62(6):617-27</Citation><ArticleIdList><ArticleId IdType="pubmed">15939839</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2004 Jan;34(1):73-82</Citation><ArticleIdList><ArticleId IdType="pubmed">14971628</ArticleId></ArticleIdList></Reference><Reference><Citation>Soc Psychiatry Psychiatr Epidemiol. 2006 Jun;41(6):457-63</Citation><ArticleIdList><ArticleId IdType="pubmed">16565917</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2007 Apr;115(4):326-30</Citation><ArticleIdList><ArticleId IdType="pubmed">17355524</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2006 Nov;96(1-2):95-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16820213</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2006 Feb;163(2):313-5</Citation><ArticleIdList><ArticleId IdType="pubmed">16449487</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2003 Jun 1;53(11):1028-42</Citation><ArticleIdList><ArticleId IdType="pubmed">12788248</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2007 Mar;37(3):341-9</Citation><ArticleIdList><ArticleId IdType="pubmed">17176505</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2004 May 1;55(9):875-81</Citation><ArticleIdList><ArticleId IdType="pubmed">15110730</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1978 Jul;35(7):837-44</Citation><ArticleIdList><ArticleId IdType="pubmed">678037</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Psychiatry. 2004 Apr;19(2):85-90</Citation><ArticleIdList><ArticleId IdType="pubmed">15051107</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17267795</PMID><DateCompleted><Year>2007</Year><Month>04</Month><Day>05</Day></DateCompleted><DateRevised><Year>2015</Year><Month>08</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-953X</ISSN><JournalIssue CitedMedium="Print"><Volume>164</Volume><Issue>2</Issue><PubDate><Year>2007</Year><Month>Feb</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Different psychophysiological and behavioral responses elicited by frustration in pediatric bipolar disorder and severe mood dysregulation.</ArticleTitle><Pagination><MedlinePgn>309-17</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Researchers disagree as to whether irritability is a diagnostic indicator for pediatric mania in bipolar disorder. The authors compared the behavioral and psychophysiological correlates of irritability among children with severe mood dysregulation (i.e., nonepisodic irritability and hyperarousal without episodes of euphoric mood) and narrow-phenotype bipolar disorder (i.e., a history of at least one manic or hypomanic episode with euphoric mood) as well as those with no diagnosis (i.e., healthy comparison children).</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Subjects with severe mood dysregulation (N=21) or narrow-phenotype bipolar disorder (N=35) and comparison subjects (N=26) completed the affective Posner task, an attentional task that manipulated emotional demands and induced frustration. Mood response, behavior (reaction time and accuracy), and brain activity (event-related potentials) were measured.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The severe mood dysregulation and narrow-phenotype bipolar disorder groups both reported significantly more arousal than comparison subjects during frustration, but behavioral and psychophysiological performance differed between the patient groups. In the frustration condition, children with narrow-phenotype bipolar disorder had lower P3 amplitude than children with severe mood dysregulation or comparison subjects, reflecting impairments in executive attention. Regardless of emotional context, children with severe mood dysregulation had lower N1 event-related potential amplitude than comparison subjects or children with narrow-phenotype bipolar disorder, reflecting impairments in the initial stages of attention. Post hoc analyses demonstrated that the N1 deficit in children with severe mood dysregulation is associated with oppositional defiant disorder symptom severity.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Results indicate that while irritability is an important feature of severe mood dysregulation and narrow-phenotype bipolar disorder, the pathophysiology of irritability may differ among the groups and is influenced by oppositional defiant disorder severity.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rich</LastName><ForeName>Brendan A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Pediatrics and Developmental Neuropsychiatry Branch, Section on Development and Affective Neuroscience, NIMH Mood and Anxiety Program, Bethesda, MD 20892, USA. brendanrich@mail.nih.gov</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmajuk</LastName><ForeName>Mariana</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Perez-Edgar</LastName><ForeName>Koraly E</ForeName><Initials>KE</Initials></Author><Author ValidYN="Y"><LastName>Fox</LastName><ForeName>Nathan A</ForeName><Initials>NA</Initials></Author><Author ValidYN="Y"><LastName>Pine</LastName><ForeName>Daniel S</ForeName><Initials>DS</Initials></Author><Author ValidYN="Y"><LastName>Leibenluft</LastName><ForeName>Ellen</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Am J Psychiatry. 2007 Feb;164(2):185-8</RefSource><PMID Version="1">17267774</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D001143" MajorTopicYN="N">Arousal</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001288" MajorTopicYN="N">Attention</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019958" MajorTopicYN="N">Attention Deficit and Disruptive Behavior Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002652" MajorTopicYN="N">Child Behavior</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004569" MajorTopicYN="N">Electroencephalography</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005071" MajorTopicYN="N">Evoked Potentials</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005625" MajorTopicYN="N">Frontal Lobe</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005639" MajorTopicYN="Y">Frustration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007508" MajorTopicYN="N">Irritable Mood</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013647" MajorTopicYN="N">Task Performance and Analysis</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>2</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>4</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>2</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17267795</ArticleId><ArticleId IdType="pii">164/2/309</ArticleId><ArticleId IdType="doi">10.1176/ajp.2007.164.2.309</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19363387</PMID><DateCompleted><Year>2009</Year><Month>05</Month><Day>11</Day></DateCompleted><DateRevised><Year>2009</Year><Month>04</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1539-736X</ISSN><JournalIssue CitedMedium="Internet"><Volume>197</Volume><Issue>4</Issue><PubDate><Year>2009</Year><Month>Apr</Month></PubDate></JournalIssue><Title>The Journal of nervous and mental disease</Title><ISOAbbreviation>J Nerv Ment Dis</ISOAbbreviation></Journal><ArticleTitle>Access to conventional mental health and medical care among users of complementary and alternative medicine with bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>287-90</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/NMD.0b013e31819dc16a</ELocationID><Abstract><AbstractText>This research examined the role of perceived barriers to treatment as a potential contributor to the increasing use of complementary and alternative medicine (CAM) among mentally ill populations. The study examined a sample of 435 patients receiving care through the Veterans Administration Health System and having a current diagnosis of bipolar disorder (I, II, NOS), cyclothymia, or schizoaffective disorder-bipolar subtype. Access to care and use of any of 14 CAM therapies within the past year were studied. Physical CAM users reported slightly better mental health service access related to getting to mental health services and obtaining emergency mental health services when needed. Effect sizes for these differences were small (r(pb) = 0.09 and 0.13, respectively). Similarly, oral and cognitive CAM users indicated that they were slightly more likely to go without medical services when needed because they were too expensive. These effect sizes were also very small (r(pb) = 0.12 and 0.10, respectively), suggesting no clinical significance. Patients who reported use of oral and/or cognitive CAM therapies were slightly more likely than nonusers to go without medical care because of excessive costs. Patients having non-Veterans Affairs insurance reported no differences in rates of CAM use. Overall, no discernable trends were observed to suggest that CAM use among this sample was associated with service access.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Perron</LastName><ForeName>Brian E</ForeName><Initials>BE</Initials><AffiliationInfo><Affiliation>School of Social Work, University of Michigan, Ann Arbor, Michigan, USA. beperron@umich.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jarman</LastName><ForeName>Christopher N</ForeName><Initials>CN</Initials></Author><Author ValidYN="Y"><LastName>Kilbourne</LastName><ForeName>Amy M</ForeName><Initials>AM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Nerv Ment Dis</MedlineTA><NlmUniqueID>0375402</NlmUniqueID><ISSNLinking>0022-3018</ISSNLinking></MedlineJournalInfo><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003156" MajorTopicYN="Y">Community Mental Health Services</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000529" MajorTopicYN="N">Complementary Therapies</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006297" MajorTopicYN="Y">Health Services Accessibility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010342" MajorTopicYN="N">Patient Acceptance of Health Care</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>4</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>4</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>5</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19363387</ArticleId><ArticleId IdType="doi">10.1097/NMD.0b013e31819dc16a</ArticleId><ArticleId IdType="pii">00005053-200904000-00012</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">6789913</PMID><DateCompleted><Year>1981</Year><Month>10</Month><Day>25</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0091-634X</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>1</Issue><PubDate><Year>1981</Year></PubDate></JournalIssue><Title>The Bulletin of the American Academy of Psychiatry and the Law</Title><ISOAbbreviation>Bull Am Acad Psychiatry Law</ISOAbbreviation></Journal><ArticleTitle>Mania, crime and the insanity defense: a case report.</ArticleTitle><Pagination><MedlinePgn>23-32</MedlinePgn></Pagination><Abstract><AbstractText>A case has been presented of a young manic depressive man whose first contact with a mental health professional was in connection with a criminal act performed during a manic episode. Information that is often not available or inadequate, especially a comprehensive family history, enabled the author to infer the presence of the illness at the time of the crime. An extended follow-up allowed the diagnosis to be confirmed, treatment to be instituted and reasonable certainty to be attained that the crimes occurred only as a manifestation of or in conjunction with the active phase of the illness. The obstacles to accurate diagnosis in such cases and their appropriate management are discussed in hopes of heightening the awareness of readers to the possibilities of such unsuspected cases in their midst.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ratner</LastName><ForeName>R A</ForeName><Initials>RA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Bull Am Acad Psychiatry Law</MedlineTA><NlmUniqueID>7503424</NlmUniqueID><ISSNLinking>0091-634X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>2BMD2GNA4V</RegistryNumber><NameOfSubstance UI="D016651">Lithium Carbonate</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000341" MajorTopicYN="N">Affective Disorders, Psychotic</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005555" MajorTopicYN="Y">Forensic Psychiatry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016651" MajorTopicYN="N">Lithium Carbonate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1981</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1981</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1981</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">6789913</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">29479787</PMID><DateCompleted><Year>2019</Year><Month>05</Month><Day>10</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1399-5618</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>7</Issue><PubDate><Year>2018</Year><Month>11</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Cardiometabolic risks and omega-3 index in recent-onset bipolar I disorder.</ArticleTitle><Pagination><MedlinePgn>658-665</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/bdi.12633</ELocationID><Abstract><AbstractText Label="OBJECTIVES">The aims of the present study were to characterize cardiometabolic risk factors in a cohort of bipolar disorder patients with limited exposure to psychotropic medications, and to evaluate their associations with mood symptoms and omega-3 polyunsaturated fatty acid (PUFA) blood levels.</AbstractText><AbstractText Label="METHODS">Cardiometabolic risk assessments were compared in individuals with bipolar I disorder experiencing a first manic or mixed episode or an early depressive episode (n=117) and healthy subjects (n=56). Patients were medication free at assessment and had no or limited exposure to mood-stabilizer or antipsychotic medications prior to the current admission. Associations among cardiometabolic parameters and Clinical Global Impression-Severity scale (CGI-S), manic (Young Mania Rating Scale [YMRS]), and depressive (Hamilton Depression Rating Scale [HDRS]) symptom ratings were evaluated within the bipolar group.</AbstractText><AbstractText Label="RESULTS">Following adjustment for demographic variables (i.e., age, gender, and parental education), significantly higher fasting triglyceride levels were observed in the bipolar group compared to the healthy group (121.7 mg/dL vs 87.0 mg/dL; P&lt;.01). There were no clear trends for other metabolic indicators, including blood pressure, body mass index, and fasting glucose. Nineteen percent of the bipolar group and 6% of the healthy group met the criteria for metabolic syndrome (P=.23). The omega-3 index was lower in the bipolar group (3.4% vs 3.9%; P&lt;.01). Within the bipolar group, no associations were found between the cardiometabolic parameters and CGI-S, YMRS, and HDRS symptom ratings.</AbstractText><AbstractText Label="CONCLUSIONS">Recent-onset medication-free bipolar disorder is associated with higher triglyceride levels. These findings are suggestive of early metabolic dysregulation prior to long-term psychotropic medication exposure. Lower omega-3 PUFA levels in individuals with bipolar I disorder represent a potential therapeutic target for additional investigation.</AbstractText><CopyrightInformation>© 2018 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wulsin</LastName><ForeName>Lawson R</ForeName><Initials>LR</Initials><Identifier Source="ORCID">0000-0002-2809-3507</Identifier><AffiliationInfo><Affiliation>Division of Bipolar Disorders Research, Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blom</LastName><ForeName>Thomas J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Division of Bipolar Disorders Research, Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Durling</LastName><ForeName>Michelle</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Bipolar Disorders Research, Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Welge</LastName><ForeName>Jeffrey A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Division of Bipolar Disorders Research, Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DelBello</LastName><ForeName>Melissa P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Division of Bipolar Disorders Research, Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adler</LastName><ForeName>Caleb M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Division of Bipolar Disorders Research, Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McNamara</LastName><ForeName>Robert K</ForeName><Initials>RK</Initials><Identifier Source="ORCID">0000-0002-9703-8114</Identifier><AffiliationInfo><Affiliation>Division of Bipolar Disorders Research, Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strakowski</LastName><ForeName>Stephen M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Division of Bipolar Disorders Research, Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 MH077138</GrantID><Acronym>RG</Acronym><Agency>CSR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>02</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015525">Fatty Acids, Omega-3</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011619">Psychotropic Drugs</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014280">Triglycerides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="Y">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015992" MajorTopicYN="N">Body Mass Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015525" MajorTopicYN="Y">Fatty Acids, Omega-3</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050356" MajorTopicYN="N">Lipid Metabolism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024821" MajorTopicYN="Y">Metabolic Syndrome</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011619" MajorTopicYN="N">Psychotropic Drugs</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061665" MajorTopicYN="N">Time-to-Treatment</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014280" MajorTopicYN="Y">Triglycerides</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">bipolar disorder</Keyword><Keyword MajorTopicYN="Y">glucose</Keyword><Keyword MajorTopicYN="Y">metabolic syndrome</Keyword><Keyword MajorTopicYN="Y">omega-3 fatty acids</Keyword><Keyword MajorTopicYN="Y">triglycerides</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>2</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>5</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>2</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29479787</ArticleId><ArticleId IdType="doi">10.1111/bdi.12633</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25383933</PMID><DateCompleted><Year>2015</Year><Month>07</Month><Day>06</Day></DateCompleted><DateRevised><Year>2014</Year><Month>11</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1439-3522</ISSN><JournalIssue CitedMedium="Internet"><Volume>82</Volume><Issue>11</Issue><PubDate><Year>2014</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Fortschritte der Neurologie-Psychiatrie</Title><ISOAbbreviation>Fortschr Neurol Psychiatr</ISOAbbreviation></Journal><ArticleTitle>[Diagnosis of affective disorders in DSM-5: changes and controversies].</ArticleTitle><Pagination><MedlinePgn>655-63; quiz 664</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1055/s-0034-1385377</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Klein</LastName><ForeName>J P</ForeName><Initials>JP</Initials></Author><Author ValidYN="Y"><LastName>Willenborg</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Schweiger</LastName><ForeName>U</ForeName><Initials>U</Initials></Author></AuthorList><Language>ger</Language><PublicationTypeList><PublicationType UI="D016456">Historical Article</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Diagnostik affektiver Störungen im DSM-5: Neuerungen und Kontroversen.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2014</Year><Month>11</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Fortschr Neurol Psychiatr</MedlineTA><NlmUniqueID>8103137</NlmUniqueID><ISSNLinking>0720-4299</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="Y">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049673" MajorTopicYN="N">History, 20th Century</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019964" MajorTopicYN="N">Mood Disorders</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011293" MajorTopicYN="N">Premenstrual Syndrome</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011570" MajorTopicYN="N">Psychiatry</DescriptorName><QualifierName UI="Q000266" MajorTopicYN="N">history</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>11</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>11</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>7</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25383933</ArticleId><ArticleId IdType="doi">10.1055/s-0034-1385377</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">6774623</PMID><DateCompleted><Year>1980</Year><Month>11</Month><Day>20</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-953X</ISSN><JournalIssue CitedMedium="Print"><Volume>137</Volume><Issue>8</Issue><PubDate><Year>1980</Year><Month>Aug</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Differentiating mania from schizophrenia by the TRH test.</ArticleTitle><Pagination><MedlinePgn>981-2</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Extein</LastName><ForeName>I</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Pottash</LastName><ForeName>A L</ForeName><Initials>AL</Initials></Author><Author ValidYN="Y"><LastName>Gold</LastName><ForeName>M S</ForeName><Initials>MS</Initials></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>D M</ForeName><Initials>DM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>5Y5F15120W</RegistryNumber><NameOfSubstance UI="D013973">Thyrotropin-Releasing Hormone</NameOfSubstance></Chemical><Chemical><RegistryNumber>9002-71-5</RegistryNumber><NameOfSubstance UI="D013972">Thyrotropin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013972" MajorTopicYN="N">Thyrotropin</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013973" MajorTopicYN="Y">Thyrotropin-Releasing Hormone</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1980</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1980</Year><Month>8</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1980</Year><Month>8</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">6774623</ArticleId><ArticleId IdType="doi">10.1176/ajp.137.8.981</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22302901</PMID><DateCompleted><Year>2012</Year><Month>06</Month><Day>12</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1745-1701</ISSN><JournalIssue CitedMedium="Internet"><Volume>38</Volume><Issue>2</Issue><PubDate><Year>2012</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Schizophrenia bulletin</Title><ISOAbbreviation>Schizophr Bull</ISOAbbreviation></Journal><ArticleTitle>Boundaries of the psychosis phenotype.</ArticleTitle><Pagination><MedlinePgn>205-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/schbul/sbs003</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Thaker</LastName><ForeName>Gunvant K</ForeName><Initials>GK</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>02</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Schizophr Bull</MedlineTA><NlmUniqueID>0236760</NlmUniqueID><ISSNLinking>0586-7614</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="Y">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011605" MajorTopicYN="N">Psychoses, Substance-Induced</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>2</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>2</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>6</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22302901</ArticleId><ArticleId IdType="pii">sbs003</ArticleId><ArticleId IdType="doi">10.1093/schbul/sbs003</ArticleId><ArticleId IdType="pmc">PMC3283147</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Acta Psychiatr Scand. 2012 Jan;125(1):54-65</Citation><ArticleIdList><ArticleId IdType="pubmed">22111670</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2012 Mar;38(2):227-30</Citation><ArticleIdList><ArticleId IdType="pubmed">22355185</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2008 Jul;34(4):774-90</Citation><ArticleIdList><ArticleId IdType="pubmed">18408230</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2008 Jul;34(4):743-59</Citation><ArticleIdList><ArticleId IdType="pubmed">18448479</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2008 Jul;34(4):760-73</Citation><ArticleIdList><ArticleId IdType="pubmed">18502737</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2000 Sep 15;48(6):531-8</Citation><ArticleIdList><ArticleId IdType="pubmed">11018225</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31962188</PMID><DateCompleted><Year>2021</Year><Month>03</Month><Day>31</Day></DateCompleted><DateRevised><Year>2021</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-4216</ISSN><JournalIssue CitedMedium="Internet"><Volume>99</Volume><PubDate><Year>2020</Year><Month>04</Month><Day>20</Day></PubDate></JournalIssue><Title>Progress in neuro-psychopharmacology &amp; biological psychiatry</Title><ISOAbbreviation>Prog Neuropsychopharmacol Biol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>The anhedonia is differently modulated by structural covariance network of NAc in bipolar disorder and major depressive disorder.</ArticleTitle><Pagination><MedlinePgn>109865</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0278-5846(19)30744-4</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.pnpbp.2020.109865</ELocationID><Abstract><AbstractText>During depressive episode, bipolar disorder (BD) patients share indistinguishable depression symptoms with major depressive disorder (MDD).However, whether neural correlates underlying the anhedonia, a core feature of depression, is different between BD and MDD remains unknown. To explore neural correlates underlying the anhedonia in BD and MDD, structural T1-weighted images from 36 depressed BD patients, 40 depressed MDD patients matched for depression severity and 34 health controls (HCs) were scanned. Considering the vital role of nucleus accumbens (NAc) in the anhedonia, we constructed the structural covariance network of NAc for each subject. Then, we explored altered structural covariance network of NAc and its interaction with the anhedonia severity in BD and MDD patients. As a result, BD and MDD patients shared decreased structural covariance of NAc connected to prefrontal gyrus, bilateral striatum extending to bilateral anterior insula. Apart from these regions, BD patients presented specifically increased structural covariance of NAc connected to left hippocampus extending to thalamus. The interaction between structural covariance network of NAc and the anhedonia severity in MDD was mainly associated anterior insula (AIC), amygdala, anterior cingulate cortex (ACC)and caudate while that in BD was mainly located in striatum and prefrontal cortex. Our results found that BD and MDD patients presented commonly and distinctly altered structural covariance network of NAc. What is more, the neural correlates underlying the anhedonia in BD and MDD might be different.</AbstractText><CopyrightInformation>Copyright © 2020. Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Shaoqiang</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>The Clinical Hospital of Chengdu Brain Science Institute, School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu 610054, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cui</LastName><ForeName>Qian</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>MOE Key Lab for Neuroinformation, High-Field Magnetic Resonance Brain Imaging Key Laboratory of Sichuan Province, University of Electronic Science and Technology of China, Chengdu 610054, PR China; School of Public Affairs and Administration, University of Electronic Science and Technology of China, Chengdu, PR China. Electronic address: qiancui26@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xiao</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>The Clinical Hospital of Chengdu Brain Science Institute, School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu 610054, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yuyan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>The Clinical Hospital of Chengdu Brain Science Institute, School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu 610054, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Di</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>The Clinical Hospital of Chengdu Brain Science Institute, School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu 610054, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Liang</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>The Clinical Hospital of Chengdu Brain Science Institute, School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu 610054, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Xiaonan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>The Clinical Hospital of Chengdu Brain Science Institute, School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu 610054, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fan</LastName><ForeName>Yun-Shuang</ForeName><Initials>YS</Initials><AffiliationInfo><Affiliation>The Clinical Hospital of Chengdu Brain Science Institute, School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu 610054, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>The Clinical Hospital of Chengdu Brain Science Institute, School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu 610054, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sheng</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>The Clinical Hospital of Chengdu Brain Science Institute, School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu 610054, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Fengmei</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>The Clinical Hospital of Chengdu Brain Science Institute, School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu 610054, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Zongling</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>The Clinical Hospital of Chengdu Brain Science Institute, School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu 610054, PR China. Electronic address: hzl_811015@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Huafu</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>The Clinical Hospital of Chengdu Brain Science Institute, School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu 610054, PR China; MOE Key Lab for Neuroinformation, High-Field Magnetic Resonance Brain Imaging Key Laboratory of Sichuan Province, University of Electronic Science and Technology of China, Chengdu 610054, PR China. Electronic address: chenhf@uestc.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>01</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Prog Neuropsychopharmacol Biol Psychiatry</MedlineTA><NlmUniqueID>8211617</NlmUniqueID><ISSNLinking>0278-5846</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059445" MajorTopicYN="N">Anhedonia</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009415" MajorTopicYN="N">Nerve Net</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009714" MajorTopicYN="N">Nucleus Accumbens</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Anhedonia</Keyword><Keyword MajorTopicYN="Y">Bipolar disorder</Keyword><Keyword MajorTopicYN="Y">Major depressive disorder</Keyword><Keyword MajorTopicYN="Y">Structural covariance network</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>09</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>01</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>01</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>1</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>1</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31962188</ArticleId><ArticleId IdType="pii">S0278-5846(19)30744-4</ArticleId><ArticleId IdType="doi">10.1016/j.pnpbp.2020.109865</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">28558365</PMID><DateCompleted><Year>2018</Year><Month>02</Month><Day>14</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>219</Volume><PubDate><Year>2017</Year><Month>09</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Reward anticipation revisited- evidence from an fMRI study in euthymic bipolar I patients and healthy first-degree relatives.</ArticleTitle><Pagination><MedlinePgn>178-186</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0165-0327(16)31671-8</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2017.04.044</ELocationID><Abstract><AbstractText Label="BACKGROUND">Symptomatic phases in bipolar disorder (BD) are hypothesized to result from a hypersensitive behavioral activation system (BAS) being sensitive to potential rewards. However, studies on the neuronal underpinnings of reward anticipation in BD are scarce with contradictory findings and possibly confounded by effects of dopaminergic medication, necessitating further research on dysfunctional motivation in BD. Moreover, its role as vulnerability marker for BD is unclear.</AbstractText><AbstractText Label="METHODS">Functional imaging was conducted in 16 euthymic BD-I patients free from dopaminergic medication and 19 healthy first-degree relatives using a monetary incentive delay task and compared to parallelized control groups. Further, reward proneness, using the BIS/BAS questionnaire, and its relationship to neural reward anticipation was investigated.</AbstractText><AbstractText Label="RESULTS">BD-I patients displayed greater anterior cingulate cortex (ACC) activity during reward anticipation and higher BIS total scores compared to controls, with a positive relationship between the two measures. There were no neural or self-report group differences between relatives and controls.</AbstractText><AbstractText Label="LIMITATIONS">Due to the experimental design, the role of the ACC during receipt of reward remains unknown, sample sizes were rather small, and patients were not naïve to dopaminergic drugs, making an exclusion of medication effects on findings impossible.</AbstractText><AbstractText Label="CONCLUSIONS">Our findings give new insights on reward anticipation in BD. BD-I patients rated themselves as more risk avoidant and showed larger recruitment of the ACC rather than ventral striatum compared to controls during reward anticipation, possibly to down-regulate hyperactive limbic reward regions. This activation seems to be a consequence of rather than a vulnerability marker for the disorder.</AbstractText><CopyrightInformation>Copyright © 2017 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kollmann</LastName><ForeName>Bianca</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Clinical Psychology and Neuropsychology, Institute for Psychology, Johannes Gutenberg-University of Mainz, Mainz, Germany; Emotion Regulation and Impulse Control Group, Department of Psychiatry and Psychotherapy, Johannes Gutenberg University Mainz, Mainz, Germany; Section for Experimental Psychopathology and Neuroimaging, Department of General Psychiatry, Center for Psychosocial Medicine, University of Heidelberg, Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scholz</LastName><ForeName>Vanessa</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Clinical Psychology and Neuropsychology, Institute for Psychology, Johannes Gutenberg-University of Mainz, Mainz, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Linke</LastName><ForeName>Julia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Clinical Psychology and Neuropsychology, Institute for Psychology, Johannes Gutenberg-University of Mainz, Mainz, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kirsch</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Clinical Psychology, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wessa</LastName><ForeName>Michèle</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Clinical Psychology and Neuropsychology, Institute for Psychology, Johannes Gutenberg-University of Mainz, Mainz, Germany. Electronic address: wessa@uni-mainz.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>05</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005190" MajorTopicYN="N">Family</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006179" MajorTopicYN="N">Gyrus Cinguli</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009042" MajorTopicYN="N">Motivation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012201" MajorTopicYN="Y">Reward</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">BIS/BAS</Keyword><Keyword MajorTopicYN="Y">bipolar</Keyword><Keyword MajorTopicYN="Y">fMRI</Keyword><Keyword MajorTopicYN="Y">first‐degree relatives</Keyword><Keyword MajorTopicYN="Y">reward anticipation</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>09</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>03</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>04</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>5</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>2</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>5</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28558365</ArticleId><ArticleId IdType="pii">S0165-0327(16)31671-8</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2017.04.044</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">6849621</PMID><DateCompleted><Year>1983</Year><Month>02</Month><Day>14</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0003-990X</ISSN><JournalIssue CitedMedium="Print"><Volume>40</Volume><Issue>1</Issue><PubDate><Year>1983</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Archives of general psychiatry</Title><ISOAbbreviation>Arch Gen Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Do the mentally retarded suffer from affective illness?</ArticleTitle><Pagination><MedlinePgn>61-7</MedlinePgn></Pagination><Abstract><AbstractText>Twenty-five published reports were reviewed regarding the occurrence of affective illness, ie, depression and mania, in mentally retarded individuals, using the DSM-III criteria to assess the validity of both diagnoses. Individuals with mental retardation (MR) were found to manifest the full range of affective disorders. Developmentally impaired social functioning and intelligence influence the clinical presentation, but not the development, of affective symptomatology. Affective disorder diagnoses can be made for patients with all levels of MR severity. In individuals with MR of mild and moderate severity, the diagnosis can be made using standard DSM-III criteria. For those with severe and profound MR, a clinically useful diagnosis can be based on changes in behavior and vegetative functioning, as well as family history of affective illness. The psychiatrically symptomatic person with MR should always be evaluated for affective symptomatology and be considered as a candidate for the full range of treatments, including psychotherapy and pharmacotherapy with antidepressants as well as lithium carbonate.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sovner</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Hurley</LastName><ForeName>A D</ForeName><Initials>AD</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Gen Psychiatry</MedlineTA><NlmUniqueID>0372435</NlmUniqueID><ISSNLinking>0003-990X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000341" MajorTopicYN="N">Affective Disorders, Psychotic</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008607" MajorTopicYN="N">Intellectual Disability</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008370" MajorTopicYN="N">Manuals as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008499" MajorTopicYN="N">Medical Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011613" MajorTopicYN="N">Psychotherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1983</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1983</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1983</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">6849621</ArticleId><ArticleId IdType="doi">10.1001/archpsyc.1983.01790010063008</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8312982</PMID><DateCompleted><Year>1994</Year><Month>03</Month><Day>23</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1040-1237</ISSN><JournalIssue CitedMedium="Print"><Volume>5</Volume><Issue>4</Issue><PubDate><Year>1993</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists</Title><ISOAbbreviation>Ann Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Women and mood disorders. Menarche to menopause.</ArticleTitle><Pagination><MedlinePgn>249-54</MedlinePgn></Pagination><Abstract><AbstractText>Considering the multiple issues affecting women and their experiences with mood disorders, several clinical observations may be pertinent: Because women are very vulnerable to depression, physicians in all patient care related specialties need to be familiar with the diagnosis of depression and related mood syndromes. Early intervention may be far more critical than previously considered in preventing chronic, tragic outcomes for major depression, bipolar disorder, and even severe premenstrual depression. Both dysphoric mania (because of its poor prognosis) and rapid cycling bipolar disorder (because the majority of cases involve women) distinguish bipolar illness in women. In these situations, anticonvulsants such as carbamazepine or valproic acid may offer treatment advantages over lithium. Premenstrual depression is very strongly linked to traditional psychiatric mood syndromes and is likely to benefit from appropriate antidepressant therapy. The serotonin-specific reuptake inhibitors are especially attractive in this situation because of their low side effect profiles (including low weight gain percentages) and safety in overdoses. Previous experience with psychiatric illness, especially bipolar disorder, is often predictive of postpartum mood episodes. Aggressive early treatment is critical to prevent or successfully manage postpartum episodes. Menopause cannot yet be linked to a specific or unique mood syndrome.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pariser</LastName><ForeName>S F</ForeName><Initials>SF</Initials><AffiliationInfo><Affiliation>Department of Clinical Psychiatry, Ohio State University College of Medicine, Columbus 43210.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Clin Psychiatry</MedlineTA><NlmUniqueID>8911021</NlmUniqueID><ISSNLinking>1040-1237</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008572" MajorTopicYN="N">Menarche</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008593" MajorTopicYN="N">Menopause</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011293" MajorTopicYN="N">Premenstrual Syndrome</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011644" MajorTopicYN="N">Puerperal Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>36</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1993</Year><Month>12</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1993</Year><Month>12</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1993</Year><Month>12</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8312982</ArticleId><ArticleId IdType="doi">10.3109/10401239309148824</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18640785</PMID><DateCompleted><Year>2008</Year><Month>12</Month><Day>09</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0306-4530</ISSN><JournalIssue CitedMedium="Print"><Volume>33</Volume><Issue>8</Issue><PubDate><Year>2008</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Psychoneuroendocrinology</Title><ISOAbbreviation>Psychoneuroendocrinology</ISOAbbreviation></Journal><ArticleTitle>Sex differences in the cortisol response to awakening in recent onset psychosis.</ArticleTitle><Pagination><MedlinePgn>1151-4</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.psyneuen.2008.04.006</ELocationID><Abstract><AbstractText>A dysregulation of the hypothalamus-pituitary-adrenal (HPA) axis has been suggested as a factor in the etiology and exacerbation of psychosis, but has not been reported consistently. Sex differences are apparent in many aspects of psychotic disorders and may explain some of the equivocation associated with the regulation of the HPA axis in the illness. The present study compared the cortisol response to awakening (CRA) in 27 patients (16 men and 11 women) with recent onset of psychosis (within the past 2 years) and 40 age and gender matched controls. Within the patient group, we also assessed the relationship between the CRA and positive and negative symptoms of psychosis, anxiety and depression. The CRA in patients was not significantly different from controls. However, within the patient group, we observed a significant sex difference, with a blunted cortisol response to awakening in men but not in women (F=7.26; p&lt;0.002). This difference could not be explained by differences between male and female patients in awakening time, medication, or diagnosis of schizophrenia vs. affective psychosis. Cortisol levels were not related to symptom measures. Our findings demonstrate a dysregulation of the HPA axis in male patients with recent onset of psychosis. This sex specificity might be related to and explain in part the unfavorable course of the illness observed in men.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pruessner</LastName><ForeName>Marita</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Prevention and Early Intervention Program for Psychosis, Douglas Mental Health University Institute, McGill University, Montréal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boekestyn</LastName><ForeName>Ludmila</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Béchard-Evans</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Abadi</LastName><ForeName>Sherezad</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Vracotas</LastName><ForeName>Nadia</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Joober</LastName><ForeName>Ridha</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Pruessner</LastName><ForeName>Jens C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Malla</LastName><ForeName>Ashok K</ForeName><Initials>AK</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>07</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Psychoneuroendocrinology</MedlineTA><NlmUniqueID>7612148</NlmUniqueID><ISSNLinking>0306-4530</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>WI4X0X7BPJ</RegistryNumber><NameOfSubstance UI="D006854">Hydrocortisone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019540" MajorTopicYN="N">Area Under Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001143" MajorTopicYN="N">Arousal</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006854" MajorTopicYN="N">Hydrocortisone</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012727" MajorTopicYN="Y">Sex Characteristics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>09</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2008</Year><Month>04</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>04</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>7</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>12</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>7</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18640785</ArticleId><ArticleId IdType="pii">S0306-4530(08)00103-0</ArticleId><ArticleId IdType="doi">10.1016/j.psyneuen.2008.04.006</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11989998</PMID><DateCompleted><Year>2002</Year><Month>10</Month><Day>29</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>26</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0033-2917</ISSN><JournalIssue CitedMedium="Print"><Volume>32</Volume><Issue>3</Issue><PubDate><Year>2002</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Psychological medicine</Title><ISOAbbreviation>Psychol Med</ISOAbbreviation></Journal><ArticleTitle>Do schizophrenic patients who managed to get to university have a non-developmental form of illness?</ArticleTitle><Pagination><MedlinePgn>535-44</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Many people who develop schizophrenia have impairments in intellectual and social functioning that are detectable from early childhood. However, some patients do not exhibit such deficits, and this suggests that they may have suffered less neurodevelopmental damage. We hypothesized that the aetiology and form of schizophrenia may differ in such patients. We therefore studied a group of schizophrenic patients who were functioning well enough to enter university prior to illness onset.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The casenotes of 46 university-educated patients and 48 non-university-educated patients were rated on several schedules including the OPCRIT checklist, and the two groups were compared using univariate statistical techniques. Principal components analysis was then performed using data from all patients, and the factor scores for each principal component were compared between groups.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Univariate analyses showed the university-educated patients had an excess of depressive symptoms, and a paucity of core schizophrenic symptoms. Four principal components emerged in the principal components analysis: mania, biological depression, schizophrenic symptoms, and a reactive depression. University-educated patients scored significantly higher on the reactive depression principal component, and lower on the schizophrenic symptoms principal component, than the non-university-educated patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>MacCabe</LastName><ForeName>J H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Division of Psychological Medicine, Institute of Psychiatry, London.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aldouri</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Fahy</LastName><ForeName>T A</ForeName><Initials>TA</Initials></Author><Author ValidYN="Y"><LastName>Sham</LastName><ForeName>P C</ForeName><Initials>PC</Initials></Author><Author ValidYN="Y"><LastName>Murray</LastName><ForeName>R M</ForeName><Initials>RM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Psychol Med</MedlineTA><NlmUniqueID>1254142</NlmUniqueID><ISSNLinking>0033-2917</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000275" MajorTopicYN="N">Adjustment Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001925" MajorTopicYN="N">Brain Damage, Chronic</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004522" MajorTopicYN="Y">Educational Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="Y">Schizophrenic Psychology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014495" MajorTopicYN="N">Universities</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>5</Month><Day>7</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>10</Month><Day>31</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>5</Month><Day>7</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11989998</ArticleId><ArticleId IdType="doi">10.1017/s0033291702005391</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8968305</PMID><DateCompleted><Year>1997</Year><Month>01</Month><Day>13</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0160-6689</ISSN><JournalIssue CitedMedium="Print"><Volume>57</Volume><Issue>11</Issue><PubDate><Year>1996</Year><Month>Nov</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Superiority of lithium over verapamil in mania: a randomized, controlled, single-blind trial.</ArticleTitle><Pagination><MedlinePgn>543-6</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Both case reports and small controlled studies suggest the efficacy of verapamil in the treatment of mania.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Forty patients with DSM-IV mania were studied in a 28-day randomized, controlled, single-blind trial of either lithium or verapamil.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The patients receiving lithium showed a significant improvement on all rating scales (Brief Psychiatric Rating Scale [BPRS], Mania Rating Scale [MRS], Global Assessment of Functioning [GAF], and Clinical Global Impression [CGI]) compared with those receiving verapamil. The mean MRS score at Day 28 in the lithium group was significantly lower than that in the verapamil group (17.47 vs. 24.43, respectively; F = 6.17, df = 1, p = .018). A similar pattern was seen with the BPRS (12.68 vs. 20.57; F = 10.69, df = 1, p = .002), CGI (2.31 vs. 3.33; F = 6.05, df = 1, p = .019), and GAF (43.52 vs. 52.31; F = 4.36, df = 1, p = .044) (ANCOVA).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This study suggests that lithium is superior to verapamil in the management of acute mania.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Walton</LastName><ForeName>S A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of the Witwatersrand Medical School, Johannesburg, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berk</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Brook</LastName><ForeName>S</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010919">Placebos</NameOfSubstance></Chemical><Chemical><RegistryNumber>2BMD2GNA4V</RegistryNumber><NameOfSubstance UI="D016651">Lithium Carbonate</NameOfSubstance></Chemical><Chemical><RegistryNumber>CJ0O37KU29</RegistryNumber><NameOfSubstance UI="D014700">Verapamil</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006778" MajorTopicYN="N">Hospitals, Psychiatric</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016651" MajorTopicYN="N">Lithium Carbonate</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010919" MajorTopicYN="N">Placebos</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016037" MajorTopicYN="N">Single-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014700" MajorTopicYN="N">Verapamil</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1996</Year><Month>11</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1996</Year><Month>11</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1996</Year><Month>11</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8968305</ArticleId><ArticleId IdType="doi">10.4088/jcp.v57n1108</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">9532711</PMID><DateCompleted><Year>1998</Year><Month>05</Month><Day>08</Day></DateCompleted><DateRevised><Year>2016</Year><Month>10</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1997-7298</ISSN><JournalIssue CitedMedium="Print"><Volume>98</Volume><Issue>2</Issue><PubDate><Year>1998</Year></PubDate></JournalIssue><Title>Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova</Title><ISOAbbreviation>Zh Nevrol Psikhiatr Im S S Korsakova</ISOAbbreviation></Journal><ArticleTitle>[Syndrome of juvenile asthenic deficiency].</ArticleTitle><Pagination><MedlinePgn>13-9</MedlinePgn></Pagination><Abstract><AbstractText>A clinical and follow-up study of 155 young adults with a symptomcomplex of "juvenile asthenic deficiency"--"endogener juveniler asthenischer Versagensyndrome" (J.Glatzel, G.Huber, 1968) was carried out. It was found that protracted states in the youth with prevalence of educational disadaptation, weakening of initiative, psychophysical fatiguability should be attributed to atypical depressions, characterized by predominance of ideatoric disturbances with obliterated thymic and motor components. Depending on the specificities of ideatoric disturbances, 3 basic typological varieties of such depressions were recognized, i.e. depressions with prevalence of inhibition, disautomatization or distortion of cognitive processes, which statistically correlated reliably with definite nosological forms (affective disorders, schizophrenia). Depending on the nosologic belonging the studied states differed also in frequency of comorbid disturbances (obsessive-phobic, depersonalization, overvalued ideas), which occurred significantly rarer in the cases of affective disorders, than in schizophrenia. On the whole, follow-up study revealed relatively favourable prognosis of youth endogenous depressions with a clinical picture of "juvenile asthenic deficiency": in cases of affective disorders the course of disease was more frequently in the form of a single cyclothymic attack, while in cases of schizophrenia it took the form of protracted atypical pubertal attack.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Oleĭchik</LastName><ForeName>I V</ForeName><Initials>IV</Initials></Author></AuthorList><Language>rus</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Sindrom iunosheskoĭ astenicheskoĭ nesostoiatel'nosti.</VernacularTitle></Article><MedlineJournalInfo><Country>Russia (Federation)</Country><MedlineTA>Zh Nevrol Psikhiatr Im S S Korsakova</MedlineTA><NlmUniqueID>9712194</NlmUniqueID><ISSNLinking>1997-7298</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000223" MajorTopicYN="N">Adaptation, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000534" MajorTopicYN="N">rehabilitation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000534" MajorTopicYN="N">rehabilitation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009440" MajorTopicYN="N">Neurasthenia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000534" MajorTopicYN="N">rehabilitation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011627" MajorTopicYN="N">Puberty</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000534" MajorTopicYN="N">rehabilitation</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1998</Year><Month>4</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1998</Year><Month>4</Month><Day>9</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1998</Year><Month>4</Month><Day>9</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">9532711</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">23820096</PMID><DateCompleted><Year>2014</Year><Month>06</Month><Day>04</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>151</Volume><Issue>1</Issue><PubDate><Year>2013</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>No evidence for association between bipolar disorder risk gene variants and brain structural phenotypes.</ArticleTitle><Pagination><MedlinePgn>291-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2013.06.008</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0165-0327(13)00485-0</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">While recent genome-wide association studies have identified several new bipolar disorder (BD) risk variants, structural imaging studies have reported enlarged ventricles and volumetric reductions among the most consistent findings. We investigated whether these genetic risk variants could explain some of the structural brain abnormalities in BD.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In a sample of 517 individuals (N=121 BD cases, 116 SZ cases, 61 other psychosis cases and 219 healthy controls), we tested the potential association between nine SNPs in the genes CACNA1C, ANK3, ODZ4 and SYNE1 and eight brain structural measures found to be altered in BD, and if these were specifically affecting the BD sample. We also assessed the polygenic effect of all these 9 SNPs on the brain phenotypes.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Our most significant result was an association between the risk allele A in CACNA1C SNP rs4775913 and decreased cerebellar volume (pnom.=0.0075) in the total sample, which did not remain significant after multiple testing correction (pthreshold&lt;0.0064). There was no evidence for diagnostic specificity for this association in the BD group. Further, no polygenic effect of these 9 SNPs was observed.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">Low statistical power might increase our type II error rate.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The present findings indicate that these risk SNPs do not explain a large proportion of the structural brain alterations in BD. Thus, these genes which are all related to neuronal functions must be involved in other pathophysiological aspects of BD development.</AbstractText><CopyrightInformation>© 2013 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tesli</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Clinical Medicine, University of Oslo, Oslo, Norway. m.s.tesli@medisin.uio.no</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Egeland</LastName><ForeName>Randi</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Sønderby</LastName><ForeName>Ida E</ForeName><Initials>IE</Initials></Author><Author ValidYN="Y"><LastName>Haukvik</LastName><ForeName>Unn K</ForeName><Initials>UK</Initials></Author><Author ValidYN="Y"><LastName>Bettella</LastName><ForeName>Francesco</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Hibar</LastName><ForeName>Derrek P</ForeName><Initials>DP</Initials></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Paul M</ForeName><Initials>PM</Initials></Author><Author ValidYN="Y"><LastName>Rimol</LastName><ForeName>Lars Morten</ForeName><Initials>LM</Initials></Author><Author ValidYN="Y"><LastName>Melle</LastName><ForeName>Ingrid</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Agartz</LastName><ForeName>Ingrid</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Djurovic</LastName><ForeName>Srdjan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Andreassen</LastName><ForeName>Ole A</ForeName><Initials>OA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>06</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000033" MajorTopicYN="N">anatomy &amp; histology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056726" MajorTopicYN="N">Genetic Association Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059906" MajorTopicYN="N">Neuroimaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019655" MajorTopicYN="Y">Quantitative Trait, Heritable</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ANK3</Keyword><Keyword MajorTopicYN="N">Bipolar disorder</Keyword><Keyword MajorTopicYN="N">CACNA1C</Keyword><Keyword MajorTopicYN="N">Genetics</Keyword><Keyword MajorTopicYN="N">MRI</Keyword><Keyword MajorTopicYN="N">Schizophrenia</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>02</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2013</Year><Month>06</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>06</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>7</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>7</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23820096</ArticleId><ArticleId IdType="pii">S0165-0327(13)00485-0</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2013.06.008</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23714262</PMID><DateCompleted><Year>2013</Year><Month>09</Month><Day>26</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-244X</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><PubDate><Year>2013</Year><Month>May</Month><Day>29</Day></PubDate></JournalIssue><Title>BMC psychiatry</Title><ISOAbbreviation>BMC Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Understanding treatment non-adherence in schizophrenia and bipolar disorder: a survey of what service users do and why.</ArticleTitle><Pagination><MedlinePgn>153</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/1471-244X-13-153</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Approximately half of service users with schizophrenia or bipolar disorder do not fully follow treatment recommendations. Studies of adherence have not adequately explored the frequency, consequences and meanings of non-adherence behaviours from service users' perspectives. This study contributes to a more fine-grained understanding of treatment choices and the support service users require in order to maximise benefit from their medications.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This was a mixed-methods questionnaire study, employing quantitative and thematic qualitative analyses. Thirty-five individuals with a diagnosis of, and receiving psycho-pharmaceutical treatment for, schizophrenia or bipolar disorder answered online or telephone questions about whether, how, and why they deviated from their treatment recommendations, and what support they currently and would like to receive.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Over half of participants identified themselves as being non-adherent, however when asked in detail about intentional and unintentional adherence, 77% reported deviating from treatment recommendations. Critically, 29% were non-adherent and satisfied with being so. Service users' satisfaction with their support was positively correlated with satisfaction with their medication. Participants' made treatment choices in order to live well. Both side-effects and symptoms could be obstacles to adherence, but feeling well also impacted on participants' treatment choices. Treatment choices were often made in the context of living well day-to-day, and did not necessarily take into account longer-term effects of non-adherence. Participants wanted more information about their medications, better emotional support (including better access to psychological therapies) and stability in their relationships with health professionals.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This study suggests that non-adherence, both intentional and unintentional, is common amongst individuals with diagnoses of schizophrenia and bipolar disorder, and that this often occurs without health professionals' knowledge or support. Treatment choices reflect a desire to live well, but are often driven by short-term needs. Given access to more information, and importantly to emotional support, service users could be helped to make treatment choices that adequately reflect the long-term risks of non-adherence, as well as allowing them to live well day-to-day. More research is required better to understand the meanings and complexities of service users' treatment choices.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gibson</LastName><ForeName>Susanne</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>SANE mental health charity, 40 Adler Street, London, UK. sgibson@sane.org.uk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brand</LastName><ForeName>Sarah L</ForeName><Initials>SL</Initials></Author><Author ValidYN="Y"><LastName>Burt</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Boden</LastName><ForeName>Zoë V R</ForeName><Initials>ZV</Initials></Author><Author ValidYN="Y"><LastName>Benson</LastName><ForeName>Outi</ForeName><Initials>O</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>05</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Psychiatry</MedlineTA><NlmUniqueID>100968559</NlmUniqueID><ISSNLinking>1471-244X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006306" MajorTopicYN="N">Health Surveys</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055118" MajorTopicYN="N">Medication Adherence</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017060" MajorTopicYN="Y">Patient Satisfaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="N">Schizophrenic Psychology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>08</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>05</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>5</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>5</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23714262</ArticleId><ArticleId IdType="pii">1471-244X-13-153</ArticleId><ArticleId IdType="doi">10.1186/1471-244X-13-153</ArticleId><ArticleId IdType="pmc">PMC3695802</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ann Gen Psychiatry. 2009 Feb 18;8:7</Citation><ArticleIdList><ArticleId IdType="pubmed">19226463</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2006 Dec;189:508-14</Citation><ArticleIdList><ArticleId IdType="pubmed">17139034</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Ment Health Nurs. 2011 Jun;18(5):418-24</Citation><ArticleIdList><ArticleId IdType="pubmed">21539687</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Nurs Stud. 2011 Jul;48(7):894-903</Citation><ArticleIdList><ArticleId IdType="pubmed">21481391</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Psychopharmacol. 2010 Jan;25(1):1-16</Citation><ArticleIdList><ArticleId IdType="pubmed">20041478</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2003 May;74(3):287-91</Citation><ArticleIdList><ArticleId IdType="pubmed">12738048</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2005 Jul;187:9-20</Citation><ArticleIdList><ArticleId IdType="pubmed">15994566</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Psychiatry. 2012 Mar 20;12:20</Citation><ArticleIdList><ArticleId IdType="pubmed">22433036</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2007 Sep;9(6):656-64</Citation><ArticleIdList><ArticleId IdType="pubmed">17845282</ArticleId></ArticleIdList></Reference><Reference><Citation>CNS Neurosci Ther. 2010 Oct;16(5):308-15</Citation><ArticleIdList><ArticleId IdType="pubmed">21050421</ArticleId></ArticleIdList></Reference><Reference><Citation>Behav Modif. 2008 May;32(3):267-301</Citation><ArticleIdList><ArticleId IdType="pubmed">18391049</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2012;7(4):e36080</Citation><ArticleIdList><ArticleId IdType="pubmed">22558336</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Serv. 2010 May 1;7(2):75-91</Citation><ArticleIdList><ArticleId IdType="pubmed">20526422</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">23664567</PMID><DateCompleted><Year>2014</Year><Month>05</Month><Day>05</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>150</Volume><Issue>2</Issue><PubDate><Year>2013</Year><Month>Sep</Month><Day>05</Day></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Mood and metabolic consequences of sleep deprivation as a potential endophenotype' in bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>284-94</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2013.04.007</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0165-0327(13)00262-0</ELocationID><Abstract><AbstractText>It has been commonly recognized that circadian rhythm and sleep/wake cycle are causally involved in bipolar disorder. There has been a paucity of systematic research considering the relations between sleep and mood states in bipolar disorder. The current study examines the possible influences of sleep deprivation on mood states and endocrine functions among first-degree relatives of patients with bipolar disorder and healthy controls. Blood samples were taken at two time points in the consecutive mornings at predeprivation and postdeprivation periods. Participants simultaneously completed the Profiles of Mood States at two time points after giving blood samples. Plasma T3 and TSH levels increased after total sleep deprivation in both groups. Sleep deprivation induced TSH levels were reversely associated with depression-dejection among healthy controls. A paradoxical effect was detected for only the first-degree relatives of the patients that changes in plasma cortisol levels negatively linked to depression-dejection and anger-hostility scores after total sleep deprivation. Plasma DHEA levels became correlated with vigor-activity scores after sleep deprivation among first-degree relatives of bipolar patients. On the contrary, significant associations of depression-dejection, anger-hostility, and confusion-bewilderment with the baseline plasma DHEA levels became statistically trivial in the postdeprivation period. Findings suggested that first-degree relatives of patients with bipolar disorder had completely distinct characteristics with respect to sleep deprivation induced responses in terms of associations between endocrine functions and mood states as compared to individuals whose relatives had no psychiatric problems. Considering the relationships between endocrine functions and mood states among relatives of the patients, it appears like sleep deprivation changes the receptor sensitivity which probably plays a pivotal role on mood outcomes among the first-degree relatives of patients with bipolar disorder. </AbstractText><CopyrightInformation>Copyright © 2013 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Aydin</LastName><ForeName>Adem</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Yuzuncu Yil University Medicine Faculty, Department of Psychiatry, Van, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Selvi</LastName><ForeName>Yavuz</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Besiroglu</LastName><ForeName>Lutfullah</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Boysan</LastName><ForeName>Murat</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Atli</LastName><ForeName>Abdullah</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Ozdemir</LastName><ForeName>Osman</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Kilic</LastName><ForeName>Sultan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Balaharoglu</LastName><ForeName>Ragıp</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>05</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>06LU7C9H1V</RegistryNumber><NameOfSubstance UI="D014284">Triiodothyronine</NameOfSubstance></Chemical><Chemical><RegistryNumber>459AG36T1B</RegistryNumber><NameOfSubstance UI="D003687">Dehydroepiandrosterone</NameOfSubstance></Chemical><Chemical><RegistryNumber>9002-71-5</RegistryNumber><NameOfSubstance UI="D013972">Thyrotropin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000339" MajorTopicYN="N">Affect</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002940" MajorTopicYN="N">Circadian Rhythm</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003687" MajorTopicYN="N">Dehydroepiandrosterone</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004703" MajorTopicYN="N">Endocrine System</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058068" MajorTopicYN="Y">Endophenotypes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012892" MajorTopicYN="N">Sleep Deprivation</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013972" MajorTopicYN="N">Thyrotropin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014284" MajorTopicYN="N">Triiodothyronine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bipolar disorder</Keyword><Keyword MajorTopicYN="N">Endocrine system</Keyword><Keyword MajorTopicYN="N">Endophenotype</Keyword><Keyword MajorTopicYN="N">Hormones</Keyword><Keyword MajorTopicYN="N">Mood states</Keyword><Keyword MajorTopicYN="N">Sleep deprivation</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>12</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2013</Year><Month>04</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>04</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>5</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>5</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>5</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23664567</ArticleId><ArticleId IdType="pii">S0165-0327(13)00262-0</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2013.04.007</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18515695</PMID><DateCompleted><Year>2008</Year><Month>08</Month><Day>07</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1545-7214</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>6</Issue><PubDate><Year>2008</Year><Month>Jun</Month></PubDate></JournalIssue><Title>The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry</Title><ISOAbbreviation>Am J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Executive dysfunction in elderly bipolar manic patients.</ArticleTitle><Pagination><MedlinePgn>506-12</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/JGP.0b013e318172b3ec</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This study used neuropsychological measures of executive skills to examine the functioning of frontostriatal networks in elderly bipolar patients.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">The authors hypothesized that elders with bipolar mania would exhibit poor executive functions relative to both elderly comparison subjects and depressed patients.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">The study was conducted in the geriatric psychiatry services of a university hospital.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">Nondemented elders: 14 with bipolar disorder I, manic (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition), 14 with unipolar major depression (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition), and 14 nonpsychiatric comparison (NC) subjects.</AbstractText><AbstractText Label="MEASUREMENTS" NlmCategory="METHODS">Executive functions were assessed with the initiation/perseveration subscale of the Dementia Rating Scale and the manual Go/No-Go tasks from the extended initiation/perseveration scale.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Manic elders demonstrated poor performance on tasks of initiation/perseveration and response inhibition, and performed significantly worse than both depressed patients and NC subjects. In this sample, there was no evidence for a relationship between severity of manic symptoms and executive performance.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These findings extend the observation that elderly bipolar manic patients have deficits in executive functioning compared with NC samples and provide evidence that the executive deficits demonstrated by bipolar manic elders can be more severe than those in unipolar depressed elders. As executive functions require frontostriatal integrity, these observations support investigation of specific frontostriatal network abnormalities in late-life bipolar disorder.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gunning-Dixon</LastName><ForeName>Faith M</ForeName><Initials>FM</Initials><AffiliationInfo><Affiliation>Weill Cornell Institute of Geriatric Psychiatry, Department of Psychiatry, Weill Medical College of Cornell University, White Plains, NY, USA. fgd2002@med.cornell.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murphy</LastName><ForeName>Christopher F</ForeName><Initials>CF</Initials></Author><Author ValidYN="Y"><LastName>Alexopoulos</LastName><ForeName>George S</ForeName><Initials>GS</Initials></Author><Author ValidYN="Y"><LastName>Majcher-Tascio</LastName><ForeName>Magdalena</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Young</LastName><ForeName>Robert C</ForeName><Initials>RC</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01 MH0704511</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 MH074818</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 MH074511</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 MH068638</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 MH067702</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K02 MH067028</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 MH68638</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Am J Geriatr Psychiatry</MedlineTA><NlmUniqueID>9309609</NlmUniqueID><ISSNLinking>1064-7481</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001288" MajorTopicYN="N">Attention</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003342" MajorTopicYN="N">Corpus Striatum</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005625" MajorTopicYN="N">Frontal Lobe</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007266" MajorTopicYN="N">Inhibition, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="Y">Neuropsychological Tests</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>6</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>8</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>6</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18515695</ArticleId><ArticleId IdType="pii">16/6/506</ArticleId><ArticleId IdType="doi">10.1097/JGP.0b013e318172b3ec</ArticleId><ArticleId IdType="pmc">PMC7179737</ArticleId><ArticleId IdType="mid">NIHMS1022289</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Affect Disord. 2007 Dec;104(1-3):61-71</Citation><ArticleIdList><ArticleId IdType="pubmed">17360041</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2005 Aug 1;58(3):204-10</Citation><ArticleIdList><ArticleId IdType="pubmed">16018984</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2001 Jun;3(3):106-50; discussion 151-3</Citation><ArticleIdList><ArticleId IdType="pubmed">11465675</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1999 Aug;56(8):713-8</Citation><ArticleIdList><ArticleId IdType="pubmed">10435605</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1988 Aug;45(8):742-7</Citation><ArticleIdList><ArticleId IdType="pubmed">3395203</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Geriatr Psychiatry. 2007 Feb;15(2):174-9</Citation><ArticleIdList><ArticleId IdType="pubmed">17272739</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nerv Ment Dis. 1980 May;168(5):297-304</Citation><ArticleIdList><ArticleId IdType="pubmed">7365494</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1978 Nov;133:429-35</Citation><ArticleIdList><ArticleId IdType="pubmed">728692</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2006 May;92(1):125-31</Citation><ArticleIdList><ArticleId IdType="pubmed">16469389</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1999 Apr 15;45(8):965-71</Citation><ArticleIdList><ArticleId IdType="pubmed">10386178</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2007 Aug;101(1-3):201-9</Citation><ArticleIdList><ArticleId IdType="pubmed">17224185</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Geriatr Psychiatry. 2007 Jul;15(7):594-603</Citation><ArticleIdList><ArticleId IdType="pubmed">17353296</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychiatry Neuropsychol Behav Neurol. 2000 Oct;13(4):246-53</Citation><ArticleIdList><ArticleId IdType="pubmed">11186160</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychologia. 2007 Apr 9;45(8):1697-706</Citation><ArticleIdList><ArticleId IdType="pubmed">17292926</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2002 Jul;159(7):1119-26</Citation><ArticleIdList><ArticleId IdType="pubmed">12091189</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Brain Mapp. 2006 Oct;27(10):799-810</Citation><ArticleIdList><ArticleId IdType="pubmed">16511886</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Geriatr Psychiatry. 2005 Mar;13(3):244-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15728756</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2004 Dec;29(12):2278-84</Citation><ArticleIdList><ArticleId IdType="pubmed">15340393</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Geriatr Psychiatry. 2004 Jan-Feb;12(1):50-6</Citation><ArticleIdList><ArticleId IdType="pubmed">14729559</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Geriatr Psychiatry. 2006 Jul;14(7):598-604</Citation><ArticleIdList><ArticleId IdType="pubmed">16816013</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2004 Apr;161(4):736-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15056521</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2001 Jun 1;102(2):139-51</Citation><ArticleIdList><ArticleId IdType="pubmed">11408053</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Geriatr Psychiatry. 2007 Jul;15(7):553-63</Citation><ArticleIdList><ArticleId IdType="pubmed">17586780</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Geriatr Psychiatry. 2006 Oct;14(10):812-22</Citation><ArticleIdList><ArticleId IdType="pubmed">17001021</ArticleId></ArticleIdList></Reference><Reference><Citation>Cereb Cortex. 2004 Feb;14(2):199-208</Citation><ArticleIdList><ArticleId IdType="pubmed">14704217</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2005 Dec;30(12):2225-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15988474</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Geriatr Psychiatry. 2002 Jan-Feb;10(1):98-106</Citation><ArticleIdList><ArticleId IdType="pubmed">11790640</ArticleId></ArticleIdList></Reference><Reference><Citation>Stroke. 1995 Jun;26(6):946-9</Citation><ArticleIdList><ArticleId IdType="pubmed">7762043</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Brain Mapp. 2001 Feb;12(2):100-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11169874</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Geriatr Psychiatry. 2000 Winter;8(1):57-65</Citation><ArticleIdList><ArticleId IdType="pubmed">10648296</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2004 Dec;29(12):2266-71</Citation><ArticleIdList><ArticleId IdType="pubmed">15340392</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Clin Neuropsychol. 2003 Jul;18(5):529-49</Citation><ArticleIdList><ArticleId IdType="pubmed">14591448</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2002 Jun;16(2):449-53</Citation><ArticleIdList><ArticleId IdType="pubmed">12030830</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Geriatr Psychiatry. 2004 Feb;19(2):109-14</Citation><ArticleIdList><ArticleId IdType="pubmed">14758576</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2005 Aug 15;58(4):290-6</Citation><ArticleIdList><ArticleId IdType="pubmed">16018981</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">23903339</PMID><DateCompleted><Year>2013</Year><Month>09</Month><Day>30</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1535-7228</ISSN><JournalIssue CitedMedium="Internet"><Volume>170</Volume><Issue>8</Issue><PubDate><Year>2013</Year><Month>Aug</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Response to Bartoli et al.</ArticleTitle><Pagination><MedlinePgn>928-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1176/appi.ajp.2013.13040447r</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vancampfort</LastName><ForeName>Davy</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Mitchell</LastName><ForeName>Alex J</ForeName><Initials>AJ</Initials></Author><Author ValidYN="Y"><LastName>Correll</LastName><ForeName>Christoph U</ForeName><Initials>CU</Initials></Author><Author ValidYN="Y"><LastName>Sienaert</LastName><ForeName>Pascal</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>De Hert</LastName><ForeName>Marc</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Am J Psychiatry. 2013 Mar;170(3):265-74</RefSource><PMID Version="1">23361837</PMID></CommentsCorrections><CommentsCorrections RefType="CommentOn"><RefSource>Am J Psychiatry. 2013 Aug;170(8):927-8</RefSource><PMID Version="1">23903338</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024821" MajorTopicYN="N">Metabolic Syndrome</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>8</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>8</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>10</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23903339</ArticleId><ArticleId IdType="pii">1722080</ArticleId><ArticleId IdType="doi">10.1176/appi.ajp.2013.13040447r</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20538341</PMID><DateCompleted><Year>2011</Year><Month>06</Month><Day>13</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>129</Volume><Issue>1-3</Issue><PubDate><Year>2011</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>New treatment guidelines for acute bipolar depression: a systematic review.</ArticleTitle><Pagination><MedlinePgn>14-26</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2010.05.018</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Bipolar depression poses a great burden on patients and their families due to its duration, associated functional impairment, and limited treatment options. Given the complexity of the disorder and the advances in treatment, a number of clinical guidelines, consensus statements and expert opinions were developed with the aim to standardize treatment and provide clinicians with treatment algorithms for every-day clinical practice. Unfortunately, they often led to conflicting conclusions and recommendations due to limitations of the available literature. As findings emerge from research literature, guidelines quickly become obsolete and need to be updated or revised. Many guidelines have been updated in the last 5 years, after the last review of bipolar disorder (BD) treatment guidelines.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The purpose of this work is to systematically review guidelines, consensus meetings and treatment algorithms on the acute treatment of bipolar depression updated or published since 2005, to critically underline common and critical points, highlight limits and strengths, and provide a starting point for future research</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">The MEDLINe/PubMed/Index Medicus, PsycINFO/PsycLIT, Excerpta Medica/EMBASE, databases were searched using "depression", "bipolar", "manic-depression", "manic-depressive" and "treatment guidelines" as key words</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The search returned 204 articles. Amongst them, there were 28 papers concerning structured treatment algorithms and/or guidelines suggested by official panels. After excluding those guidelines that were not performed by scientific societies or international groups and those published before 2005, the final selection yielded 7 papers When looking into guidelines content, the results indicate a trend to the gradual acceptance of the use of the atypical antipsychotic quetiapine as monotherapy as first-line treatment. Antidepressant monotherapy is discouraged in most of them, although some support the use of antidepressants in combination with antimanic agents for a limited period of time. Lamotrigine has become a highly controversial option.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The management of bipolar depression is complex and should be differentiated from management of unipolar depression. Guidelines may be useful instruments for helping clinicians to choose and plan bipolar depression treatment by integrating the more updated scientific knowledge with every-day clinical practice and patient-specific factors; however, a further effort is needed in order to improve guidelines implementation in clinical practice. The latest updates on treatment guidelines for bipolar depression give priority to novel treatment approaches, such as quetiapine, over more traditional ones, such as lithium or antidepressants. Lamotrigine is a controversial option.</AbstractText><CopyrightInformation>Copyright © 2010 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nivoli</LastName><ForeName>Alessandra M A</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Bipolar Disorders Program, Institute of Neuroscience, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colom</LastName><ForeName>Francesc</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Murru</LastName><ForeName>Andrea</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Pacchiarotti</LastName><ForeName>Isabella</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Castro-Loli</LastName><ForeName>Piero</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>González-Pinto</LastName><ForeName>Ana</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Fountoulakis</LastName><ForeName>Kostas N</ForeName><Initials>KN</Initials></Author><Author ValidYN="Y"><LastName>Vieta</LastName><ForeName>Eduard</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>06</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017410" MajorTopicYN="Y">Practice Guidelines as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011613" MajorTopicYN="N">Psychotherapy</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>10</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2010</Year><Month>05</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>05</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>6</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>6</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>6</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20538341</ArticleId><ArticleId IdType="pii">S0165-0327(10)00403-9</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2010.05.018</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">27371906</PMID><DateCompleted><Year>2017</Year><Month>12</Month><Day>04</Day></DateCompleted><DateRevised><Year>2019</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>204</Volume><PubDate><Year>2016</Year><Month>Nov</Month><Day>01</Day></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Medically unexplained somatic symptoms and bipolar spectrum disorders: A systematic review and meta-analysis.</ArticleTitle><Pagination><MedlinePgn>205-13</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2016.06.029</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0165-0327(16)30373-1</ELocationID><Abstract><AbstractText Label="BACKGROUND">Patients with bipolar spectrum disorders (BSD) frequently report medically unexplained somatic symptoms. However, the prevalence and the consequences for treatment and outcome are currently unknown.</AbstractText><AbstractText Label="METHODS">To estimate the prevalence of somatic symptoms in BSD, we conducted a systematic review and meta-analysis of empirical studies published between 1980 and 2015. The odds for somatic symptoms in BSD were compared with unipolar depression (UPD) and general population or mixed psychiatric controls. Studies were retrieved from four electronic databases utilizing Boolean operations and reference list searches. Pooled data estimates were derived using random-effects methods.</AbstractText><AbstractText Label="RESULTS">Out of 2634 studies, 23 were eligible for inclusion, yielding an N of 106,785 patients. The estimated prevalence of somatic symptoms in BSD was 47.8%. The estimated prevalence of BSD in persons with somatic symptoms was 1.4%. Persons with BSD had a higher prevalence of somatic symptoms compared with population or mixed psychiatric controls (OR 1.82, 95% CI 1.14-2.92). Persons with BSD had a similar prevalence of somatic symptoms compared with UPD controls (OR 0.99, 95% CI 0.68-1.44).</AbstractText><AbstractText Label="LIMITATIONS">This study is correlational; thus causal inferences cannot be made. Reporting of somatic symptoms likely varies with BSD severity and subtype. Some studies reported insufficient information regarding comorbid medical conditions and medications.</AbstractText><AbstractText Label="CONCLUSIONS">Persons with BSD suffer from somatic symptoms at a rate nearly double that of the general population, a rate similar to persons with UPD. Our results suggest the utility of an integrated care model in which primary care and specialist physicians collaborate with mental health professionals to jointly address psychological and bodily symptoms.</AbstractText><CopyrightInformation>Copyright © 2016 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Edgcomb</LastName><ForeName>Juliet Beni</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>David Geffen School of Medicine at UCLA, University of California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tseng</LastName><ForeName>Chi-Hong</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine at UCLA, University of California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kerner</LastName><ForeName>Berit</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Berit Kerner, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, CA, USA; Witten/Herdecke University, Witten, Germany. Electronic address: bkerner@mednet.ucla.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>06</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071896" MajorTopicYN="Y">Medically Unexplained Symptoms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016017" MajorTopicYN="N">Odds Ratio</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Bipolar disorder</Keyword><Keyword MajorTopicYN="Y">Depression</Keyword><Keyword MajorTopicYN="Y">Functional</Keyword><Keyword MajorTopicYN="Y">Somatic</Keyword><Keyword MajorTopicYN="Y">Symptom</Keyword><Keyword MajorTopicYN="Y">Unipolar</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>03</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>06</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>7</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>7</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>12</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27371906</ArticleId><ArticleId IdType="pii">S0165-0327(16)30373-1</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2016.06.029</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23806623</PMID><DateCompleted><Year>2014</Year><Month>05</Month><Day>30</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-7123</ISSN><JournalIssue CitedMedium="Internet"><Volume>210</Volume><Issue>1</Issue><PubDate><Year>2013</Year><Month>Nov</Month><Day>30</Day></PubDate></JournalIssue><Title>Psychiatry research</Title><ISOAbbreviation>Psychiatry Res</ISOAbbreviation></Journal><ArticleTitle>Relapses in recurrent depression 1 year after maintenance cognitive-behavioral therapy: the role of therapist adherence, competence, and the therapeutic alliance.</ArticleTitle><Pagination><MedlinePgn>140-5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.psychres.2013.05.036</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0165-1781(13)00314-4</ELocationID><Abstract><AbstractText>The prevention of relapse in recurrent depression is considered a central aim in cognitive-behavioral therapy, given the high risk of relapse. In this study, patients with recurrent major depressive disorder (currently remitted) received 16 sessions of Maintenance Cognitive-Behavioral Therapy (M-CBT) over a period of 8 months, in order to prevent relapse. Therapist adherence and competence, as well as the therapeutic alliance, were investigated as predictors for reducing the risk of recurrence in depression. Videotapes of 80 participants were analyzed in order to evaluate therapist adherence and competence. Additionally, the therapeutic alliance was assessed by questionnaire. No associations were found between therapist adherence or competence, and the risk of relapse 1 year after treatment. By contrast, the therapeutic alliance was a significant predictor of the time to relapse. Moreover, we found that the number of previous depressive episodes (≥ 5 vs. ≤ 4) was a significant moderator variable. This indicates that the alliance-outcome relationship was particularly important when patients with five or more previous depressive episodes were taken into account, in comparison to patients with four or fewer episodes. For the psychotherapeutic treatment of recurrent depression and the prevention of relapse, sufficient attention should be paid to the therapeutic alliance.</AbstractText><CopyrightInformation>Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Weck</LastName><ForeName>Florian</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Clinical Psychology and Psychotherapy, University of Frankfurt, Frankfurt, Germany. Electronic address: weck@psych.uni-frankfurt.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rudari</LastName><ForeName>Visar</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Hilling</LastName><ForeName>Christine</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Hautzinger</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Heidenreich</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Schermelleh-Engel</LastName><ForeName>Karin</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Stangier</LastName><ForeName>Ulrich</ForeName><Initials>U</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>06</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Psychiatry Res</MedlineTA><NlmUniqueID>7911385</NlmUniqueID><ISSNLinking>0165-1781</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000534" MajorTopicYN="Y">rehabilitation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015928" MajorTopicYN="N">Cognitive Behavioral Therapy</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017063" MajorTopicYN="N">Outcome Assessment, Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010349" MajorTopicYN="Y">Patient Compliance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011361" MajorTopicYN="N">Professional Competence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012044" MajorTopicYN="N">Regression Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055502" MajorTopicYN="N">Secondary Prevention</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014741" MajorTopicYN="N">Video Recording</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adherence</Keyword><Keyword MajorTopicYN="N">Alliance</Keyword><Keyword MajorTopicYN="N">Competence</Keyword><Keyword MajorTopicYN="N">Maintenance cognitive therapy</Keyword><Keyword MajorTopicYN="N">Outcome</Keyword><Keyword MajorTopicYN="N">Recurrent depression</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>08</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2013</Year><Month>05</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>05</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>6</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>6</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>5</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23806623</ArticleId><ArticleId IdType="pii">S0165-1781(13)00314-4</ArticleId><ArticleId IdType="doi">10.1016/j.psychres.2013.05.036</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21055823</PMID><DateCompleted><Year>2011</Year><Month>11</Month><Day>07</Day></DateCompleted><DateRevised><Year>2011</Year><Month>08</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>133</Volume><Issue>1-2</Issue><PubDate><Year>2011</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Clinical differentiation of bipolar II disorder from personality-based "emotional dysregulation" conditions.</ArticleTitle><Pagination><MedlinePgn>16-21</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2010.10.015</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The non-psychotic mood swings experienced by those with a bipolar II disorder can lead to diagnostic dilemmas, especially in differentiating this condition from personality styles marked by emotional dysregulation. This paper provides a clinical vignette and then offers some indicative parameters that might assist differentiation.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A clinical vignette is provided of a patient who had longitudinal features consistent with either a bipolar II disorder or of distinct personality-based dysregulation and the reader is invited to consider the likely diagnosis. A relevant literature is overviewed and, in conjunction with clinical observations, diagnostic parameters for differentiating the two diagnostic groupings are derived.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">It is suggested that the derived parameters assist diagnostic clarification in most instances but reference back to the clinical vignette tempers that level of confidence.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">Many of the identified differentiating features are clinically derived and are subject to limitations of clinical observation and biases.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The importance of differentiating a primary bipolar II disorder from a personality-based condition is of high clinical importance. This overview seeks to advance the objective.</AbstractText><CopyrightInformation>Copyright © 2010. Published by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Parker</LastName><ForeName>Gordon</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>School of Psychiatry, University of New South Wales, and Black Dog Institute, Sydney, Australia. g.parker@unsw.edu.au</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>11</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003527" MajorTopicYN="N">Cyclothymic Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004644" MajorTopicYN="N">Emotions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007508" MajorTopicYN="N">Irritable Mood</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019964" MajorTopicYN="N">Mood Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010551" MajorTopicYN="N">Personality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010554" MajorTopicYN="N">Personality Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013694" MajorTopicYN="N">Temperament</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>07</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2010</Year><Month>10</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>10</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>11</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>11</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>11</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21055823</ArticleId><ArticleId IdType="pii">S0165-0327(10)00629-4</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2010.10.015</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20965308</PMID><DateCompleted><Year>2011</Year><Month>03</Month><Day>22</Day></DateCompleted><DateRevised><Year>2010</Year><Month>10</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-8384</ISSN><JournalIssue CitedMedium="Internet"><Volume>51</Volume><Issue>6</Issue><PubDate><MedlineDate>2010 Nov-Dec</MedlineDate></PubDate></JournalIssue><Title>Comprehensive psychiatry</Title><ISOAbbreviation>Compr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Temperament and character in patients with bipolar II disorder and recurrent brief depression.</ArticleTitle><Pagination><MedlinePgn>607-17</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.comppsych.2010.03.003</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">We compared the temperament and character profiles of 21 patients with bipolar II disorder, 40 patients with recurrent brief depression (RBD; at least monthly depressive episodes meeting the diagnostic criteria for major depressive episode except for duration that is less than 2 weeks, typically 2-3 days, without fixed relation to menstrual cycle) of which 21 had no history of hypomania and 19 had experienced hypomanic episodes, and 21 age- and sex-matched controls.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Assessments included the Montgomery-Åsberg Depression Rating Scale, Hypomania Checklist, and Temperament and Character Inventory-125. Patients with cluster A and B personality disorders were excluded.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Bipolar II and RBD patients had higher harm avoidance (HA) and lower self-directedness (SD) compared with controls. Excluding panic disorder comorbidity effaced this difference in HA and SD (bipolar II only) and harm avoidance. No other differences were found.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In this first study comparing personality profiles of patients with bipolar II vs RBD, when controlling for confounders, neither bipolar II nor RBD patients differed significantly from healthy controls. The lower SD scores among RBD patients may reflect sampling bias (a higher rate of Axis 2 cluster C disorders).</AbstractText><CopyrightInformation>Copyright © 2010 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lövdahl</LastName><ForeName>H</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Clinical Neurosciences, Department of Neuropsychiatry and Psychosomatic Medicine, Oslo University Hospital-Rikshospitalet, Oslo, Norway. hans.lovdahl@sshf.no</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bøen</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Falkum</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Hynnekleiv</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Malt</LastName><ForeName>U F</ForeName><Initials>UF</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>04</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Compr Psychiatry</MedlineTA><NlmUniqueID>0372612</NlmUniqueID><ISSNLinking>0010-440X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002605" MajorTopicYN="Y">Character</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D040261" MajorTopicYN="N">Harm Reduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010555" MajorTopicYN="N">Personality Inventory</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012016" MajorTopicYN="N">Reference Values</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012927" MajorTopicYN="N">Social Control, Informal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013694" MajorTopicYN="Y">Temperament</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>09</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2010</Year><Month>02</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>03</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>10</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>10</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>3</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20965308</ArticleId><ArticleId IdType="pii">S0010-440X(10)00018-0</ArticleId><ArticleId IdType="doi">10.1016/j.comppsych.2010.03.003</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">7726717</PMID><DateCompleted><Year>1995</Year><Month>05</Month><Day>25</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0003-990X</ISSN><JournalIssue CitedMedium="Print"><Volume>52</Volume><Issue>5</Issue><PubDate><Year>1995</Year><Month>May</Month></PubDate></JournalIssue><Title>Archives of general psychiatry</Title><ISOAbbreviation>Arch Gen Psychiatry</ISOAbbreviation></Journal><ArticleTitle>A family study of manic-depressive (bipolar I) disease. Is it a distinct illness separable from primary unipolar depression?</ArticleTitle><Pagination><MedlinePgn>367-73</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine whether bipolar I illness is autonomous or part of a multifactorial continuum with unipolar depression. In this study, we compare familial bipolar I illness and depression among three groups: probands with bipolar I disorder; probands with primary unipolar disorder; and controls. We also examine a continuum of severity between psychotic and nonpsychotic patients with bipolar I disorder. Considerable data suggest that bipolar I illness is distinct from unipolar illness as regards epidemiology, familial psychiatric illness, course, response to treatment, and biologic findings.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Probands were separated into bipolar I and primary unipolar depressive groups. Personally interviewed family members of these patients were compared on variables of bipolar illness or schizoaffective mania and unipolar or schizoaffective depression. A personally examined control group was compared with the relatives of the two proband groups. Similar analyses were performed using data obtained by a systematic family history method. For the same familial variables, psychotic and nonpsychotic manic probands were compared.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Familial mania is more frequent in families of patients with bipolar disease than in controls or in families of patients with primary unipolar disorder. The latter two groups did not differ in amount of mania. Unipolar depressive illness or schizoaffective depression was higher in families of probands with bipolar and unipolar disorder than in controls. Probands with bipolar disease separated into those who had psychotic symptoms (including schizoaffective mania) and no psychotic symptoms did not differ from each other in risk for familial mania or depression.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Bipolar I illness is a separate illness from primary unipolar illness because of an increase in familial mania. Patients with primary unipolar disease and controls show the same amount of familial mania. Lack of an increase in familial illness according to the severity of bipolar disease is against an affective continuum.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Winokur</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>National Institute of Mental Health Collaborative Program on the Psychobiology of Depression--Clinical Studies, Bethesda, Md, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coryell</LastName><ForeName>W</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Keller</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Endicott</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Leon</LastName><ForeName>A</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 MH025478</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Gen Psychiatry</MedlineTA><NlmUniqueID>0372435</NlmUniqueID><ISSNLinking>0003-990X</ISSNLinking></MedlineJournalInfo><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005190" MajorTopicYN="Y">Family</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1995</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1995</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1995</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">7726717</ArticleId><ArticleId IdType="doi">10.1001/archpsyc.1995.03950170041006</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27307288</PMID><DateCompleted><Year>2017</Year><Month>03</Month><Day>14</Day></DateCompleted><DateRevised><Year>2017</Year><Month>08</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1440-1614</ISSN><JournalIssue CitedMedium="Internet"><Volume>50</Volume><Issue>8</Issue><PubDate><Year>2016</Year><Month>Aug</Month></PubDate></JournalIssue><Title>The Australian and New Zealand journal of psychiatry</Title><ISOAbbreviation>Aust N Z J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Reduced heart rate variability in remitted bipolar disorder and recurrent depression.</ArticleTitle><Pagination><MedlinePgn>793-804</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/0004867416652734</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">There is evidence that mood disorders are associated with impaired parasympathetic nervous system function and consequently increased morbidity and mortality. Our study addresses whether this impairment persists into remission in unipolar and bipolar disorders.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Heart Rate Variability was measured in groups of subjects during remission, with Bipolar Affective Disorder I (n = 29), recurrent Major Depressive Disorder (n = 41) and a healthy control group (n = 38), during the bedtime period.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Heart Rate Variability was found to be lower in the bipolar and depression groups, compared with control subjects, using the Root Mean Square of Successive Distances variable, and lower in the depression group using the Standard Deviation of Normal to Normal variable and the Standard Deviation, Poincare Plot variable.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Autonomic function during bedtime was impaired in subjects with Bipolar I and recurrent Major Depressive Disorder, despite clinical remission. This has significant implications for the morbidity and mortality of patients with major mood disorders.</AbstractText><CopyrightInformation>© The Royal Australian and New Zealand College of Psychiatrists 2016.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bassett</LastName><ForeName>Darryl</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>University of Notre Dame, Fremantle, WA, Australia The University of Western Australia, Nedlands, WA, Australia Hollywood Specialist Centre, Nedlands, WA, Australia dbassett@drbassett.com.au.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bear</LastName><ForeName>Natasha</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Telethon Kids Institute, Subiaco, WA, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nutt</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Imperial College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hood</LastName><ForeName>Sean</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>School of Psychiatry and Clinical Neurosciences, The University of Western Australia, Nedlands, WA, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bassett</LastName><ForeName>Sherylee</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Hollywood Specialist Centre, Nedlands, WA, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hans</LastName><ForeName>Davinder</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Sir Charles Gairdner Hospital, Nedlands, WA, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>06</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Aust N Z J Psychiatry</MedlineTA><NlmUniqueID>0111052</NlmUniqueID><ISSNLinking>0004-8674</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001342" MajorTopicYN="N">Autonomic Nervous System Diseases</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006339" MajorTopicYN="N">Heart Rate</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Heart rate variability</Keyword><Keyword MajorTopicYN="N">bipolar</Keyword><Keyword MajorTopicYN="N">depression</Keyword><Keyword MajorTopicYN="N">remission</Keyword><Keyword MajorTopicYN="N">sleep</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>6</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>6</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>3</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27307288</ArticleId><ArticleId IdType="pii">0004867416652734</ArticleId><ArticleId IdType="doi">10.1177/0004867416652734</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28960527</PMID><DateCompleted><Year>2018</Year><Month>10</Month><Day>15</Day></DateCompleted><DateRevised><Year>2020</Year><Month>03</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1098-2396</ISSN><JournalIssue CitedMedium="Internet"><Volume>72</Volume><Issue>2</Issue><PubDate><Year>2018</Year><Month>02</Month></PubDate></JournalIssue><Title>Synapse (New York, N.Y.)</Title><ISOAbbreviation>Synapse</ISOAbbreviation></Journal><ArticleTitle>Diffusion Entropy: A Potential Neuroimaging Biomarker of Bipolar Disorder in the Temporal Pole.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/syn.22015</ELocationID><Abstract><AbstractText>Despite much research, bipolar depression remains poorly understood, with no clinically useful biomarkers for its diagnosis. The paralimbic system has become a target for biomarker research, with paralimbic structural connectivity commonly reported to distinguish bipolar patients from controls in tractography-based diffusion MRI studies, despite inconsistent findings in voxel-based studies. The purpose of this analysis was to validate existing findings with traditional diffusion MRI metrics and investigate the utility of a novel diffusion MRI metric, entropy of diffusion, in the search for bipolar depression biomarkers. We performed group-level analysis on 9 un-medicated (6 medication-naïve; 3 medication-free for at least 33 days) bipolar patients in a major depressive episode and 9 matched healthy controls to compare: (1) average mean diffusivity (MD) and fractional anisotropy (FA) and; (2) MD and FA histogram entropy-a statistical measure of distribution homogeneity-in the amygdala, hippocampus, orbitofrontal cortex and temporal pole. We also conducted classification analyses with leave-one-out and separate testing dataset (N = 11) approaches. We did not observe statistically significant differences in average MD or FA between the groups in any region. However, in the temporal pole, we observed significantly lower MD entropy in bipolar patients; this finding suggests a regional difference in MD distributions in the absence of an average difference. This metric allowed us to accurately characterize bipolar patients from controls in leave-one-out (accuracy = 83%) and prediction (accuracy = 73%) analyses. This novel application of diffusion MRI yielded not only an interesting separation between bipolar patients and healthy controls, but also accurately classified bipolar patients from controls.</AbstractText><CopyrightInformation>© 2017 Wiley Periodicals, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Spuhler</LastName><ForeName>Karl</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Biomedical Engineering, Stony Brook University, Biomedical Engineering, Stony Brook, New York 11794.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bartlett</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Biomedical Engineering, Stony Brook University, Biomedical Engineering, Stony Brook, New York 11794.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ding</LastName><ForeName>Jie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biomedical Engineering, Stony Brook University, Biomedical Engineering, Stony Brook, New York 11794.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeLorenzo</LastName><ForeName>Christine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Biomedical Engineering, Stony Brook University, Biomedical Engineering, Stony Brook, New York 11794.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Stony Brook Medicine, Stony Brook, New York 11794.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parsey</LastName><ForeName>Ramin</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Stony Brook Medicine, Stony Brook, New York 11794.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Chuan</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-6052-0663</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Engineering, Stony Brook University, Biomedical Engineering, Stony Brook, New York 11794.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Stony Brook Medicine, Stony Brook, New York 11794.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology, Stony Brook Medicine, Stony Brook, New York 11794.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 MH090276</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>10</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Synapse</MedlineTA><NlmUniqueID>8806914</NlmUniqueID><ISSNLinking>0887-4476</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019540" MajorTopicYN="N">Area Under Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D038524" MajorTopicYN="N">Diffusion Magnetic Resonance Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056324" MajorTopicYN="N">Diffusion Tensor Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019277" MajorTopicYN="N">Entropy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007091" MajorTopicYN="N">Image Processing, Computer-Assisted</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012372" MajorTopicYN="N">ROC Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">bipolar depression</Keyword><Keyword MajorTopicYN="Y">diffusion</Keyword><Keyword MajorTopicYN="Y">diffusion MRI</Keyword><Keyword MajorTopicYN="Y">temporal pole</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>07</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>09</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>09</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>10</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28960527</ArticleId><ArticleId IdType="doi">10.1002/syn.22015</ArticleId><ArticleId IdType="pmc">PMC5823690</ArticleId><ArticleId IdType="mid">NIHMS943161</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lancet. 2013 Nov 9;382(9904):1575-86</Citation><ArticleIdList><ArticleId IdType="pubmed">23993280</ArticleId></ArticleIdList></Reference><Reference><Citation>Magn Reson Med. 1997 Jun;37(6):932-42</Citation><ArticleIdList><ArticleId IdType="pubmed">9178246</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2016 Feb 15;79(4):293-302</Citation><ArticleIdList><ArticleId IdType="pubmed">25891219</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2017 Jan 01;207:367-376</Citation><ArticleIdList><ArticleId IdType="pubmed">27744225</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Inj. 2003 Apr;17(4):355-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12637187</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2005 Nov;162(11):2033-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16263839</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1993 Jun;150(6):916-21</Citation><ArticleIdList><ArticleId IdType="pubmed">8494069</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Pract Epidemiol Ment Health. 2009 Jan 23;5:3</Citation><ArticleIdList><ArticleId IdType="pubmed">19166608</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2006 Jul 1;31(3):968-80</Citation><ArticleIdList><ArticleId IdType="pubmed">16530430</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Neuropsychopharmacol. 2005 Aug;15(4):425-34</Citation><ArticleIdList><ArticleId IdType="pubmed">15935623</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Brain Mapp. 2015 Sep;36(9):3472-85</Citation><ArticleIdList><ArticleId IdType="pubmed">26033168</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2014 Oct 1;76(7):567-74</Citation><ArticleIdList><ArticleId IdType="pubmed">24690111</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2001 May 1;49(9):741-52</Citation><ArticleIdList><ArticleId IdType="pubmed">11331082</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2013 May 11;381(9878):1663-71</Citation><ArticleIdList><ArticleId IdType="pubmed">23663952</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Brain Mapp. 2016 Sep;37(9):3203-13</Citation><ArticleIdList><ArticleId IdType="pubmed">27151536</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 2007 Jul;130(Pt 7):1718-31</Citation><ArticleIdList><ArticleId IdType="pubmed">17392317</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Clin North Am. 2016 Mar;39(1):1-10</Citation><ArticleIdList><ArticleId IdType="pubmed">26876315</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2000 Oct 15;20(20):7752-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11027238</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Brain Mapp. 2012 Feb;33(2):466-77</Citation><ArticleIdList><ArticleId IdType="pubmed">21391276</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoeconomics. 2003;21(9):601-22</Citation><ArticleIdList><ArticleId IdType="pubmed">12807364</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Neurosci. 2011 Jul 12;12:66</Citation><ArticleIdList><ArticleId IdType="pubmed">21749711</ArticleId></ArticleIdList></Reference><Reference><Citation>Aust N Z J Psychiatry. 2013 Apr;47(4):321-32</Citation><ArticleIdList><ArticleId IdType="pubmed">23411094</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2011 Aug;132(3):344-55</Citation><ArticleIdList><ArticleId IdType="pubmed">21470688</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2011 Dec 1;35(8):1820-6</Citation><ArticleIdList><ArticleId IdType="pubmed">21624424</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc SPIE Int Soc Opt Eng. 2010 Mar 11;7628:</Citation><ArticleIdList><ArticleId IdType="pubmed">24353379</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Hum Neurosci. 2014 Feb 03;8:20</Citation><ArticleIdList><ArticleId IdType="pubmed">24550805</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2000 Oct;3(10):1049-56</Citation><ArticleIdList><ArticleId IdType="pubmed">11017179</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Psychiatry. 2013 Mar 06;4:5</Citation><ArticleIdList><ArticleId IdType="pubmed">23508528</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16683978</PMID><DateCompleted><Year>2006</Year><Month>10</Month><Day>26</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0004-8674</ISSN><JournalIssue CitedMedium="Print"><Volume>40</Volume><Issue>5</Issue><PubDate><Year>2006</Year><Month>May</Month></PubDate></JournalIssue><Title>The Australian and New Zealand journal of psychiatry</Title><ISOAbbreviation>Aust N Z J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Successful treatment with lamotrigine in bipolar depression: a study from Turkey.</ArticleTitle><Pagination><MedlinePgn>498-500</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Savas</LastName><ForeName>Haluk A</ForeName><Initials>HA</Initials></Author><Author ValidYN="Y"><LastName>Selek</LastName><ForeName>Salih</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Bulbul</LastName><ForeName>Feridun</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Kaya</LastName><ForeName>M Cemal</ForeName><Initials>MC</Initials></Author><Author ValidYN="Y"><LastName>Savas</LastName><ForeName>Esen</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Aust N Z J Psychiatry</MedlineTA><NlmUniqueID>0111052</NlmUniqueID><ISSNLinking>0004-8674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014227">Triazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>U3H27498KS</RegistryNumber><NameOfSubstance UI="D000077213">Lamotrigine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Aust N Z J Psychiatry. 2007 Feb;41(2):195</RefSource><PMID Version="1">17479512</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077213" MajorTopicYN="N">Lamotrigine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014227" MajorTopicYN="N">Triazines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014421" MajorTopicYN="N">Turkey</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>5</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>10</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>5</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16683978</ArticleId><ArticleId IdType="pii">ANP1829</ArticleId><ArticleId IdType="doi">10.1111/j.1440-1614.2006.01829.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">1498923</PMID><DateCompleted><Year>1992</Year><Month>09</Month><Day>14</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>12</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0362-5664</ISSN><JournalIssue CitedMedium="Print"><Volume>15 Suppl 1 Pt A</Volume><PubDate><Year>1992</Year></PubDate></JournalIssue><Title>Clinical neuropharmacology</Title><ISOAbbreviation>Clin Neuropharmacol</ISOAbbreviation></Journal><ArticleTitle>WHO cross cultural study on lithium every second day.</ArticleTitle><Pagination><MedlinePgn>487A-488A</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Plenge</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Institute of Neuropsychiatry, University of Copenhagen, Rigshospitalet, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mellerup</LastName><ForeName>E T</ForeName><Initials>ET</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Neuropharmacol</MedlineTA><NlmUniqueID>7607910</NlmUniqueID><ISSNLinking>0362-5664</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003431" MajorTopicYN="N">Cross-Cultural Comparison</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014944" MajorTopicYN="N">World Health Organization</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1992</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1992</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1992</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">1498923</ArticleId><ArticleId IdType="doi">10.1097/00002826-199201001-00254</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">637151</PMID><DateCompleted><Year>1978</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-953X</ISSN><JournalIssue CitedMedium="Print"><Volume>135</Volume><Issue>4</Issue><PubDate><Year>1978</Year><Month>Apr</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Plasma 3-methoxy-4-hydroxyphenylglycol in manic psychosis.</ArticleTitle><Pagination><MedlinePgn>493-4</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Halaris</LastName><ForeName>A E</ForeName><Initials>AE</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006018">Glycols</NameOfSubstance></Chemical><Chemical><RegistryNumber>534-82-7</RegistryNumber><NameOfSubstance UI="D008734">Methoxyhydroxyphenylglycol</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002849" MajorTopicYN="N">Chromatography, Gas</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006018" MajorTopicYN="N">Glycols</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008734" MajorTopicYN="N">Methoxyhydroxyphenylglycol</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012075" MajorTopicYN="N">Remission, Spontaneous</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1978</Year><Month>4</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1978</Year><Month>4</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1978</Year><Month>4</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">637151</ArticleId><ArticleId IdType="doi">10.1176/ajp.135.4.493</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">14525561</PMID><DateCompleted><Year>2003</Year><Month>12</Month><Day>16</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1398-5647</ISSN><JournalIssue CitedMedium="Print"><Volume>5</Volume><Issue>5</Issue><PubDate><Year>2003</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Thyrotoxicosis after complete or partial lithium withdrawal in two patients with bipolar affective disorder.</ArticleTitle><Pagination><MedlinePgn>381-4</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To highlight and discuss thyrotoxicosis after lithium withdrawal as a potential complication of lithium therapy for bipolar disorder.</AbstractText><AbstractText Label="CASE REPORTS" NlmCategory="METHODS">Both patients presented developed thyrotoxicosis, the first patient after stopping the lithium completely, and the second patient after a reduction in the lithium dose.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Clinicians should be alert to the possibility of thyrotoxicosis emerging when lithium is being completely or partially withdrawn. Such withdrawal could unmask a latent hyperthyroidism.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Carmaciu</LastName><ForeName>C D</ForeName><Initials>CD</Initials><AffiliationInfo><Affiliation>Mental Health Department, Clacton and District Hospital, Clacton on Sea, Essex, UK. cdcarmaciu@aol.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anderson</LastName><ForeName>C S</ForeName><Initials>CS</Initials></Author><Author ValidYN="Y"><LastName>Lawton</LastName><ForeName>C A</ForeName><Initials>CA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013375" MajorTopicYN="N">Substance Withdrawal Syndrome</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013971" MajorTopicYN="N">Thyrotoxicosis</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>10</Month><Day>4</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>12</Month><Day>17</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>10</Month><Day>4</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">14525561</ArticleId><ArticleId IdType="pii">052</ArticleId><ArticleId IdType="doi">10.1034/j.1399-5618.2003.00052.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">7921722</PMID><DateCompleted><Year>1994</Year><Month>11</Month><Day>04</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0007-1250</ISSN><JournalIssue CitedMedium="Print"><Volume>164</Volume><Issue>5</Issue><PubDate><Year>1994</Year><Month>May</Month></PubDate></JournalIssue><Title>The British journal of psychiatry : the journal of mental science</Title><ISOAbbreviation>Br J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>ANA negative systemic lupus erythematosus.</ArticleTitle><Pagination><MedlinePgn>682-3</MedlinePgn></Pagination><Abstract><AbstractText>It is usually assumed that psychiatric disturbance cannot be caused by SLE alone. We report two cases of ANA-negative SLE presenting with psychiatric features.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Moorhead</LastName><ForeName>S R</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>Mid-Trent Rotational Training Scheme, Professorial Unit, Mapperley Hospital, Nottingham.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>A S</ForeName><Initials>AS</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Br J Psychiatry</MedlineTA><NlmUniqueID>0342367</NlmUniqueID><ISSNLinking>0007-1250</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000974">Antibodies, Antinuclear</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C035356">SS-A antibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-49-2</RegistryNumber><NameOfSubstance UI="D004247">DNA</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000974" MajorTopicYN="N">Antibodies, Antinuclear</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004247" MajorTopicYN="N">DNA</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="N">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019965" MajorTopicYN="N">Neurocognitive Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1994</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1994</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1994</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">7921722</ArticleId><ArticleId IdType="pii">S0007125000034486</ArticleId><ArticleId IdType="doi">10.1192/bjp.164.5.682</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8432957</PMID><DateCompleted><Year>1993</Year><Month>03</Month><Day>15</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0165-0327</ISSN><JournalIssue CitedMedium="Print"><Volume>27</Volume><Issue>1</Issue><PubDate><Year>1993</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Effects of tricyclic antidepressant treatment on tyramine-O-sulfate excretion in depressed patients.</ArticleTitle><Pagination><MedlinePgn>29-34</MedlinePgn></Pagination><Abstract><AbstractText>The urinary excretion of tyramine-O-sulfate following an oral load of tyramine (Tyramine Challenge Test, 'TCT') was measured in a group of fourteen inpatients with unipolar and bipolar major depressive episode. TCT was done both during a pretreatment baseline period and following four weeks of treatment with tricyclic antidepressants. The change in TCT values after treatment correlated with improvement in depression. The previously described ability of TCT to discriminate between endogenous and nonendogenous depressed patients was confirmed at baseline. However, following tricyclic antidepressant treatment, TCT values were not significantly different between endogenous and nonendogenous patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Steinberg</LastName><ForeName>J L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Department of Veterans Affairs Medical Center, Dallas, Texas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Orsulak</LastName><ForeName>P J</ForeName><Initials>PJ</Initials></Author><Author ValidYN="Y"><LastName>Raese</LastName><ForeName>J D</ForeName><Initials>JD</Initials></Author><Author ValidYN="Y"><LastName>Gregory</LastName><ForeName>R R</ForeName><Initials>RR</Initials></Author><Author ValidYN="Y"><LastName>Zielinski</LastName><ForeName>M H</ForeName><Initials>MH</Initials></Author><Author ValidYN="Y"><LastName>Wittman</LastName><ForeName>P D</ForeName><Initials>PD</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MH-4115</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000929">Antidepressive Agents, Tricyclic</NameOfSubstance></Chemical><Chemical><RegistryNumber>SIA20BP28W</RegistryNumber><NameOfSubstance UI="C027957">tyramine O-sulfate</NameOfSubstance></Chemical><Chemical><RegistryNumber>X8ZC7V0OX3</RegistryNumber><NameOfSubstance UI="D014439">Tyramine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000929" MajorTopicYN="N">Antidepressive Agents, Tricyclic</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000652" MajorTopicYN="N">urine</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000652" MajorTopicYN="N">urine</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010555" MajorTopicYN="N">Personality Inventory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014439" MajorTopicYN="N">Tyramine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1993</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1993</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1993</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8432957</ArticleId><ArticleId IdType="pii">0165-0327(93)90093-Y</ArticleId><ArticleId IdType="doi">10.1016/0165-0327(93)90093-y</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18370614</PMID><DateCompleted><Year>2008</Year><Month>07</Month><Day>01</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1548-5943</ISSN><JournalIssue CitedMedium="Print"><Volume>4</Volume><PubDate><Year>2008</Year></PubDate></JournalIssue><Title>Annual review of clinical psychology</Title><ISOAbbreviation>Annu Rev Clin Psychol</ISOAbbreviation></Journal><ArticleTitle>Pharmacotherapy of mood disorders.</ArticleTitle><Pagination><MedlinePgn>53-91</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1146/annurev.clinpsy.2.022305.095301</ELocationID><Abstract><AbstractText>The mood disorders-primarily major depressive disorder and bipolar affective disorder-constitute one of the world's greatest public health problems and are associated with significant reductions in productivity, health, and longevity. In addition, people who suffer from these common illnesses, along with their families and loved ones, experience an incalculable toll on quality of life. Dating to the introduction of the first effective therapies for mood disorders in the late 1950s and 1960s, various types of pharmacotherapy have become a mainstay for the management of mood disorders, particularly more severe, chronic, and recurrent forms of depression and most forms of bipolar disorder. This review examines recent developments in the pharmacotherapy of both forms of mood disorder, comparing the newer antidepressants such as the selective serotonin reuptake inhibitors and serotonin norepinephrine reuptake inhibitors with their predecessors (the monoamine oxidase inhibitors and tricyclic antidepressants) and likewise comparing the older standard for management of bipolar disorder, lithium, with newer classes of medications, such as a selected group of anticonvulsants and the atypical antipsychotics. Although these newer classes of medications have generally improved upon the earlier treatments in terms of better tolerability and safety, there are no universally effective pharmacologic treatments for mood disorders, and careful medical management of these medications is still warranted.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Thase</LastName><ForeName>Michael E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>University of Pennsylvania School of Medicine and Veterans Administration Medical Center, Philadelphia, Pennsylvania 19104, USA. thase@mail.med.upenn.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Denko</LastName><ForeName>Timothey</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Annu Rev Clin Psychol</MedlineTA><NlmUniqueID>101235325</NlmUniqueID><ISSNLinking>1548-5943</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>2BMD2GNA4V</RegistryNumber><NameOfSubstance UI="D016651">Lithium Carbonate</NameOfSubstance></Chemical><Chemical><RegistryNumber>614OI1Z5WI</RegistryNumber><NameOfSubstance UI="D014635">Valproic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016651" MajorTopicYN="N">Lithium Carbonate</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019964" MajorTopicYN="N">Mood Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014635" MajorTopicYN="N">Valproic Acid</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>218</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>3</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>7</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>3</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18370614</ArticleId><ArticleId IdType="doi">10.1146/annurev.clinpsy.2.022305.095301</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">23902127</PMID><DateCompleted><Year>2014</Year><Month>10</Month><Day>01</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1502-4725</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>4</Issue><PubDate><Year>2014</Year><Month>May</Month></PubDate></JournalIssue><Title>Nordic journal of psychiatry</Title><ISOAbbreviation>Nord J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Metacognitive beliefs in unipolar and bipolar depression: a comparative study.</ArticleTitle><Pagination><MedlinePgn>275-81</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3109/08039488.2013.814710</ELocationID><Abstract><AbstractText Label="AIMS" NlmCategory="OBJECTIVE">The purpose of this study was to perform a comparative investigation of metacognitive beliefs regarding pathological worry in patients with unipolar and bipolar depressive disorder.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Those subjects with acute depressive episodes among patients diagnosed with major depressive disorder (unipolar) or bipolar disorder on the basis of DSM-IV diagnostic criteria (unipolar n = 51, bipolar n = 45), and healthy controls (n = 60), were included in the study. Participants were administered the Meta-Cognitions Questionnaire (MCQ-30) in order to determine metacognitive beliefs. The relationship between metacognitive beliefs and anxiety severity, depression severity and self-esteem in the unipolar and bipolar patients groups was then examined.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Scores for negative beliefs about worry concerning uncontrollability and danger and for beliefs about the need to control thoughts were higher in both the unipolar and bipolar depression groups than in the healthy controls (P &lt; 0.05). Lack of cognitive confidence scores were higher in the bipolar group than in the healthy controls (P &lt; 0.05). Metacognitive beliefs (to a greater extent in parameters in the bipolar group) were correlated with anxiety level, depression level and self-esteem in both patient groups.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In addition to metacognitive beliefs known to be associated with ruminations in unipolar and bipolar depression, metacognitive beliefs can also be seen in association with worry. Worry-associated metacognitive beliefs should be the subject of focus in the identification of metacognitive beliefs in depression patients and in metacognitive therapy in these patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sarisoy</LastName><ForeName>Gökhan</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Psychiatry Department, School of Medicine, Ondokuz Mayis University , Samsun , Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pazvantoğlu</LastName><ForeName>Ozan</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Ozturan</LastName><ForeName>Deniz Deniz</ForeName><Initials>DD</Initials></Author><Author ValidYN="Y"><LastName>Ay</LastName><ForeName>Naile Dila</ForeName><Initials>ND</Initials></Author><Author ValidYN="Y"><LastName>Yilman</LastName><ForeName>Tuba</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Mor</LastName><ForeName>Sema</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Korkmaz</LastName><ForeName>Işil Zabun</ForeName><Initials>IZ</Initials></Author><Author ValidYN="Y"><LastName>Kaçar</LastName><ForeName>Omer Faruk</ForeName><Initials>OF</Initials></Author><Author ValidYN="Y"><LastName>Gümüş</LastName><ForeName>Kübra</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>08</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nord J Psychiatry</MedlineTA><NlmUniqueID>100927567</NlmUniqueID><ISSNLinking>0803-9488</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001007" MajorTopicYN="N">Anxiety</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="Y">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007389" MajorTopicYN="N">Internal-External Control</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012649" MajorTopicYN="N">Self Concept</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012959" MajorTopicYN="N">Socioeconomic Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>8</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>8</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>10</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23902127</ArticleId><ArticleId IdType="doi">10.3109/08039488.2013.814710</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31841251</PMID><DateCompleted><Year>2020</Year><Month>12</Month><Day>14</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1440-1819</ISSN><JournalIssue CitedMedium="Internet"><Volume>74</Volume><Issue>3</Issue><PubDate><Year>2020</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Psychiatry and clinical neurosciences</Title><ISOAbbreviation>Psychiatry Clin Neurosci</ISOAbbreviation></Journal><ArticleTitle>Altered ethanolamine plasmalogen and phosphatidylethanolamine levels in blood plasma of patients with bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>204-210</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/pcn.12967</ELocationID><Abstract><AbstractText Label="AIM" NlmCategory="OBJECTIVE">Ethanolamine-containing phospholipids are synthesized in endoplasmic reticulum (ER) and mitochondria. ER stress and mitochondrial dysfunction have been implicated in bipolar disorder (BP). In this study, we aimed to examine the relationship of ethanolamine plasmalogen (PLE) and phosphatidylethanolamine (PTE) levels in blood plasma with BP.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Plasma PLE and PTE levels were compared between 34 patients with BP (DSM-IV) and 38 healthy control participants matched for age, sex, and ethnicity (Japanese). Furthermore, the relationships of plasma PLE and PTE levels with clinical variables were explored.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Plasma PLE levels were significantly lower in patients with BP than in healthy controls (P = 0.0033). In subgroup analyses, plasma PLE levels were significantly lower in patients with BP type I (BP I) than in healthy controls (P = 0.0047); furthermore, plasma PTE levels were significantly lower in patients with BP I than in controls (P = 0.016) and patients with BP type II (BP II) (P = 0.010). Receiver-operating characteristic curve analysis revealed that the discriminatory power of plasma PTE levels for distinguishing between BP I and II was fair (area under the curve = 0.78; P = 0.0095). There were no significant correlations of plasma PLE or PTE levels with depression or manic symptoms in patients.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Plasma PLE and PTE levels were associated with BP I, but not with BP II. Moreover, plasma PTE levels differed between patients with BP I and II. Our findings highlight the importance of ethanolamine phospholipids in the pathophysiology of BP, especially BP I.</AbstractText><CopyrightInformation>© 2019 The Authors. Psychiatry and Clinical Neurosciences © 2019 Japanese Society of Psychiatry and Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ogawa</LastName><ForeName>Shintaro</ForeName><Initials>S</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-9568-8981</Identifier><AffiliationInfo><Affiliation>Department of Mental Disorder Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hattori</LastName><ForeName>Kotaro</ForeName><Initials>K</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-4411-2317</Identifier><AffiliationInfo><Affiliation>Department of Mental Disorder Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Genome Center, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ota</LastName><ForeName>Miho</ForeName><Initials>M</Initials><Identifier Source="ORCID">https://orcid.org/0000-0001-8873-0822</Identifier><AffiliationInfo><Affiliation>Department of Mental Disorder Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hidese</LastName><ForeName>Shinsuke</ForeName><Initials>S</Initials><Identifier Source="ORCID">https://orcid.org/0000-0001-7541-2075</Identifier><AffiliationInfo><Affiliation>Department of Mental Disorder Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miyakawa</LastName><ForeName>Tomoko</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Mental Disorder Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Genome Center, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matsumura</LastName><ForeName>Ryo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Medical Genome Center, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yokota</LastName><ForeName>Yuuki</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Mental Disorder Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Genome Center, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ishida</LastName><ForeName>Ikki</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Mental Disorder Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matsuo</LastName><ForeName>Junko</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Mental Disorder Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoshida</LastName><ForeName>Sumiko</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, National Center Hospital, National Center of Neurology and Psychiatry, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamazaki</LastName><ForeName>Yasuyo</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Prodrome Sciences Inc., Saskatoon, Saskatchewan, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goodenowe</LastName><ForeName>Dayan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Prodrome Sciences Inc., Saskatoon, Saskatchewan, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kunugi</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-7209-3790</Identifier><AffiliationInfo><Affiliation>Department of Mental Disorder Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>18dk0307075h0001</GrantID><Agency>Japan Agency for Medical Research and Development</Agency><Country/></Grant><Grant><GrantID>27-1</GrantID><Agency>National Center of Neurology and Psychiatry</Agency><Country/></Grant><Grant><GrantID>30-1</GrantID><Agency>National Center of Neurology and Psychiatry</Agency><Country/></Grant><Grant><GrantID>30-7</GrantID><Agency>National Center of Neurology and Psychiatry</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>02</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>Psychiatry Clin Neurosci</MedlineTA><NlmUniqueID>9513551</NlmUniqueID><ISSNLinking>1323-1316</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010714">Phosphatidylethanolamines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010955">Plasmalogens</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C020791">phosphatidal ethanolamines</NameOfSubstance></Chemical><Chemical><RegistryNumber>39382-08-6</RegistryNumber><NameOfSubstance UI="C483858">phosphatidylethanolamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059865" MajorTopicYN="N">Endoplasmic Reticulum Stress</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D028361" MajorTopicYN="N">Mitochondrial Diseases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010714" MajorTopicYN="N">Phosphatidylethanolamines</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010955" MajorTopicYN="N">Plasmalogens</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">bipolar disorder</Keyword><Keyword MajorTopicYN="N">endoplasmic reticulum stress</Keyword><Keyword MajorTopicYN="N">ethanolamine plasmalogen</Keyword><Keyword MajorTopicYN="N">mitochondrial dysfunction</Keyword><Keyword MajorTopicYN="N">phosphatidylethanolamine</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>09</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>11</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>12</Month><Day>02</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31841251</ArticleId><ArticleId IdType="doi">10.1111/pcn.12967</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. DSM-5, 5th edn. American Psychiatric Publishing, Arlington, VA, 2013.</Citation></Reference><Reference><Citation>Merikangas KR, Jin R, He JP et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch. Gen. Psychiatry 2011; 68: 241-251.</Citation></Reference><Reference><Citation>Geddes JR, Miklowitz DJ. Treatment of bipolar disorder. Lancet 2013; 381: 1672-1682.</Citation></Reference><Reference><Citation>Ogawa S, Hattori K, Sasayama D et al. Reduced cerebrospinal fluid ethanolamine concentration in major depressive disorder. Sci. Rep. 2015; 5: 7796.</Citation></Reference><Reference><Citation>Dorninger F, Brodde A, Braverman NE et al. Homeostasis of phospholipids - The level of phosphatidylethanolamine tightly adapts to changes in ethanolamine plasmalogens. Biochim. Biophys. Acta 2015; 1851: 117-128.</Citation></Reference><Reference><Citation>Patel D, Witt SN. Ethanolamine and Phosphatidylethanolamine: Partners in Health and Disease. Oxid. Med. Cell. Longev. 2017; 2017: 4829180.</Citation></Reference><Reference><Citation>Arthur G, Page L. Synthesis of phosphatidylethanolamine and ethanolamine plasmalogen by the CDP-ethanolamine and decarboxylase pathways in rat heart, kidney and liver. Biochem. J. 1991; 273: 121-125.</Citation></Reference><Reference><Citation>Braverman NE, Moser AB. Functions of plasmalogen lipids in health and disease. Biochim. Biophys. Acta 2012; 1822: 1442-1452.</Citation></Reference><Reference><Citation>Vance JE. Phosphatidylserine and phosphatidylethanolamine in mammalian cells: Two metabolically related aminophospholipids. J. Lipid Res. 2008; 49: 1377-1387.</Citation></Reference><Reference><Citation>Lindholm D, Korhonen L, Eriksson O, Koks S. Recent insights into the role of unfolded protein response in ER stress in health and disease. Front. Cell Dev. Biol. 2017; 5: 48.</Citation></Reference><Reference><Citation>So J, Warsh JJ, Li PP. Impaired endoplasmic reticulum stress response in B-lymphoblasts from patients with bipolar-I disorder. Biol. Psychiatry 2007; 62: 141-147.</Citation></Reference><Reference><Citation>Kato T. Neurobiological basis of bipolar disorder: Mitochondrial dysfunction hypothesis and beyond. Schizophr. Res. 2017; 187: 62-66.</Citation></Reference><Reference><Citation>Breen MS, White CH, Shekhtman T et al. Lithium-responsive genes and gene networks in bipolar disorder patient-derived lymphoblastoid cell lines. Pharmacogenomics J. 2016; 16: 446-453.</Citation></Reference><Reference><Citation>Kim AJ, Shi Y, Austin RC, Werstuck GH. Valproate protects cells from ER stress-induced lipid accumulation and apoptosis by inhibiting glycogen synthase kinase-3. J. Cell Sci. 2005; 118: 89-99.</Citation></Reference><Reference><Citation>Bachmann RF, Wang Y, Yuan P et al. Common effects of lithium and valproate on mitochondrial functions: Protection against methamphetamine-induced mitochondrial damage. Int. J. Neuropsychopharmacol. 2009; 12: 805-822.</Citation></Reference><Reference><Citation>Wood PL, Filiou MD, Otte DM, Zimmer A, Turck CW. Lipidomics reveals dysfunctional glycosynapses in schizophrenia and the G72/G30 transgenic mouse. Schizophr. Res. 2014; 159: 365-369.</Citation></Reference><Reference><Citation>Wood PL, Holderman NR. Dysfunctional glycosynapses in schizophrenia: Disease and regional specificity. Schizophr. Res. 2015; 166: 235-237.</Citation></Reference><Reference><Citation>Beasley CL, Honer WG, Ramos-Miguel A, Vila-Rodriguez F, Barr AM. Prefrontal fatty acid composition in schizophrenia and bipolar disorder: Association with reelin expression. Schizophr. Res. 2017. https://doi.org/10.1016/j.schres.2017.05.033</Citation></Reference><Reference><Citation>Ghosh S, Dyer RA, Beasley CL. Evidence for altered cell membrane lipid composition in postmortem prefrontal white matter in bipolar disorder and schizophrenia. J. Psychiatr. Res. 2017; 95: 135-142.</Citation></Reference><Reference><Citation>Taha AY, Cheon Y, Ma K, Rapoport SI, Rao JS. Altered fatty acid concentrations in prefrontal cortex of schizophrenic patients. J. Psychiatr. Res. 2013; 47: 636-643.</Citation></Reference><Reference><Citation>McNamara RK, Moser AB, Jones RI et al. Familial risk for bipolar disorder is not associated with impaired peroxisomal function: Dissociation from docosahexaenoic acid deficits. Psychiatry Res. 2016; 246: 803-807.</Citation></Reference><Reference><Citation>Aizawa E, Tsuji H, Asahara T et al. Bifidobacterium and lactobacillus counts in the gut microbiota of patients with bipolar disorder and healthy controls. Front. Psych. 2018; 9: 730.</Citation></Reference><Reference><Citation>Hori H, Yamamoto N, Teraishi T et al. Cognitive effects of the ANK3 risk variants in patients with bipolar disorder and healthy individuals. J. Affect. Disord. 2014; 158: 90-96.</Citation></Reference><Reference><Citation>Ota M, Noda T, Sato N et al. The use of diffusional kurtosis imaging and neurite orientation dispersion and density imaging of the brain in bipolar disorder. J. Affect. Disord. 2019; 251: 231-234.</Citation></Reference><Reference><Citation>Sasayama D, Hori H, Teraishi T et al. More severe impairment of manual dexterity in bipolar disorder compared to unipolar major depression. J. Affect. Disord. 2012; 136: 1047-1052.</Citation></Reference><Reference><Citation>Matsuo J, Ota M, Hidese S et al. Sensorimotor gating in depressed and euthymic patients with bipolar disorder: Analysis on prepulse inhibition of acoustic startle response stratified by gender and state. Front. Psych. 2018; 9: 123.</Citation></Reference><Reference><Citation>Teixeira AL, Colpo GD, Fries GR, Bauer IE, Selvaraj S. Biomarkers for bipolar disorder: Current status and challenges ahead. Expert Rev. Neurother. 2019; 19: 67-81.</Citation></Reference><Reference><Citation>Atagun MI, Sikoglu EM, Can SS et al. Neurochemical differences between bipolar disorder type I and II in superior temporal cortices: A proton magnetic resonance spectroscopy study. J. Affect. Disord. 2018; 235: 15-19.</Citation></Reference><Reference><Citation>Lee SY, Chen SL, Chen SH et al. The COMT and DRD3 genes interacted in bipolar I but not bipolar II disorder. World J. Biol. Psychiatry 2011; 12: 385-391.</Citation></Reference><Reference><Citation>Kato T, Hamakawa H, Shioiri T et al. Choline-containing compounds detected by proton magnetic resonance spectroscopy in the basal ganglia in bipolar disorder. J. Psychiatry Neurosci. 1996; 21: 248-254.</Citation></Reference><Reference><Citation>Sheehan DV, Lecrubier Y, Sheehan KH et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry 1998; 59: 22-33 quiz 34-57.</Citation></Reference><Reference><Citation>Otsubo T, Tanaka K, Koda R et al. Reliability and validity of Japanese version of the Mini-International Neuropsychiatric Interview. Psychiatry Clin. Neurosci. 2005; 59: 517-526.</Citation></Reference><Reference><Citation>American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV. American Psychiatric Association, Washington, D.C., 1994.</Citation></Reference><Reference><Citation>Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 1960; 23: 56-62.</Citation></Reference><Reference><Citation>Tabuse H, Kalali A, Azuma H et al. The new GRID Hamilton Rating Scale for Depression demonstrates excellent inter-rater reliability for inexperienced and experienced raters before and after training. Psychiatry Res. 2007; 153: 61-67.</Citation></Reference><Reference><Citation>Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: Reliability, validity and sensitivity. Br. J. Psychiatry 1978; 133: 429-435.</Citation></Reference><Reference><Citation>Naganuma H. Manic episode. Jpn J Clin Psychiatry 1999; Suppl.(Dec): 128-134. (in Japanese).</Citation></Reference><Reference><Citation>Inagaki A, Inada T, Fujii Y, Yagi G. Equivalent Dose of Psychotropics. Seiwa Shoten, Tokyo, 2013.</Citation></Reference><Reference><Citation>Maeba R, Nishimukai M, Sakasegawa S, Sugimori D, Hara H. Plasma/serum plasmalogens: Methods of analysis and clinical significance. Adv. Clin. Chem. 2015; 70: 31-94.</Citation></Reference><Reference><Citation>Paul S, Lancaster GI, Meikle PJ. Plasmalogens: A potential therapeutic target for neurodegenerative and cardiometabolic disease. Prog. Lipid Res. 2019; 74: 186-195.</Citation></Reference><Reference><Citation>Ifuku M, Katafuchi T, Mawatari S et al. Anti-inflammatory/anti-amyloidogenic effects of plasmalogens in lipopolysaccharide-induced neuroinflammation in adult mice. J. Neuroinflammation 2012; 9: 197.</Citation></Reference><Reference><Citation>Kim HK, Andreazza AC, Elmi N, Chen W, Young LT. Nod-like receptor pyrin containing 3 (NLRP3) in the post-mortem frontal cortex from patients with bipolar disorder: A potential mediator between mitochondria and immune-activation. J. Psychiatr. Res. 2016; 72: 43-50.</Citation></Reference><Reference><Citation>Kim HK, Chen W, Andreazza AC. The potential role of the NLRP3 inflammasome as a link between mitochondrial complex I dysfunction and inflammation in bipolar disorder. Neural Plast. 2015; 2015: 408136.</Citation></Reference><Reference><Citation>Munakata K, Tanaka M, Mori K et al. Mitochondrial DNA 3644T-&gt;C mutation associated with bipolar disorder. Genomics 2004; 84: 1041-1050.</Citation></Reference><Reference><Citation>Kasahara T, Ishiwata M, Kakiuchi C et al. Enrichment of deleterious variants of mitochondrial DNA polymerase gene (POLG1) in bipolar disorder. Psychiatry Clin. Neurosci. 2017; 71: 518-529.</Citation></Reference><Reference><Citation>Kazuno AA, Munakata K, Mori K et al. Mitochondrial DNA haplogroup analysis in patients with bipolar disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2009; 150B: 243-247.</Citation></Reference><Reference><Citation>Munakata K, Fujii K, Nanko S, Kunugi H, Kato T. Sequence and functional analyses of mtDNA in a maternally inherited family with bipolar disorder and depression. Mutat. Res. 2007; 617: 119-124.</Citation></Reference><Reference><Citation>Kakiuchi C, Ishiwata M, Nanko S et al. Association analysis of HSP90B1 with bipolar disorder. J. Hum. Genet. 2007; 52: 794-803.</Citation></Reference><Reference><Citation>Kakiuchi C, Ishiwata M, Nanko S et al. Functional polymorphisms of HSPA5: Possible association with bipolar disorder. Biochem. Biophys. Res. Commun. 2005; 336: 1136-1143.</Citation></Reference><Reference><Citation>Kakiuchi C, Iwamoto K, Ishiwata M et al. Impaired feedback regulation of XBP1 as a genetic risk factor for bipolar disorder. Nat. Genet. 2003; 35: 171-175.</Citation></Reference><Reference><Citation>Uemura T, Green M, Corson TW, Perova T, Li PP, Warsh JJ. Bcl-2 SNP rs956572 associates with disrupted intracellular calcium homeostasis in bipolar I disorder. Bipolar Disord. 2011; 13: 41-51.</Citation></Reference><Reference><Citation>Bai YM, Su TP, Tsai SJ et al. Comparison of inflammatory cytokine levels among type I/type II and manic/hypomanic/euthymic/depressive states of bipolar disorder. J. Affect. Disord. 2014; 166: 187-192.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">23332644</PMID><DateCompleted><Year>2013</Year><Month>11</Month><Day>15</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>150</Volume><Issue>1</Issue><PubDate><Year>2013</Year><Month>Aug</Month><Day>15</Day></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>A three generations nation-wide population study of family load estimates in bipolar disorder with different age at onset.</ArticleTitle><Pagination><MedlinePgn>146-51</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2012.12.013</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0165-0327(12)00846-4</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">This nation-wide register-based study investigates how often bipolar disorder (BD) occurs in affected families compared to control families by estimating the family load as a random effect; this effect measures the degree of dependence among family members in relation to BD. Furthermore, the study addresses the impact of certain risk factors, namely, sex, age at onset of BD, degree of urbanization, year of birth, month of birth, and maternal and paternal age at birth.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">A total of N=1204 children and adolescent psychiatric cases born between 1950 and 1997 and registered in the Danish Central Psychiatric Register (DPCR) developed BD before the age of 58 years. N=3553 controls without any psychiatric diagnosis were matched for age, gender, and region of residence. Psychiatric diagnoses were also obtained on the relatives, e.g. parents, siblings, and offspring as a part of the Danish Three Generation Study (3GS). A family component was obtained by using different regression models.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Familial factors accounted for 20% of the variation in disease outcome when controlling for year and month of birth, sex, and degree of urbanization. Only female sex was associated with an increased hazard ratio of BD. Also having a mother, father or a sibling with the disorder was proven to be a significant risk factor. Furthermore, case relatives did not develop BD earlier than control relatives.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These findings based on a very large and representative dataset provide further and very solid evidence for the high family aggregation of BD.</AbstractText><CopyrightInformation>Copyright © 2012 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Helenius</LastName><ForeName>Dorte</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Research Unit of Child and Adolescent Psychiatry, Aalborg Psychiatric University Hospital, Mølleparkvej 10, 9000 Aalborg, Denmark. dorte.helenius@rn.dk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jørgensen</LastName><ForeName>Povl Munk</ForeName><Initials>PM</Initials></Author><Author ValidYN="Y"><LastName>Steinhausen</LastName><ForeName>Hans-Christoph</ForeName><Initials>HC</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>01</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003718" MajorTopicYN="N">Denmark</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005190" MajorTopicYN="N">Family</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="N">Registries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bipolar disorder</Keyword><Keyword MajorTopicYN="N">Early onset</Keyword><Keyword MajorTopicYN="N">Family aggregation</Keyword><Keyword MajorTopicYN="N">Register study</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>09</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2012</Year><Month>12</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>12</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>1</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>1</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>11</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23332644</ArticleId><ArticleId IdType="pii">S0165-0327(12)00846-4</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2012.12.013</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">25462394</PMID><DateCompleted><Year>2015</Year><Month>08</Month><Day>13</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>173</Volume><PubDate><Year>2015</Year><Month>Mar</Month><Day>01</Day></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Temperament and prodromal symptoms prior to first manic/hypomanic episodes: results from a pilot study.</ArticleTitle><Pagination><MedlinePgn>39-44</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2014.10.031</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0165-0327(14)00653-3</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Prodromal symptoms prior to first episode mania/hypomania have been reported. However, the relationship between temperament and manic/hypomanic prodromal symptoms has not been investigated. We hypothesized that subjects scoring higher on cyclothymic and irritable temperament scales show more manic/hypomanic prodromal symptoms.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Euthymic patients diagnosed with bipolar-I or -II disorder within 8 years underwent retrospective assessments with the Temperament Evaluation of Memphis, Pisa, Paris and San Diego-autoquestionnaire (TEMPS-A) and the Bipolar Prodrome Symptom Scale-Retrospective (BPSS-R).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 39 subjects (36.1 ± 9.9 years, females = 59%, bipolar-I = 62%) 100% and 92.3% reported subthreshold mania (mean = 7.4 ± 2.9) or subthreshold depressive symptoms (mean = 2.4 ± 1.5), and 87.2% and 43.6% reported general psychopathology (mean = 3.2 ± 2.0) or subthreshold psychotic symptoms (mean = 0.7 ± 1.0) prior to their first hypo-/manic episode. Subjects with higher cyclothymic and irritable temperament scores showed more subthreshold symptoms prior to the first manic/hypomanic episode, mainly subthreshold hypo-/manic symptoms (cyclothymic temperament r = 0.430; p = 0.006; irritable temperament r = 0.330; p = 0.040), general psychopathology symptoms (cyclothymic temperament r = 0.316; p = 0.05; irritable temperament r = 0.349; p = 0.029) and subthreshold psychotic symptoms (cyclothymic temperament r = 0.413; p = 0.009). In regression analyses, cyclothymic temperament explained 16.1% and 12.5% of the variance of the BPSS-R total score (p = 0.045) and psychosis subscore (p = 0.029).</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">Retrospective study, no control group, small sample size.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">We present data, which indicate a relationship between cyclothymic and irritable temperament and prodromal symptoms prior to the first manic/hypomanic episode. These findings support the notion that assessing cyclothymic temperament to identify people at-risk of developing bipolar-I and -II disorder may help to increase the predictive validity of applied at-risk criteria.</AbstractText><CopyrightInformation>Copyright © 2014 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zeschel</LastName><ForeName>Eike</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Ruhr-University Bochum, LWL University Hospital, Bochum, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bingmann</LastName><ForeName>Tiffany</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, University of Cologne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bechdolf</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, University of Cologne, Germany. Electronic address: andreas.bechdolf@vivantes.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krüger-Oezguerdal</LastName><ForeName>Seza</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Ruhr-University Bochum, LWL University Hospital, Bochum, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Correll</LastName><ForeName>Christoph U</ForeName><Initials>CU</Initials><AffiliationInfo><Affiliation>Division of Psychiatry Research, The Zucker Hillside Hospital, Glen Oaks, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leopold</LastName><ForeName>Karolina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, Carl Gustav Carus University Hospital, Technische Universität Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pfennig</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, Carl Gustav Carus University Hospital, Technische Universität Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bauer</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, Carl Gustav Carus University Hospital, Technische Universität Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Juckel</LastName><ForeName>Georg</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Ruhr-University Bochum, LWL University Hospital, Bochum, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>10</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007508" MajorTopicYN="N">Irritable Mood</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062706" MajorTopicYN="Y">Prodromal Symptoms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013694" MajorTopicYN="Y">Temperament</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bipolar disorder</Keyword><Keyword MajorTopicYN="N">Hypomania</Keyword><Keyword MajorTopicYN="N">Mania</Keyword><Keyword MajorTopicYN="N">Prodrome</Keyword><Keyword MajorTopicYN="N">Temperament</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>03</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>10</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>10</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>12</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>12</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>8</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25462394</ArticleId><ArticleId IdType="pii">S0165-0327(14)00653-3</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2014.10.031</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11311838</PMID><DateCompleted><Year>2002</Year><Month>01</Month><Day>25</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0738-3991</ISSN><JournalIssue CitedMedium="Print"><Volume>43</Volume><Issue>1</Issue><PubDate><Year>2001</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Patient education and counseling</Title><ISOAbbreviation>Patient Educ Couns</ISOAbbreviation></Journal><ArticleTitle>Usefulness of the retrospective Life-Chart method manual in outpatients with a mood disorder: a feasibility study.</ArticleTitle><Pagination><MedlinePgn>43-8</MedlinePgn></Pagination><Abstract><AbstractText>The aim of this project was to evaluate whether the Life-Chart Manual (LCM) can help patients to complete their own Life-Chart (LC). All patients were recruited via the outpatient department for affective disorders of the Academic Hospital Maastricht. They were diagnosed as having a unipolar or bipolar disorder according to DSM-IV criteria. Following a short briefing interview, these patients were asked to complete their own LC for the last 6 years, using the manual. Seventy-four patients were selected, of whom 44 were willing to participate in the study. About half of these patients (n=20) completed the LC adequately (60-80% of the items completed) with only minimal professional help. Although patients found it difficult to complete the LC, most considered it worthwhile. The LCM is an adequate tool to help patients with a major affective disorder to complete their own LC with minimal professional assistance.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Honig</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Maastricht, Academic Hospital Maastricht, PO Box 5800, 6202 AZ, Maastricht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hendriks</LastName><ForeName>C H</ForeName><Initials>CH</Initials></Author><Author ValidYN="Y"><LastName>Akkerhuis</LastName><ForeName>G W</ForeName><Initials>GW</Initials></Author><Author ValidYN="Y"><LastName>Nolen</LastName><ForeName>W A</ForeName><Initials>WA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Patient Educ Couns</MedlineTA><NlmUniqueID>8406280</NlmUniqueID><ISSNLinking>0738-3991</ISSNLinking></MedlineJournalInfo><CitationSubset>N</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005240" MajorTopicYN="N">Feasibility Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008016" MajorTopicYN="Y">Life Change Events</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008370" MajorTopicYN="Y">Manuals as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009426" MajorTopicYN="N" Type="Geographic">Netherlands</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018709" MajorTopicYN="N">Statistics, Nonparametric</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>4</Month><Day>20</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>1</Month><Day>26</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>4</Month><Day>20</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11311838</ArticleId><ArticleId IdType="pii">S0738399100001440</ArticleId><ArticleId IdType="doi">10.1016/s0738-3991(00)00144-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12165371</PMID><DateCompleted><Year>2002</Year><Month>10</Month><Day>30</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0920-9964</ISSN><JournalIssue CitedMedium="Print"><Volume>57</Volume><Issue>1</Issue><PubDate><Year>2002</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>Schizophrenia research</Title><ISOAbbreviation>Schizophr Res</ISOAbbreviation></Journal><ArticleTitle>Historical aspects of the dichotomy between manic-depressive disorders and schizophrenia.</ArticleTitle><Pagination><MedlinePgn>5-13</MedlinePgn></Pagination><Abstract><AbstractText>The history of psychiatric classification is highly complex and this presentation must be restricted to a simplified overview. Guislain [Guislain, J., 1833. Traité des phrénopathies ou doctrine nouvelle des maladies mentales. Etablissement Encyclopédique, Brussels] and Zeller [Beil. Med. Corresp.-Bl. Würtemb. Arztl. Ver. 7 (1837) 321] established a unitarian concept of psychiatric disorder, permutations of which have survived until the present day. Kraepelin's [Kraepelin, E., 1899. Psychiatrie. Ein Lehrbuch für Studierende und Arzte (6th edn.). Johann Ambrosius Barth, Leipzig] dichotomy between "manic-depressive insanity" and dementia praecox was built mainly on Kahlbaum's [Kahlbaum, K., 1863. Die Gruppirung der Psychischen Krankheiten und die Eintheilung der Seelenstörungen. AW Kafemann, Danzig] classification, which took clinical symptoms, course and outcome into account. Kraepelin's well-accepted approach sought to provide a basis for diagnosis, prognosis, choice of treatment and causal research. Kraepelin's dichotomy came to be questioned on several grounds: (1) doubts about his unification of bipolar disorder [Gaz. Hôp. 24 (1851) 18] with melancholia, (2) doubts about the significance of Kraepelin's diagnostic groups for causal research [Z. Gesamte Neurol. Psychiatr. 12 (1912) 540], illustrated best by the work of Bonhoeffer [Bonhoefferm, K., 1912. Die symptomatischen Psychosen im Gefolge akuter Infektionen, Allgemeinerkrankungen und innerer Krankheiten. In: Aschaffenburg, G. (Ed.), Handbuch der Psychiatrie, 3. Abt., 1. Hälfte. Deuticke, Leipzig Wien], (3) the complex psychopathological descriptions and classifications of numerous subgroups of psychoses by Kleist [Monatsschr. Psychiatr. Neurol. 125 (1953) 526] and Leonhard [Leonhard, K., 1968. Aufteilung der endogenen Psychosen (4th edn.). Akademie Verlag, Berlin] and (4) description of the psychoses between affective and schizophrenic disorders (intermediate psychoses, mixed psychoses, schizo-affective psychoses) beginning with Kehrer and Kretschmer [Kehrer, F., Kretschmer, E., 1924. Die Veranlagung zu seelischen Störungen. (Monographien aus dem Gesamtgebiete der Neurologie 40) Springer, Berlin] and persisting up to the modern findings of a continuum between the two major groups of psychiatric disorders. Kraepelin's simplification has so far been more successful than the Kleist-Leonhard approach, but the modern and more descriptive trend in psychiatric classification favours the syndromal concept of Hoche and the concepts of continua between affective and schizophrenic disorders and between normal and pathological behaviour.</AbstractText><CopyrightInformation>Copyright 2002 Elsevier Science B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Angst</LastName><ForeName>Jules</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Epidemiological Research, Zurich University Psychiatric Hospital, Lenggstrasse 31, Mail Box 68, 8029 Zurich, Switzerland. jangst@bli.unizh.ch</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016456">Historical Article</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Schizophr Res</MedlineTA><NlmUniqueID>8804207</NlmUniqueID><ISSNLinking>0920-9964</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000266" MajorTopicYN="Y">history</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049672" MajorTopicYN="N">History, 19th Century</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049673" MajorTopicYN="N">History, 20th Century</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000266" MajorTopicYN="N">history</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000266" MajorTopicYN="Y">history</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>8</Month><Day>8</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>11</Month><Day>1</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>8</Month><Day>8</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12165371</ArticleId><ArticleId IdType="pii">S0920996402003286</ArticleId><ArticleId IdType="doi">10.1016/s0920-9964(02)00328-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">29525354</PMID><DateCompleted><Year>2018</Year><Month>09</Month><Day>12</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>234</Volume><PubDate><Year>2018</Year><Month>07</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Clinical and psychopathological features associated with treatment-emergent mania in bipolar-II depressed outpatients exposed to antidepressants.</ArticleTitle><Pagination><MedlinePgn>131-138</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0165-0327(17)32518-1</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2018.02.085</ELocationID><Abstract><AbstractText Label="BACKGROUND">Treatment-emergent affective switch (TEAS), including treatment-emergent mania (TEM), carry significant burden in the clinical management of bipolar depression, whereas the use of antidepressants raises both efficacy, safety and tolerability concerns. The present study assesses the prevalence and clinical correlates of TEM in selected sample of Bipolar Disorder (BD) Type-II (BD-II) acute depression outpatients.</AbstractText><AbstractText Label="METHODS">Post-hoc analysis of the clinical and psychopathological features associated with TEM among 91 BD-II depressed outpatients exposed to antidepressants.</AbstractText><AbstractText Label="RESULTS">Second-generation antipsychotics (SGA) (p = .005), lithium (≤ .001), cyclothymic/irritable/hyperthymic temperaments (p = ≤ .001; p = .001; p = .003, respectively), rapid-cycling (p = .005) and depressive mixed features (p = .003) differed between TEM<sup>+</sup> cases vs. TEM<sup>-</sup> controls. Upon multinomial logistic regression, the accounted psychopathological features correctly classified as much as 88.6% of TEM<sup>+</sup> cases (35/91 overall sample, or 38.46% of the sample), yet not statistically significantly [Exp(B) = .032; p = ns]. Specifically, lithium [B = - 2.385; p = .001], SGAs [B = - 2.354; p = .002] predicted lower rates of TEM<sup>+</sup> in contrast to the number of lifetime previous psychiatric hospitalizations [B = 2.380; p = .002], whereas mixed features did not [B = 1.267; p = ns].</AbstractText><AbstractText Label="LIMITATIONS">Post-hoc analysis. Lack of systematic pharmacological history record; chance of recall bias and Berkson's biases. Permissive operational criterion for TEM. Relatively small sample size.</AbstractText><AbstractText Label="CONCLUSIONS">Cyclothymic temperament and mixed depression discriminated TEM<sup>+</sup> between TEM<sup>-</sup> cases, although only lithium and the SGAs reliably predicted TEM<sup>+/-</sup> grouping. Larger-sampled/powered longitudinal replication studies are warranted to allow firm conclusions on the matter, ideally contributing to the identification of clear-cut sub-phenotypes of BD towards patient-tailored-pharmacotherapy.</AbstractText><CopyrightInformation>Copyright © 2018 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fornaro</LastName><ForeName>Michele</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>New York State Psychiatric Institute, Columbia University, NYC, NY, USA; Federico II University, Section of Psychiatry, Department of Neuroscience, Reproductive Sciences and Odontostomatology, Naples, Italy. Electronic address: dott.fornaro@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anastasia</LastName><ForeName>Annalisa</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Federico II University, Section of Psychiatry, Department of Neuroscience, Reproductive Sciences and Odontostomatology, Naples, Italy. Electronic address: annalisa.anastasia@yahoo.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Monaco</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Medicine, Surgery and Dentistry 'Scuola Medica Salernitana', Section of Neuroscience, University of Salerno, Salerno, Italy. Electronic address: fmonaco1980@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Novello</LastName><ForeName>Stefano</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Federico II University, Section of Psychiatry, Department of Neuroscience, Reproductive Sciences and Odontostomatology, Naples, Italy. Electronic address: stefano.novello1@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fusco</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Federico II University, Section of Psychiatry, Department of Neuroscience, Reproductive Sciences and Odontostomatology, Naples, Italy. Electronic address: andreafusco1990@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iasevoli</LastName><ForeName>Felice</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Federico II University, Section of Psychiatry, Department of Neuroscience, Reproductive Sciences and Odontostomatology, Naples, Italy. Electronic address: felix_ias@hotmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Berardis</LastName><ForeName>Domenico</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>National Health Service, Department of Mental Health, Psychiatric Service of Diagnosis and Treatment, Hospital "G. Mazzini", ASL 4, 64100 Teramo, Italy. Electronic address: dodebera@aliceposta.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Veronese</LastName><ForeName>Nicola</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>National Research Council, Ageing Branch, Padua, Italy. Electronic address: ilmannato@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Solmi</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Azienda Ospedaliera di Padova, Padua Hospital, Psychiatry Unit, Padua, Italy. Electronic address: marco.solmi83@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Bartolomeis</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Federico II University, Section of Psychiatry, Department of Neuroscience, Reproductive Sciences and Odontostomatology, Naples, Italy. Electronic address: adebarto@unina.it.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>03</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010045" MajorTopicYN="N">Outpatients</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Antidepressant</Keyword><Keyword MajorTopicYN="Y">Bipolar Disorder (BD)</Keyword><Keyword MajorTopicYN="Y">Depression</Keyword><Keyword MajorTopicYN="Y">Treatment-emergent-mania</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>12</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>01</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>02</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>3</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>9</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>3</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29525354</ArticleId><ArticleId IdType="pii">S0165-0327(17)32518-1</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2018.02.085</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">4580489</PMID><DateCompleted><Year>1973</Year><Month>11</Month><Day>03</Day></DateCompleted><DateRevised><Year>2019</Year><Month>10</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0037-7856</ISSN><JournalIssue CitedMedium="Print"><Volume>7</Volume><Issue>5</Issue><PubDate><Year>1973</Year><Month>May</Month></PubDate></JournalIssue><Title>Social science &amp; medicine</Title><ISOAbbreviation>Soc Sci Med</ISOAbbreviation></Journal><ArticleTitle>Occupational class and symptoms of depression.</ArticleTitle><Pagination><MedlinePgn>327-40</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bagley</LastName><ForeName>C</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Soc Sci Med</MedlineTA><NlmUniqueID>0121744</NlmUniqueID><ISSNLinking>0037-7856</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001008" MajorTopicYN="N">Anxiety Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004522" MajorTopicYN="N">Educational Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006677" MajorTopicYN="N">Histrionic Personality Disorder</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009790" MajorTopicYN="N">Occupations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012923" MajorTopicYN="Y">Social Class</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012937" MajorTopicYN="N">Social Mobility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012959" MajorTopicYN="N">Socioeconomic Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013405" MajorTopicYN="N">Suicide</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>71</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1973</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1973</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1973</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">4580489</ArticleId><ArticleId IdType="doi">10.1016/0037-7856(73)90042-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">27882644</PMID><DateCompleted><Year>2017</Year><Month>08</Month><Day>04</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1399-5618</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>8</Issue><PubDate><Year>2016</Year><Month>12</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Sleep-wake cycle phenotypes in young people with familial and non-familial mood disorders.</ArticleTitle><Pagination><MedlinePgn>642-649</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/bdi.12450</ELocationID><Abstract><AbstractText Label="OBJECTIVES">Converging evidence identifies that the offspring of parents with bipolar disorder (BD), individuals at clinical high risk of BD, and young people with recent onset BD may differ from other clinical cases or healthy controls in terms of sleep-wake profiles. However, it is possible that these differences may reflect current mental state, subtype of mood disorder, or familial traits. This study aimed to determine objective and subjective sleep-wake profiles in individuals aged 15-25 years with a current major depressive episode, in relation to familial traits.</AbstractText><AbstractText Label="METHODS">Frequency matching was employed to ensure that each individual with a confirmed family history of BD (FH+) could be compared to four controls who did not have a familial mood disorder (FH-). Pre-selected objective actigraphy and subjective Pittsburgh Sleep Quality Index (PSQI) ratings were compared using one-way analysis of variance (ANOVA) and applying the Benjamini-Hochberg (BH) correction for false discoveries.</AbstractText><AbstractText Label="RESULTS">The sample comprised 60 individuals with a mean age of 19 years. The FH+ (n=12) and FH- groups (n=48) differed on three key sleep parameters: mean sleep duration on week nights (P=.049), variability in waking after sleep onset (P=.038), and daily disturbances (PSQI dimension of sleep disturbance and daytime dysfunction; P=.01).</AbstractText><AbstractText Label="CONCLUSIONS">The sleep profiles we identified in this study, especially the daily disturbances phenotype, provide support for research into endophenotypes for BD. Also, the findings may offer the opportunity for more tailored, personalized interventions that target specific components of the sleep-wake cycle in individuals with a family history of BD.</AbstractText><CopyrightInformation>© 2016 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Scott</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Academic Psychiatry, Institute of Neuroscience, Newcastle University, Newcastle, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naismith</LastName><ForeName>Sharon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Charles Perkins Centre, Brain and Mind Centre, The University of Sydney, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grierson</LastName><ForeName>Ashlee</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Brain and Mind Centre, The University of Sydney, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carpenter</LastName><ForeName>Joanne</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-9766-6700</Identifier><AffiliationInfo><Affiliation>Brain and Mind Centre, The University of Sydney, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hermens</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Brain and Mind Centre, The University of Sydney, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scott</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Brain and Mind Centre, The University of Sydney, Sydney, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Notre Dame University, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hickie</LastName><ForeName>Ian</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Brain and Mind Centre, The University of Sydney, Sydney, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>11</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D056044" MajorTopicYN="N">Actigraphy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="Y">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008487" MajorTopicYN="Y">Medical History Taking</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019964" MajorTopicYN="Y">Mood Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012890" MajorTopicYN="N">Sleep</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020178" MajorTopicYN="Y">Sleep Disorders, Circadian Rhythm</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Pittsburgh Sleep Quality Index (PSQI)</Keyword><Keyword MajorTopicYN="Y">actigraphy</Keyword><Keyword MajorTopicYN="Y">biomarkers</Keyword><Keyword MajorTopicYN="Y">bipolar disorder</Keyword><Keyword MajorTopicYN="Y">circadian</Keyword><Keyword MajorTopicYN="Y">familial</Keyword><Keyword MajorTopicYN="Y">offspring</Keyword><Keyword MajorTopicYN="Y">phenotypes</Keyword><Keyword MajorTopicYN="Y">sleep</Keyword><Keyword MajorTopicYN="Y">sleep homeostasis</Keyword><Keyword MajorTopicYN="Y">unipolar disorder</Keyword><Keyword MajorTopicYN="Y">variability</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>05</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>10</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>11</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>8</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>11</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27882644</ArticleId><ArticleId IdType="doi">10.1111/bdi.12450</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">2673478</PMID><DateCompleted><Year>1989</Year><Month>10</Month><Day>18</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0007-1250</ISSN><JournalIssue CitedMedium="Print"><Volume>154</Volume><PubDate><Year>1989</Year><Month>Jan</Month></PubDate></JournalIssue><Title>The British journal of psychiatry : the journal of mental science</Title><ISOAbbreviation>Br J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>The switch mechanism and the bipolar/unipolar dichotomy.</ArticleTitle><Pagination><MedlinePgn>48-51</MedlinePgn></Pagination><Abstract><AbstractText>During open trials of intravenous and oral S-adenosyl methionine (SAM) and a placebo-controlled trial of intravenous SAM in 29 patients, 25 patients had SAM and four had placebo (27 courses of SAM, two of the patients receiving two trials a piece). Nine of 11 bipolar patients (all SAM-treated) switched into elevated mood state (hypomania, mania and euphoria) and two did not respond. Six endogenous unipolar patients improved and five did not. No non-endogenous patient or placebo patient responded for more than 14 days. No unipolar patient switched into elated mood. In eleven (38%) trials and nine (33%) patients there was a switch from depression to elation. Biochemical data from the cerebrospinal fluid of eight patients suggested that the role of the dopaminergic system should be further explored.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Carney</LastName><ForeName>M W</ForeName><Initials>MW</Initials><AffiliationInfo><Affiliation>Northwick Park Hospital, Harrow, Middlesex.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chary</LastName><ForeName>T K</ForeName><Initials>TK</Initials></Author><Author ValidYN="Y"><LastName>Bottiglieri</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Reynolds</LastName><ForeName>E H</ForeName><Initials>EH</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D018848">Controlled Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Br J Psychiatry</MedlineTA><NlmUniqueID>0342367</NlmUniqueID><ISSNLinking>0007-1250</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>7LP2MPO46S</RegistryNumber><NameOfSubstance UI="D012436">S-Adenosylmethionine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Br J Psychiatry. 1989 Jun;154:884</RefSource><PMID Version="1">2631713</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005059" MajorTopicYN="N">Euphoria</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007275" MajorTopicYN="N">Injections, Intravenous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012436" MajorTopicYN="N">S-Adenosylmethionine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1989</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1989</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1989</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2673478</ArticleId><ArticleId IdType="pii">S0007125000225129</ArticleId><ArticleId IdType="doi">10.1192/bjp.154.1.48</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">32553378</PMID><DateCompleted><Year>2021</Year><Month>02</Month><Day>15</Day></DateCompleted><DateRevised><Year>2021</Year><Month>07</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>272</Volume><PubDate><Year>2020</Year><Month>07</Month><Day>01</Day></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Cognitive impairment in individuals with bipolar disorder with and without comorbid alcohol and/or cocaine use disorders.</ArticleTitle><Pagination><MedlinePgn>355-362</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0165-0327(19)31322-9</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2020.03.179</ELocationID><Abstract><AbstractText Label="BACKGROUND">Bipolar disorder (BD) frequently co-occurs with substance use disorders (SUDs), and both are associated with cognitive impairment. This study compares cognition between individuals with BD with and without current alcohol use disorder (AUD), cocaine use disorder (CUD), or both, as these disorders may be linked with additive cognitive impairment.</AbstractText><AbstractText Label="METHODS">Baseline data were analyzed from five clinical studies of individuals with the aforementioned disorders (N = 373). Participants were grouped as follows: BD-only, BD + AUD, BD + CUD, or BD + AUD + CUD. Cognition was assessed with the Rey Auditory Verbal Learning Test (RAVLT) (verbal learning and memory) and Stroop Color Word Test (executive function). Multiple linear regression models determined if SUD diagnosis, among other demographic and clinical variables, predicted each cognitive test's T-score. Regression equations were used to compute each group's mean T-scores.</AbstractText><AbstractText Label="RESULTS">All groups demonstrated below-average mean T-scores on all tests, with no significant between-group score differences. RAVLT total T-scores were lower than Stroop color-word T-scores within all groups (non-overlapping 95% confidence intervals). Higher daily cocaine use predicted higher Stroop T-scores (p &lt; 0.01) and RAVLT delayed recall T-scores (p &lt; 0.05). No other non-demographic variable, including AUD/CUD group status, predicted cognitive performance.</AbstractText><AbstractText Label="LIMITATIONS">A full cognitive battery and some relevant variables (e.g. BD lifetime illness course) were not available. Many participants (42.1%) had additional SUDs.</AbstractText><AbstractText Label="CONCLUSIONS">BD with and without AUD/CUD was found to be associated with greater deficits in verbal learning and memory than in executive function. Addressing these impaired domains in dually-diagnosed patients may improve treatment and functional outcomes.</AbstractText><CopyrightInformation>Copyright © 2020. Published by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Chengxi</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, The University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd. MC 8849, Dallas, TX 75390-8849, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palka</LastName><ForeName>Jayme M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, The University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd. MC 8849, Dallas, TX 75390-8849, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>E Sherwood</ForeName><Initials>ES</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, The University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd. MC 8849, Dallas, TX 75390-8849, USA. Electronic address: Sherwood.Brown@UTSouthwestern.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 DA022460</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>04</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>I5Y540LHVR</RegistryNumber><NameOfSubstance UI="D003042">Cocaine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000437" MajorTopicYN="Y">Alcoholism</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="Y">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003042" MajorTopicYN="Y">Cocaine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="Y">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019966" MajorTopicYN="Y">Substance-Related Disorders</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Alcohol use disorder</Keyword><Keyword MajorTopicYN="Y">Bipolar disorder</Keyword><Keyword MajorTopicYN="Y">Cocaine use disorder</Keyword><Keyword MajorTopicYN="Y">Cognitive impairment</Keyword><Keyword MajorTopicYN="Y">Dual diagnosis</Keyword><Keyword MajorTopicYN="Y">Executive function</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest Dr. Brown has grants from NIH, the Stanley Medical Research Institute, and Otsuka, and serves on an advisory board for Allergan. No other authors have anything to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>05</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>02</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>03</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>2</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32553378</ArticleId><ArticleId IdType="pii">S0165-0327(19)31322-9</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2020.03.179</ArticleId><ArticleId IdType="pmc">PMC7305419</ArticleId><ArticleId IdType="mid">NIHMS1595219</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Biol Psychiatry. 2003 Sep 1;54(5):573-83</Citation><ArticleIdList><ArticleId IdType="pubmed">12946886</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2019 Apr 15;249:315-318</Citation><ArticleIdList><ArticleId IdType="pubmed">30802696</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2015 Oct;172(10):1014-21</Citation><ArticleIdList><ArticleId IdType="pubmed">25998279</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2008 May;69(5):701-5</Citation><ArticleIdList><ArticleId IdType="pubmed">18312058</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2016 Jun 08;11(6):e0157060</Citation><ArticleIdList><ArticleId IdType="pubmed">27275781</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2016 Sep 30;243:225-231</Citation><ArticleIdList><ArticleId IdType="pubmed">27423121</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Neuropsychopharmacol. 2017 Aug 1;20(8):670-680</Citation><ArticleIdList><ArticleId IdType="pubmed">28498954</ArticleId></ArticleIdList></Reference><Reference><Citation>J Subst Abuse Treat. 2015 Feb;49:15-20</Citation><ArticleIdList><ArticleId IdType="pubmed">25108685</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2016 Feb;73:102-107</Citation><ArticleIdList><ArticleId IdType="pubmed">26714201</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement. 2011 May;7(3):270-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21514249</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Rev Neurother. 2006 Apr;6(4):591-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16623657</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2012 Oct;37(11):2347-54</Citation><ArticleIdList><ArticleId IdType="pubmed">22669171</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychopharmacol. 2007 Oct;27(5):498-502</Citation><ArticleIdList><ArticleId IdType="pubmed">17873684</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Psychopharmacol. 2008 Mar;23(2):95-105</Citation><ArticleIdList><ArticleId IdType="pubmed">18058849</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Gen Psychiatry. 2015 Dec 01;14:42</Citation><ArticleIdList><ArticleId IdType="pubmed">26628905</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1978 Nov;133:429-35</Citation><ArticleIdList><ArticleId IdType="pubmed">728692</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2009 Apr;34(5):1112-22</Citation><ArticleIdList><ArticleId IdType="pubmed">18496524</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2016 Dec;206:331-349</Citation><ArticleIdList><ArticleId IdType="pubmed">27476137</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcohol Clin Exp Res. 2017 Aug;41(8):1432-1443</Citation><ArticleIdList><ArticleId IdType="pubmed">28618018</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Neuropsychopharmacol. 2005 Dec;8(4):549-56</Citation><ArticleIdList><ArticleId IdType="pubmed">15916717</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1998 Jan;55(1):41-6</Citation><ArticleIdList><ArticleId IdType="pubmed">9435759</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Clin Psychiatry. 2012 May;24(2):143-54</Citation><ArticleIdList><ArticleId IdType="pubmed">22563570</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2014 Aug;39(9):2200-10</Citation><ArticleIdList><ArticleId IdType="pubmed">24651468</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2016 Dec;206:321-330</Citation><ArticleIdList><ArticleId IdType="pubmed">27426694</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Alcohol Depend. 2018 Nov 1;192:16-28</Citation><ArticleIdList><ArticleId IdType="pubmed">30195242</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62</Citation><ArticleIdList><ArticleId IdType="pubmed">14399272</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Biobehav Rev. 2011 Jan;35(3):377-406</Citation><ArticleIdList><ArticleId IdType="pubmed">20451551</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2012 Dec 30;200(2-3):252-7</Citation><ArticleIdList><ArticleId IdType="pubmed">22769049</ArticleId></ArticleIdList></Reference><Reference><Citation>Addict Biol. 2013 Mar;18(2):203-13</Citation><ArticleIdList><ArticleId IdType="pubmed">22264351</ArticleId></ArticleIdList></Reference><Reference><Citation>Harv Rev Psychiatry. 2009;17(3):226-30</Citation><ArticleIdList><ArticleId IdType="pubmed">19499421</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 1998 Jan 16;77(1):35-42</Citation><ArticleIdList><ArticleId IdType="pubmed">10710173</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2009 Aug;70(8):1120-7</Citation><ArticleIdList><ArticleId IdType="pubmed">19758523</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Psychol. 2016 Nov 18;12(4):659-678</Citation><ArticleIdList><ArticleId IdType="pubmed">27872673</ArticleId></ArticleIdList></Reference><Reference><Citation>J Addict Med. 2014 Sep-Oct;8(5):368-76</Citation><ArticleIdList><ArticleId IdType="pubmed">25187977</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2010 Sep 28;5(9):</Citation><ArticleIdList><ArticleId IdType="pubmed">20927392</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Physiol. 2015 Apr 07;6:108</Citation><ArticleIdList><ArticleId IdType="pubmed">25904869</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2008 Oct 30;161(1):28-35</Citation><ArticleIdList><ArticleId IdType="pubmed">18752854</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2006 Jul;93(1-3):105-15</Citation><ArticleIdList><ArticleId IdType="pubmed">16677713</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2012 Dec 30;200(2-3):242-5</Citation><ArticleIdList><ArticleId IdType="pubmed">22818174</ArticleId></ArticleIdList></Reference><Reference><Citation>Soc Psychiatry Psychiatr Epidemiol. 2015 Nov;50(11):1609-40</Citation><ArticleIdList><ArticleId IdType="pubmed">26210739</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Psychol Rev. 2018 Feb;59:126-136</Citation><ArticleIdList><ArticleId IdType="pubmed">29195773</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2013 Sep;128(3):149-62</Citation><ArticleIdList><ArticleId IdType="pubmed">23617548</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2013 Dec 30;210(3):871-9</Citation><ArticleIdList><ArticleId IdType="pubmed">24012163</ArticleId></ArticleIdList></Reference><Reference><Citation>Subst Abuse Treat Prev Policy. 2007 Oct 01;2:29</Citation><ArticleIdList><ArticleId IdType="pubmed">17908301</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22978083</PMID><DateCompleted><Year>2012</Year><Month>10</Month><Day>11</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0091-2174</ISSN><JournalIssue CitedMedium="Print"><Volume>43</Volume><Issue>3</Issue><PubDate><Year>2012</Year></PubDate></JournalIssue><Title>International journal of psychiatry in medicine</Title><ISOAbbreviation>Int J Psychiatry Med</ISOAbbreviation></Journal><ArticleTitle>Adjunctive treatment with gabapentin in bipolar patients during acute mania.</ArticleTitle><Pagination><MedlinePgn>261-71</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">In this clinical trial, we studied the effects of adjunctive treatment with gabapentin in controlling the symptoms of acute mania in patients admitted with bipolar disorder.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Sixty patients with bipolar disorder (30 men and 30 women) admitted in the acute phase of mania were categorized as case and control groups, each holding 30 patients. Both groups were treated with lithium for 6 weeks and the case group received an adjunctive treatment with 900 mg gabapentin simultaneously. All patients were evaluated at the beginning and the end of the trial using Young's Mania Rating Scale (YMRS), and two groups were compared for improvement in acute symptoms.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">The final score of YMRS was significantly improved in the case group compared to the control group (p = 0.00). The improvement of YMRS score was not significantly different between men and women and between different age groups.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Adjunctive treatment with gabapentin is effective for controlling symptoms of acute mania.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Astaneh</LastName><ForeName>Ali Nazeri</ForeName><Initials>AN</Initials><AffiliationInfo><Affiliation>University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rezaei</LastName><ForeName>Omid</ForeName><Initials>O</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Int J Psychiatry Med</MedlineTA><NlmUniqueID>0365646</NlmUniqueID><ISSNLinking>0091-2174</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000588">Amines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003509">Cyclohexanecarboxylic Acids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018020">Lithium Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>56-12-2</RegistryNumber><NameOfSubstance UI="D005680">gamma-Aminobutyric Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>6CW7F3G59X</RegistryNumber><NameOfSubstance UI="D000077206">Gabapentin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017677" MajorTopicYN="N">Age Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000588" MajorTopicYN="N">Amines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003509" MajorTopicYN="N">Cyclohexanecarboxylic Acids</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077206" MajorTopicYN="N">Gabapentin</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007492" MajorTopicYN="N">Iran</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018020" MajorTopicYN="N">Lithium Compounds</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017678" MajorTopicYN="N">Sex Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005680" MajorTopicYN="N">gamma-Aminobutyric Acid</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>9</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>9</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22978083</ArticleId><ArticleId IdType="doi">10.2190/PM.43.3.e</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">7878158</PMID><DateCompleted><Year>1995</Year><Month>04</Month><Day>06</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0033-2674</ISSN><JournalIssue CitedMedium="Print"><Volume>29</Volume><Issue>1</Issue><PubDate><MedlineDate>1995 Jan-Feb</MedlineDate></PubDate></JournalIssue><Title>Psychiatria polska</Title><ISOAbbreviation>Psychiatr Pol</ISOAbbreviation></Journal><ArticleTitle>[Factors influencing the clinical picture, course and effectiveness of therapy in patients with manic-depressive psychoses].</ArticleTitle><Pagination><MedlinePgn>87-92</MedlinePgn></Pagination><Abstract><AbstractText>The long lasting (5-8 years) clinical observations of 496 patients suffering from manic-depressive psychoses had allowed the authors to distinguish some factors which influence (in a positive and negative way) the clinical features and therapeutic effectiveness as well as to follow the origin of psychoses. The attached specification of these factors is not complete, further tests and investigations are needed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wesołowski</LastName><ForeName>W</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Kliniki i Katedry Psychiatrii Fakultetu Szkolenia Podyplomowego Lekarzy, Instytutu Medycznego we Lwowie.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doliszna</LastName><ForeName>N</ForeName><Initials>N</Initials></Author></AuthorList><Language>pol</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Niektóre czynniki wpływajace na obraz kliniczny, przebieg i skuteczność terapii chorych na psychoze maniakalno-depresyjna.</VernacularTitle></Article><MedlineJournalInfo><Country>Poland</Country><MedlineTA>Psychiatr Pol</MedlineTA><NlmUniqueID>0103314</NlmUniqueID><ISSNLinking>0033-2674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011619">Psychotropic Drugs</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011619" MajorTopicYN="N">Psychotropic Drugs</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1995</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1995</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1995</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">7878158</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">7095670</PMID><DateCompleted><Year>1982</Year><Month>09</Month><Day>24</Day></DateCompleted><DateRevised><Year>2019</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0015-5721</ISSN><JournalIssue CitedMedium="Print"><Volume>36</Volume><Issue>1</Issue><PubDate><Year>1982</Year></PubDate></JournalIssue><Title>Folia psychiatrica et neurologica japonica</Title><ISOAbbreviation>Folia Psychiatr Neurol Jpn</ISOAbbreviation></Journal><ArticleTitle>Melancholia and excessive CNV recovery after nonresponse condition.</ArticleTitle><Pagination><MedlinePgn>81-8</MedlinePgn></Pagination><Abstract><AbstractText>The effect of nonresponse on the Cz-CNV recovery was studied in 13 depressed patients on the hypothesis that the excessive CNV recovery had a relation to melancholia. The depressed patients had a significantly small Control CNV area before the nonresponse as compared with a matched group of healthy controls. The dysthymic patients by the Maudsley Personality Inventory (MPI) showed a significantly smaller Control CNV area than the non-dysthymic patients. Melancholic patients who met the DSM-III criteria had a significantly longer control reaction time and more excessive CNV recovery than the non-melancholics. The excessive CNV recovery is useful as a predictor for melancholia, and the motivational facilitation and preparatory motor inhibition underlying the psychomotor retardation and hence "endogenous process" were discussed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nakamura</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Iida</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Fukui</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Takahashi</LastName><ForeName>S</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Folia Psychiatr Neurol Jpn</MedlineTA><NlmUniqueID>0372774</NlmUniqueID><ISSNLinking>0015-5721</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001307" MajorTopicYN="N">Auditory Perception</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003265" MajorTopicYN="Y">Contingent Negative Variation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004569" MajorTopicYN="Y">Electroencephalography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004594" MajorTopicYN="Y">Electrophysiology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010551" MajorTopicYN="N">Personality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011930" MajorTopicYN="N">Reaction Time</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1982</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1982</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1982</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">7095670</ArticleId><ArticleId IdType="doi">10.1111/j.1440-1819.1982.tb00258.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31291208</PMID><DateCompleted><Year>2020</Year><Month>06</Month><Day>19</Day></DateCompleted><DateRevised><Year>2021</Year><Month>09</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-1145</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>4</Issue><PubDate><Year>2019</Year><Month>07</Month></PubDate></JournalIssue><Title>Journal of psychiatric practice</Title><ISOAbbreviation>J Psychiatr Pract</ISOAbbreviation></Journal><ArticleTitle>Borderline Personality Features in Inpatients with Bipolar Disorder: Impact on Course and Machine Learning Model Use to Predict Rapid Readmission.</ArticleTitle><Pagination><MedlinePgn>279-289</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/PRA.0000000000000392</ELocationID><Abstract><AbstractText Label="BACKGROUND">Earlier research indicated that nearly 20% of patients diagnosed with either bipolar disorder (BD) or borderline personality disorder (BPD) also met criteria for the other diagnosis. Yet limited data are available concerning the potential impact of co-occurring BPD and/or BPD features on the course or outcome in patients with BD. Therefore, this study examined this comorbidity utilizing the standardized Borderline Personality Questionnaire (BPQ).</AbstractText><AbstractText Label="METHODS">This study involved 714 adult patients with a primary diagnosis of BD per DSM-IV criteria who were admitted to the psychiatric unit at an academic hospital in Houston, TX between July 2013 and July 2018. All patients completed the BPQ within 72 hours of admission. Statistical analysis was used to detect correlations between severity of BD, length of stay (LOS), and scores on the BPQ. A machine learning model was constructed to predict the parameters affecting patients' readmission rates within 30 days.</AbstractText><AbstractText Label="RESULTS">Analysis revealed that the severity of certain BPD traits at baseline was associated with mood state and outcome measured by LOS. Inpatients with BD who were admitted during acute depressive episodes had significantly higher mean scores on 7 of the 9 BPQ subscales (P&lt;0.05) compared with those admitted during acute manic episodes. Inpatients with BD with greater BPQ scores on 4 of the 9 BPQ subscales had significantly shorter LOS than those with lower BPQ scores (P&lt;0.05). The machine learning model identified 6 variables as predictors for likelihood of 30-day readmission with a high sensitivity (83%), specificity (77%), and area under the receiver operating characteristic curve of 86%.</AbstractText><AbstractText Label="CONCLUSIONS">Although preliminary, these results suggest that inpatients with BD who have higher levels of BPD features were more likely to have depressive rather than manic symptoms, fewer psychotic symptoms, and a shorter LOS. Moreover, machine learning models may be particularly valuable in identifying patients with BD who are at the highest risk for adverse consequences including rapid readmission.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Salem</LastName><ForeName>Haitham</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Ruiz</LastName><ForeName>Ana</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Hernandez</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Wahid</LastName><ForeName>Kareem</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Fei</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Karnes</LastName><ForeName>Brandi</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Beasley</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Sanches</LastName><ForeName>Marsal</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Ashtari</LastName><ForeName>Elaheh</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Pigott</LastName><ForeName>Teresa</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Psychiatr Pract</MedlineTA><NlmUniqueID>100901141</NlmUniqueID><ISSNLinking>1527-4160</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000339" MajorTopicYN="N">Affect</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001883" MajorTopicYN="N">Borderline Personality Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007297" MajorTopicYN="N">Inpatients</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069550" MajorTopicYN="Y">Machine Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015233" MajorTopicYN="N">Models, Statistical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010359" MajorTopicYN="Y">Patient Readmission</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010551" MajorTopicYN="N">Personality</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>7</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>7</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>6</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31291208</ArticleId><ArticleId IdType="doi">10.1097/PRA.0000000000000392</ArticleId><ArticleId IdType="pii">00131746-201907000-00005</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wilson ST, Stanley B, Oquendo MA, et al. Comparing impulsiveness, hostility, and depression in borderline personality disorder and bipolar II disorder. J Clin Psychiatry. 2007;68:1533–1539.</Citation></Reference><Reference><Citation>Paris J, Gunderson J, Weinberg I. The interface between borderline personality disorder and bipolar spectrum disorders. Compr Psychiatry. 2007;48:145–154.</Citation></Reference><Reference><Citation>Benazzi F. Borderline personality disorder and bipolar II disorder in private practice depressed outpatients. Compr Psychiatry. 2000;41:106–110.</Citation></Reference><Reference><Citation>Benazzi F. Borderline personality-bipolar spectrum relationship. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30:68–74.</Citation></Reference><Reference><Citation>Zimmerman M, Morgan TA. Problematic boundaries in the diagnosis of bipolar disorder: the interface with borderline personality disorder. Curr Psychiatry Rep. 2013;15:422.</Citation></Reference><Reference><Citation>Garno JL, Goldberg JF, Ramirez PM, et al. Bipolar disorder with comorbid cluster B personality disorder features: impact on suicidality. J Clin Psychiatry. 2005;66:339–345.</Citation></Reference><Reference><Citation>Latalova K, Prasko J, Kamaradova D, et al. Comorbidity bipolar disorder and personality disorders. Neuro Endocrinol Lett. 2013;34:1–8.</Citation></Reference><Reference><Citation>Fonseka TM, Swampillai B, Timmins V, et al. Significance of borderline personality-spectrum symptoms among adolescents with bipolar disorder. J Affect Disord. 2015;170:39–45.</Citation></Reference><Reference><Citation>Riemann G, Weisscher N, Post RM, et al. The relationship between self-reported borderline personality features and prospective illness course in bipolar disorder. Int J Bipolar Disord. 2017;5:31.</Citation></Reference><Reference><Citation>Poreh AM, Rawlings D, Claridge G, et al. The BPQ: a scale for the assessment of borderline personality based on DSM-IV criteria. J Pers Disord. 2006;20:247–260.</Citation></Reference><Reference><Citation>Ceylan V, Kose S, Akin E, et al. Normative data and factorial structure of the Turkish version of the Borderline Personality Questionnaire (Turkish BPQ). Psychiat Clin Psych. 2017;27:143–151. DOI: 10.1080/24750573.2017.1298422.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/24750573.2017.1298422</ArticleId></ArticleIdList></Reference><Reference><Citation>Furnham A, Milner R, Akhtar R, et al. A review of the measures designed to assess DSM-5 personality disorders. Psychology. 2014;5:1646–1686. Available at: http://dx.doi.org/10.4236/psych.2014.514175.</Citation><ArticleIdList><ArticleId IdType="doi">10.4236/psych.2014.514175</ArticleId></ArticleIdList></Reference><Reference><Citation>Awad A, Bader-El -Den M, McNicholas J. Patient length of stay and mortality prediction: a survey. Health Serv Manage Res. 2017;30:105–120.</Citation></Reference><Reference><Citation>Keefler J, Duder S, Lechman C. Predicting length of stay in an acute care hospital: the role of psychosocial problems. Soc Work Health Care. 2001;33:1–16.</Citation></Reference><Reference><Citation>Richter D. Psychiatric inpatient length of stay. An overview of methods, influences and consequences. Fortschr Neurol Psychiatr. 2001;69:19–31.</Citation></Reference><Reference><Citation>Hoger C, Zieger H, Presting G, et al. Predictors of length of stay in inpatient child and adolescent psychiatry: failure to validate an evidence-based model. Eur Child Adolesc Psychiatry. 2002;11:281–288.</Citation></Reference><Reference><Citation>Imai H, Hosomi J, Nakao H, et al. Characteristics of psychiatric hospitals associated with length of stay in Japan. Health Policy. 2005;74:115–121.</Citation></Reference><Reference><Citation>Creed F, Tomenson B, Anthony P, et al. Predicting length of stay in psychiatry. Psychol Med. 1997;27:961–966.</Citation></Reference><Reference><Citation>Scheytt D, Kaiser P, Priebe S. Duration of treatment and case cost in different inpatient psychiatric facilities in Berlin. Psychiatr Prax. 1996;23:10–14.</Citation></Reference><Reference><Citation>Oiesvold T, Saarento O, Sytema S, et al. The Nordic Comparative Study on Sectorized Psychiatry—length of in-patient stay. Acta Psychiatr Scand. 1999;100:220–228.</Citation></Reference><Reference><Citation>Huntley DA, Cho DW, Christman J, et al. Predicting length of stay in an acute psychiatric hospital. Psychiatr Serv. 1998;49:1049–1053.</Citation></Reference><Reference><Citation>Stevens A, Hammer K, Buchkremer G. A statistical model for length of psychiatric in-patient treatment and an analysis of contributing factors. Acta Psychiatr Scand. 2001;103:203–211.</Citation></Reference><Reference><Citation>Pertile R, Donisi V, Grigoletti L, et al. DRGs and other patient-, service- and area-level factors influencing length of stay in acute psychiatric wards: The Veneto Region experience. Soc Psychiatry Psychiatr Epidemiol. 2010;46:651–660.</Citation></Reference><Reference><Citation>Blais MA, Matthews J, Lipkis-Orlando R, et al. Predicting length of stay on an acute care medical psychiatric inpatient service. Adm Policy Ment Health. 2003;31:15–29.</Citation></Reference><Reference><Citation>Jiménez RE, Lam RM, Marot M, et al. Observed-predicted length of stay for an acute psychiatric department, as an indicator of inpatient care inefficiencies. Retrospective case-series study. BMC Health Serv Res. 2004;4:4.</Citation></Reference><Reference><Citation>Ithman MH, Goplarkrishna G, Beck NC, et al. Predictors of length of stay in an acute psychiatric hospital. J Biosafety Health Educ. 2014;2:119. Doi:10.4172/2332-0893.1000119.</Citation><ArticleIdList><ArticleId IdType="doi">10.4172/2332-0893.1000119</ArticleId></ArticleIdList></Reference><Reference><Citation>Compton MT, Craw J, Rudisch BE. Determinants of inpatient psychiatric length of stay in an urban county hospital. Psychiatr Q. 2006;77:173–188.</Citation></Reference><Reference><Citation>Machado V, Leonidas C, Santos MA, et al. Psychiatric readmission: an integrative review of the literature. Int Nurs Rev. 2012;59:447–457.</Citation></Reference><Reference><Citation>Durbin J, Lin E, Layne C, et al. Is readmission a valid indicator of the quality of inpatient psychiatric care. J Behav Health Serv Res. 2007;34:137–150.</Citation></Reference><Reference><Citation>Rumball-Smith J, Hider P. The validity of readmission rate as a marker of the quality of hospital care, and a recommendation for its definition. NZ Med J. 2009;122:63–70.</Citation></Reference><Reference><Citation>Pope HG Jr, Jonas JM, Hudson JI, et al. The validity of DSM-III borderline personality disorder. A phenomenologic, family history, treatment response, and long-term follow-up study. Arch Gen Psychiatry. 1983;40:23–30.</Citation></Reference><Reference><Citation>McGlashan TH. The Chestnut Lodge follow-up study. III. Long-term outcome of borderline personalities. Arch Gen Psychiatry. 1986;43:20–30.</Citation></Reference><Reference><Citation>Links PS, Steiner M, Offord DR, et al. Characteristics of borderline personality disorder: a Canadian study. Can J Psychiatry. 1988;33:336–340.</Citation></Reference><Reference><Citation>Zanarini MC, Frankenburg FR, Dubo ED, et al. Axis I comorbidity of borderline personality disorder. Am J Psychiatry. 1998;155:1733–1739.</Citation></Reference><Reference><Citation>Alnæs R, Torgersen S. Personality and personality disorders among patients with various affective disorders. J Pers Disord. 1991;5:107–121.</Citation></Reference><Reference><Citation>Hudziak JJ, Boffeli TJ, Kreisman JJ, et al. Clinical study of the relation of borderline personality disorder to Briquet’s syndrome (hysteria), somatization disorder, antisocial personality disorder, and substance abuse disorders. Am J Psychiatry. 1996;153:1598–1606.</Citation></Reference><Reference><Citation>Deltito J, Martin L, Riefkohl J, et al. Do patients with borderline personality disorder belong to the bipolar spectrum? J Affect Disord. 2001;67:221–228.</Citation></Reference><Reference><Citation>Akiskal HS. Demystifying borderline personality: critique of the concept and unorthodox reflections on its natural kinship with the bipolar spectrum. Acta Psychiatr Scand. 2004;110:401–407.</Citation></Reference><Reference><Citation>Axelson DA, Birmaher B, Strober MA, et al. Course of subthreshold bipolar disorder in youth: diagnostic progression from bipolar disorder not otherwise specified. J Am Acad Child Adolesc Psychiatry. 2011;50:1001–1016.e3.</Citation></Reference><Reference><Citation>Hafeman D, Axelson D, Demeter C, et al. Phenomenology of bipolar disorder not otherwise specified in youth: a comparison of clinical characteristics across the spectrum of manic symptoms. Bipolar Disord. 2013;15:240–252.</Citation></Reference><Reference><Citation>Drake RE, Mercer-McFadden C, Mueser KT, et al. Review of integrated mental health and substance abuse treatment for patients with dual disorders. Schizophr Bull. 1998;24:589–608.</Citation></Reference><Reference><Citation>Horsfall J, Cleary M, Hunt GE, et al. Psychosocial treatments for people with co-occurring severe mental illnesses and substance use disorders (dual diagnosis): a review of empirical evidence. Harv Rev Psychiatry. 2009;17:24–34.</Citation></Reference><Reference><Citation>Krawczyk N, Feder KA, Saloner B, et al. The association of psychiatric comorbidity with treatment completion among clients admitted to substance use treatment programs in a US national sample. Drug Alcohol Depend. 2017;175:157–163.</Citation></Reference><Reference><Citation>American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (Text Revision (DSM-IV-TR)), 4th ed. Washington, DC: American Psychiatric Association; 2000.</Citation></Reference><Reference><Citation>Chanen AM, Jovev M, Djaja D, et al. Screening for borderline personality disorder in outpatient youth. J Pers Disord. 2008;22:353–364.</Citation></Reference><Reference><Citation>Gulshan V, Peng L, Coram M, et al. Development and validation of a deep learning algorithm for detection of diabetic retinopathy in retinal fundus photographs. JAMA. 2016;316:2402–2410.</Citation></Reference><Reference><Citation>Manyika J, Chui M, Brown B, et al. Big data: the next frontier for innovation, competition, and productivity. Technical report. Washington, DC: McKinsey Global Institute; 2011.</Citation></Reference><Reference><Citation>Efron B, Hastie T. Computer-Age Statistical Inference. Cambridge, UK: Cambridge University Press; 2016.</Citation></Reference><Reference><Citation>Shalev-Shwartz S, Ben-David S. Understanding Machine Learning: From Theory to Algorithms. Cambridge, UK: Cambridge University Press; 2014.</Citation></Reference><Reference><Citation>Drysdale AT, Grosenick L, Downar J, et al. Resting-state connectivity biomarkers define neurophysiological subtypes of depression. Nat Med. 2017;23:28–38.</Citation></Reference><Reference><Citation>Bzdok D, Meyer-Lindenberg A. Machine learning for precision psychiatry: opportunities and challenges. Biol Psychiatry Cogn Neurosci Neuroimaging. 2018;3:223–230.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11269910</PMID><DateCompleted><Year>2001</Year><Month>06</Month><Day>07</Day></DateCompleted><DateRevised><Year>2011</Year><Month>01</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1139-9287</ISSN><JournalIssue CitedMedium="Print"><Volume>28</Volume><Issue>5</Issue><PubDate><MedlineDate>2000 Sep-Oct</MedlineDate></PubDate></JournalIssue><Title>Actas espanolas de psiquiatria</Title><ISOAbbreviation>Actas Esp Psiquiatr</ISOAbbreviation></Journal><ArticleTitle>[Non-specific differences in neurocognitive performance in psychotic disorders?].</ArticleTitle><Pagination><MedlinePgn>312-24</MedlinePgn></Pagination><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">In the last years, there has been a growing interest in the study of cognitive functioning, not only in schizophrenia but also in other psychoses and psychiatric disorders. Attention, memory and information processing deficits may have great relevance as predictors of social adjustment and quality of life.</AbstractText><AbstractText Label="OBJECTIVE AND METHODS" NlmCategory="OBJECTIVE">[corrected] We revised literature concerning comparative studies of neuropsychological performance in schizophrenia and affective disorders, mainly bipolar disorders.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Studies analyzed show contradictory results. Some authors report a more global dysfunction or a more limited and concrete dysfunction in schizophrenia. However, most of the studies, especially those with homogeneous samples of psychotic affective disorders do not find any difference in cognitive functioning between schizophrenic and bipolar patients.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">Although some factors as sample selection, clinical state, course of the disorder, make difficult the interpretation of results, it would not exist specific deficits in any of the diagnostic groups studied.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Selva</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Servicio de Psiquiatría, Hospital Clínico Universitario de Valencia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tabarés</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Salazar</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Balanzá</LastName><ForeName>V</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Ballester</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Cózar</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Leal</LastName><ForeName>C</ForeName><Initials>C</Initials></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Inespecificidad de los hallazgos neurocognitivos en las psicosis?</VernacularTitle></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Actas Esp Psiquiatr</MedlineTA><NlmUniqueID>100886502</NlmUniqueID><ISSNLinking>1139-9287</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>63</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>3</Month><Day>29</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>6</Month><Day>8</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>3</Month><Day>29</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11269910</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">1728160</PMID><DateCompleted><Year>1992</Year><Month>01</Month><Day>24</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-953X</ISSN><JournalIssue CitedMedium="Print"><Volume>149</Volume><Issue>1</Issue><PubDate><Year>1992</Year><Month>Jan</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Verapamil versus lithium in acute mania.</ArticleTitle><Pagination><MedlinePgn>121-2</MedlinePgn></Pagination><Abstract><AbstractText>Twenty acutely manic patients were studied in a double-blind randomized trial comparing verapamil with lithium. The Petterson Mania Scale, the Brief Psychiatric Rating Scale (BPRS), and the Clinical Global Impression (CGI) were administered before treatment and weekly during 4 weeks of treatment to evaluate response to verapamil and lithium. Both treatment groups improved significantly, and there were no significant overall differences between treatments.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Garza-Treviño</LastName><ForeName>E S</ForeName><Initials>ES</Initials><AffiliationInfo><Affiliation>University of Texas Health Science Center, San Antonio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Overall</LastName><ForeName>J E</ForeName><Initials>JE</Initials></Author><Author ValidYN="Y"><LastName>Hollister</LastName><ForeName>L E</ForeName><Initials>LE</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>2BMD2GNA4V</RegistryNumber><NameOfSubstance UI="D016651">Lithium Carbonate</NameOfSubstance></Chemical><Chemical><RegistryNumber>CJ0O37KU29</RegistryNumber><NameOfSubstance UI="D014700">Verapamil</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Am J Psychiatry. 1992 Nov;149(11):1614-5</RefSource><PMID Version="1">1357993</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Am J Psychiatry. 1993 Mar;150(3):529-30</RefSource><PMID Version="1">8434684</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016651" MajorTopicYN="N">Lithium Carbonate</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014700" MajorTopicYN="N">Verapamil</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1992</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1992</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1992</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">1728160</ArticleId><ArticleId IdType="doi">10.1176/ajp.149.1.121</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">3529151</PMID><DateCompleted><Year>1986</Year><Month>10</Month><Day>22</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0165-1781</ISSN><JournalIssue CitedMedium="Print"><Volume>18</Volume><Issue>4</Issue><PubDate><Year>1986</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Psychiatry research</Title><ISOAbbreviation>Psychiatry Res</ISOAbbreviation></Journal><ArticleTitle>Calcium antagonists in mania: a double-blind study of verapamil.</ArticleTitle><Pagination><MedlinePgn>309-20</MedlinePgn></Pagination><Abstract><AbstractText>Five of seven acutely manic patients improved significantly when taking verapamil but not placebo in a double-blind crossover study. This finding adds support to two other formal studies of verapamil, several case reports of verapamil in manic patients, and one small study of nifedipine suggesting that some calcium antagonists may have antimanic properties. Indirect evidence links this antimanic action to correction of a disturbance of intracellular calcium dynamics in affective disorders. However, the effectiveness of calcium antagonist drugs could also be related to some property other than interference with the action of calcium within brain neurons.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dubovsky</LastName><ForeName>S L</ForeName><Initials>SL</Initials></Author><Author ValidYN="Y"><LastName>Franks</LastName><ForeName>R D</ForeName><Initials>RD</Initials></Author><Author ValidYN="Y"><LastName>Allen</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Murphy</LastName><ForeName>J</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D018848">Controlled Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Psychiatry Res</MedlineTA><NlmUniqueID>7911385</NlmUniqueID><ISSNLinking>0165-1781</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>CJ0O37KU29</RegistryNumber><NameOfSubstance UI="D014700">Verapamil</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014700" MajorTopicYN="N">Verapamil</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1986</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1986</Year><Month>8</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1986</Year><Month>8</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">3529151</ArticleId><ArticleId IdType="pii">0165-1781(86)90016-8</ArticleId><ArticleId IdType="doi">10.1016/0165-1781(86)90016-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8679795</PMID><DateCompleted><Year>1996</Year><Month>08</Month><Day>16</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0006-3223</ISSN><JournalIssue CitedMedium="Print"><Volume>39</Volume><Issue>6</Issue><PubDate><Year>1996</Year><Month>Mar</Month><Day>15</Day></PubDate></JournalIssue><Title>Biological psychiatry</Title><ISOAbbreviation>Biol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Abnormal phosphatidylinositol (PI)-signalling in bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>461-4</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Soares</LastName><ForeName>J C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Mallinger</LastName><ForeName>A G</ForeName><Initials>AG</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016420">Comment</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biol Psychiatry</MedlineTA><NlmUniqueID>0213264</NlmUniqueID><ISSNLinking>0006-3223</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010716">Phosphatidylinositols</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.3.5</RegistryNumber><NameOfSubstance UI="D015720">5'-Nucleotidase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>1996 Jul 1;40(1):78</RefSource></CommentsCorrections><CommentsCorrections RefType="CommentOn"><RefSource>Biol Psychiatry. 1995 Jun 1;37(11):761-3</RefSource><PMID Version="1">7647160</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D015720" MajorTopicYN="N">5'-Nucleotidase</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001792" MajorTopicYN="N">Blood Platelets</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010716" MajorTopicYN="N">Phosphatidylinositols</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1996</Year><Month>3</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1996</Year><Month>3</Month><Day>15</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1996</Year><Month>3</Month><Day>15</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8679795</ArticleId><ArticleId IdType="pii">0006322395005277</ArticleId><ArticleId IdType="doi">10.1016/0006-3223(95)00527-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">7875950</PMID><DateCompleted><Year>1995</Year><Month>03</Month><Day>31</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0333-7308</ISSN><JournalIssue CitedMedium="Print"><Volume>31</Volume><Issue>4</Issue><PubDate><Year>1994</Year></PubDate></JournalIssue><Title>The Israel journal of psychiatry and related sciences</Title><ISOAbbreviation>Isr J Psychiatry Relat Sci</ISOAbbreviation></Journal><ArticleTitle>Jews and their intraethnic differential vulnerability to affective disorders, fact or artifact? I: An overview of the literature.</ArticleTitle><Pagination><MedlinePgn>261-70</MedlinePgn></Pagination><Abstract><AbstractText>The observation that Ashkenazim have higher rates of affective disorders than either Sephardi or Oriental Jews was reanalyzed from the available literature. Statistical reanalysis of these studies was consistent with rates being elevated for Ashkenazim. The results of these treatment-based studies, however, suffer from biases due to differential help-seeking patterns, lack of accounting for readmission rates, diagnostic unreliability, misuse of frequency ratios relative to other disorders and failure to control for confounding variables. As a result of these causes for biases and in the absence of a true incidence or prevalence study serving as a basis for these observations, the assumption that Ashkenazim are at an increased risk for affective disorders is questionable and may be a mere result of methodological artifacts.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kohn</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Brown University, Department of Psychiatry and Human Behavior, Providence, RI.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levav</LastName><ForeName>I</ForeName><Initials>I</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Israel</Country><MedlineTA>Isr J Psychiatry Relat Sci</MedlineTA><NlmUniqueID>8108287</NlmUniqueID><ISSNLinking>0333-7308</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000208" MajorTopicYN="N">ethnology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000208" MajorTopicYN="N">ethnology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007557" MajorTopicYN="N" Type="Geographic">Israel</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007585" MajorTopicYN="N">Jews</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019964" MajorTopicYN="N">Mood Disorders</DescriptorName><QualifierName UI="Q000208" MajorTopicYN="N">ethnology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>34</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1994</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1994</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1994</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">7875950</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11982536</PMID><DateCompleted><Year>2002</Year><Month>10</Month><Day>10</Day></DateCompleted><DateRevised><Year>2017</Year><Month>02</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0004-8674</ISSN><JournalIssue CitedMedium="Print"><Volume>36</Volume><Issue>2</Issue><PubDate><Year>2002</Year><Month>Apr</Month></PubDate></JournalIssue><Title>The Australian and New Zealand journal of psychiatry</Title><ISOAbbreviation>Aust N Z J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>First-episode mania: a neglected priority for early intervention.</ArticleTitle><Pagination><MedlinePgn>158-72</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">While first-episode (FE) psychosis has become an important field of research, FE affective psychoses, and mania in particular, have been relatively neglected. This paper summarizes current knowledge about FE mania and explores the potential for early intervention.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">The main computerized psychiatric literature databases were accessed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">When functional as well as symptomatic variables are considered, the outcome of mania is not as good as was formerly believed, a characteristic which is already present from the first episode. Various factors (lower socio-economic status, younger age at onset of illness, poor adherence to treatment, presence of comorbidity) have been identified as possible predictors of poor outcome. The prognostic value of the presence of psychotic symptoms and their congruence to mood, as well as the diagnostic subgroup, is less well established. This literature review also reveals striking similarities between manic and schizophreniform first episodes. Poor functional outcome in a significant proportion of patients following the first episode, high risk of suicide, high prevalence of comorbid diagnoses, worse outcome with a younger age at onset and with longer delay until treatment is initiated, and finally early presence of neuro-anatomical changes, are observed in both syndromes.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This pattern justifies the development of early intervention strategies for FE manic patients and supports more exploratory research to identify prodromal symptoms, which might ultimately lead to even earlier focus on preventive interventions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Conus</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Early Psychosis Prevention and Intervention Centre, Parville, Victoria, Australia. conusmichaelis@bigpond.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McGorry</LastName><ForeName>Patrick D</ForeName><Initials>PD</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Aust N Z J Psychiatry</MedlineTA><NlmUniqueID>0111052</NlmUniqueID><ISSNLinking>0004-8674</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>104</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>5</Month><Day>2</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>10</Month><Day>11</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>5</Month><Day>2</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11982536</ArticleId><ArticleId IdType="pii">994</ArticleId><ArticleId IdType="doi">10.1046/j.1440-1614.2002.00994.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21425259</PMID><DateCompleted><Year>2011</Year><Month>11</Month><Day>02</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4679</ISSN><JournalIssue CitedMedium="Internet"><Volume>67</Volume><Issue>7</Issue><PubDate><Year>2011</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Journal of clinical psychology</Title><ISOAbbreviation>J Clin Psychol</ISOAbbreviation></Journal><ArticleTitle>Positive and negative cognitive style correlates of the vulnerability to hypomania.</ArticleTitle><Pagination><MedlinePgn>673-90</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/jclp.20789</ELocationID><Abstract><AbstractText>Specific forms of ruminative cognitive styles and self-appraisals have been implicated in the development of bipolar symptomatology. This study investigated the associations between measures of positive and negative forms of appraisals and rumination with vulnerability to hypomania, and also investigated the conceptual overlap between these measures in terms of the responses to emotional experiences captured. Hypomania vulnerability was predicted by measures of positive cognitive styles, whilst current depressive symptoms were explained by scores on measures of negative cognitive styles in an analogue sample of 353 participants. A principal components analysis conducted upon the rumination and appraisal measures yielded three components representing positive and negative cognitive styles, and a normalizing of symptoms component. The implications of these results are discussed.</AbstractText><CopyrightInformation>© 2011 Wiley Periodicals, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dempsey</LastName><ForeName>Robert C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>School of Psychological Sciences, University of Manchester, United Kingdom. robert.c.dempsey@postgrad.manchester.ac.uk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gooding</LastName><ForeName>Patricia A</ForeName><Initials>PA</Initials></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Steven H</ForeName><Initials>SH</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>03</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychol</MedlineTA><NlmUniqueID>0217132</NlmUniqueID><ISSNLinking>0021-9762</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="Y">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004739" MajorTopicYN="N" Type="Geographic">England</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009341" MajorTopicYN="Y">Negativism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>3</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>3</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21425259</ArticleId><ArticleId IdType="doi">10.1002/jclp.20789</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28906604</PMID><DateCompleted><Year>2018</Year><Month>05</Month><Day>22</Day></DateCompleted><DateRevised><Year>2018</Year><Month>05</Month><Day>22</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2155-7780</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>4</Issue><PubDate><Year>2017</Year><Month>Aug</Month><Day>31</Day></PubDate></JournalIssue><Title>The primary care companion for CNS disorders</Title><ISOAbbreviation>Prim Care Companion CNS Disord</ISOAbbreviation></Journal><ArticleTitle>A Multisymptomatic Child With Bipolar Disorder: How to Track and Sequence Treatment.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.4088/PCC.17r02122</ELocationID><ELocationID EIdType="pii" ValidYN="Y">17r02122</ELocationID><Abstract><AbstractText>Treatment sequences for the multisymptomatic child with bipolar disorder are not adequately described or based on a systematic clinical trial database, and systems for longitudinal tracking of symptoms are rarely utilized. We present a patient whose symptoms of depression, anxiety, attention-deficit/hyperactivity disorder, oppositional behavior, and mania are rated by a parent and plotted on a weekly basis in the Child Network under a Johns Hopkins Institutional Review Board-approved protocol. This 9-year-old girl remained inadequately responsive to lithium or risperidone. We describe a range of other treatment options and a possible sequence for their introduction. We encourage the use of systematic longitudinal ratings to help better visualize course of symptom fluctuations and response of the child to treatment. Given the highly fluctuating course of many symptoms in very young children as illustrated here, prospective monitoring appears essential. The current case also highlights the great unmet need for comparative effectiveness data in children less than 10 years of age to better guide clinical therapeutics.</AbstractText><CopyrightInformation>© Copyright 2017 Physicians Postgraduate Press, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Post</LastName><ForeName>Robert M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Bipolar Collaborative Network, 5415 W Cedar Ln, Ste 201-B, Bethesda, MD 20814. robert.post@speakeasy.net.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, George Washington University School of Medicine, Washington, DC, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Bipolar Collaborative Network, Bethesda, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rowe</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Bipolar Collaborative Network, Bethesda, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaplan</LastName><ForeName>Dana</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Division of Child and Adolescent Psychiatry, Johns Hopkins Hospital/Bloomberg Children's Center, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Findling</LastName><ForeName>Robert L</ForeName><Initials>RL</Initials><AffiliationInfo><Affiliation>Division of Child and Adolescent Psychiatry, Johns Hopkins Hospital/Bloomberg Children's Center, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>08</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Prim Care Companion CNS Disord</MedlineTA><NlmUniqueID>101547532</NlmUniqueID><ISSNLinking>2155-7780</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001007" MajorTopicYN="N">Anxiety</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001289" MajorTopicYN="N">Attention Deficit Disorder with Hyperactivity</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019468" MajorTopicYN="Y">Disease Management</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016903" MajorTopicYN="N">Drug Monitoring</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>02</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>05</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>5</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28906604</ArticleId><ArticleId IdType="doi">10.4088/PCC.17r02122</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">6082141</PMID><DateCompleted><Year>1968</Year><Month>04</Month><Day>10</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-3018</ISSN><JournalIssue CitedMedium="Print"><Volume>145</Volume><Issue>6</Issue><PubDate><Year>1967</Year><Month>Dec</Month></PubDate></JournalIssue><Title>The Journal of nervous and mental disease</Title><ISOAbbreviation>J Nerv Ment Dis</ISOAbbreviation></Journal><ArticleTitle>The community, the mental hospital and psychotic patients' unusual behavior.</ArticleTitle><Pagination><MedlinePgn>492-9</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Linn</LastName><ForeName>E L</ForeName><Initials>EL</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Nerv Ment Dis</MedlineTA><NlmUniqueID>0375402</NlmUniqueID><ISSNLinking>0022-3018</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014149">Tranquilizing Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001519" MajorTopicYN="Y">Behavior</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006778" MajorTopicYN="Y">Hospitals, Psychiatric</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011613" MajorTopicYN="Y">Psychotherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013808" MajorTopicYN="N">Therapeutic Community</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014149" MajorTopicYN="N">Tranquilizing Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1967</Year><Month>12</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1967</Year><Month>12</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1967</Year><Month>12</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">6082141</ArticleId><ArticleId IdType="doi">10.1097/00005053-196712000-00007</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17489716</PMID><DateCompleted><Year>2007</Year><Month>06</Month><Day>28</Day></DateCompleted><DateRevised><Year>2007</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1044-5463</ISSN><JournalIssue CitedMedium="Print"><Volume>17</Volume><Issue>2</Issue><PubDate><Year>2007</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Journal of child and adolescent psychopharmacology</Title><ISOAbbreviation>J Child Adolesc Psychopharmacol</ISOAbbreviation></Journal><ArticleTitle>Proposed definitions of bipolar I disorder episodes and daily rapid cycling phenomena in preschoolers, school-aged children, adolescents, and adults.</ArticleTitle><Pagination><MedlinePgn>217-22</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Recent data from several large studies of pediatric bipolar I disorder reported baseline (current) episode duration ranging from less than a month to &gt;or=1 year. These data may reflect actual sample differences, but the absence of uniformly applied definitions of episode duration, number of lifetime episodes and daily rapid cycling patterns during episodes may also account for these differences.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Proposals for definitions of episode and cycling phenomena were based upon data from the Washington University in St. Louis Kiddie Schedule for Affective Disorders and Schizophrenia (WASH-U-KSADS).</AbstractText><AbstractText Label="RESULT" NlmCategory="RESULTS">Episode would be used for the interval between onset and offset of full DSM-IV criteria for bipolar I disorder. Cycling would be used only to describe daily (ultradian) switching of mood states that occurs during an episode.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Historically, in the adult bipolar literature the words "episode" and "cycle" were used interchangeably. "Rapid cycling," in this earlier literature, actually referred to multiple episodes per year. To avoid confusing episodes with daily cycling, the proposal is to use "episode" for the duration of DSM-IV criteria, to use "cycling" for daily switching phenomena during an episode, and to replace the historical term "rapid cycling" with "multiple episodes per year." These clarifications will be especially important for phenomenological research on preschool populations.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Geller</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Washington University School of Medicine, Department of Psychiatry, St. Louis, Missouri 63110, USA. gellerb@medicine.wustl.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tillman</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Bolhofner</LastName><ForeName>Kristine</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 MH-53063</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 MH-64846</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Child Adolesc Psychopharmacol</MedlineTA><NlmUniqueID>9105358</NlmUniqueID><ISSNLinking>1044-5463</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010507" MajorTopicYN="Y">Periodicity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012075" MajorTopicYN="N">Remission, Spontaneous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009626" MajorTopicYN="Y">Terminology as Topic</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>5</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>6</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>5</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17489716</ArticleId><ArticleId IdType="doi">10.1089/cap.2007.0017</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11772118</PMID><DateCompleted><Year>2002</Year><Month>03</Month><Day>18</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1172-7047</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>1</Issue><PubDate><Year>2002</Year></PubDate></JournalIssue><Title>CNS drugs</Title><ISOAbbreviation>CNS Drugs</ISOAbbreviation></Journal><ArticleTitle>The Bech-Rafaelsen Mania Scale in clinical trials of therapies for bipolar disorder: a 20-year review of its use as an outcome measure.</ArticleTitle><Pagination><MedlinePgn>47-63</MedlinePgn></Pagination><Abstract><AbstractText>Over the last two decades the Bech-Rafaelsen Mania Scale (MAS) has been used extensively in trials that have assessed the efficacy of treatments for bipolar disorder. The extent of its use makes it possible to evaluate the psychometric properties of the scale according to the principles of internal validity, reliability, and external validity. Studies of the internal validity of the MAS have demonstrated that the simple sum of the 11 items of the scale is a sufficient statistic for the assessment of the severity of manic states. Both factor analysis and latent structure analysis (the Rasch analysis) have been used to demonstrate this. The total score of the MAS has been standardised such that scores below 15 indicate hypomania, scores around 20 indicate moderate mania, and scores around 28 indicate severe mania. The inter-observer reliability has been found to be high in a number of studies conducted in various countries. The MAS has shown an acceptable external validity, in terms of both sensitivity and responsiveness. Thus, the MAS was found to be superior to the Clinical Global Impression scale with regard to responsiveness, and sensitivity has been found to be adequate, with the MAS able to demonstrate large drug-placebo differences. Based on pretreatment scores, trials of antimanic therapies can be classified into: (i) ultrashort (1 week) therapy of severe mania; (ii) short-term therapy (3 to 8 weeks) of moderate mania; (iii) short-term therapy of hypomanic or mixed bipolar states; and (iv) long-term (12 months) therapy of bipolar states. The responsiveness of MAS is such that the scale has been able to demonstrated that typical antipsychotics are effective as an ultrashort therapy of severe mania; that lithium and anticonvulsants are effective in the short-term therapy of moderate mania; and that atypical antipsychotics, electroconvulsive therapy (ECT) and transcranial magnetic stimulation seem to have promising effects in the short-term therapy of moderate mania. In contrast, the scale has been used to demonstrate that calcium antagonists (e.g. verapamil) are ineffective in the treatment of mania. MAS has also been used to add to the literature on the evidence-based effect of lithium as a short-term therapy for hypomania or mixed bipolar states and as a long-term therapy of bipolar states.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bech</LastName><ForeName>Per</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Psychiatric Research Unit, WHO Collaborating Centre for Mental Health, Frederiksborg General Hospital, Hillerød, Denmark. pebe@fa.dk</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>CNS Drugs</MedlineTA><NlmUniqueID>9431220</NlmUniqueID><ISSNLinking>1172-7047</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008134" MajorTopicYN="N">Long-Term Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015588" MajorTopicYN="N">Observer Variation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="Y">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011614" MajorTopicYN="N">Psychotherapy, Brief</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>112</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>1</Month><Day>5</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>3</Month><Day>19</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>1</Month><Day>5</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11772118</ArticleId><ArticleId IdType="pii">160104</ArticleId><ArticleId IdType="doi">10.2165/00023210-200216010-00004</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arch Gen Psychiatry. 2000 Sep;57(9):841-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10986547</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2001 Jul;104(1):25-30</Citation><ArticleIdList><ArticleId IdType="pubmed">11437746</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1999 Jul;54(1-2):119-28</Citation><ArticleIdList><ArticleId IdType="pubmed">10403155</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychopharmacol. 1991 Feb;11(1):3-21</Citation><ArticleIdList><ArticleId IdType="pubmed">1674948</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Soc Clin Psychol. 1967 Dec;6(4):278-96</Citation><ArticleIdList><ArticleId IdType="pubmed">6080235</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 1988 Jul 16;2(8603):119-25</Citation><ArticleIdList><ArticleId IdType="pubmed">2899186</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 1989;13(1-2):127-36</Citation><ArticleIdList><ArticleId IdType="pubmed">2664882</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1987 Mar-Apr;12(2):153-7</Citation><ArticleIdList><ArticleId IdType="pubmed">2955007</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 1998 Sep-Oct;32(5):261-4</Citation><ArticleIdList><ArticleId IdType="pubmed">9789203</ArticleId></ArticleIdList></Reference><Reference><Citation>World J Biol Psychiatry. 2000 Apr;1(2):65-74</Citation><ArticleIdList><ArticleId IdType="pubmed">12607202</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand Suppl. 1986;326:1-37</Citation><ArticleIdList><ArticleId IdType="pubmed">3458353</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 1999 Nov;60(11):759-62</Citation><ArticleIdList><ArticleId IdType="pubmed">10584764</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 1979 Apr;59(4):420-30</Citation><ArticleIdList><ArticleId IdType="pubmed">433633</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 1996 Nov;57(11):543-6</Citation><ArticleIdList><ArticleId IdType="pubmed">8968305</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1980 Dec;2(4):279-88</Citation><ArticleIdList><ArticleId IdType="pubmed">6450787</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1986 Nov;143(11):1450-3</Citation><ArticleIdList><ArticleId IdType="pubmed">3535543</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1999 May;156(5):702-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10327902</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1998 Nov;51(2):145-51</Citation><ArticleIdList><ArticleId IdType="pubmed">10743847</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1986 Nov;149:541-7</Citation><ArticleIdList><ArticleId IdType="pubmed">3814947</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacology (Berl). 1996 Nov;128(2):115-29</Citation><ArticleIdList><ArticleId IdType="pubmed">8956373</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1967 Jan;16(1):118-26</Citation><ArticleIdList><ArticleId IdType="pubmed">5333776</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 1971 Jun 26;1(7713):1319-25</Citation><ArticleIdList><ArticleId IdType="pubmed">4103395</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2000 Aug;61(8):585-93</Citation><ArticleIdList><ArticleId IdType="pubmed">10982202</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 1954 Nov;17(4):250-60</Citation><ArticleIdList><ArticleId IdType="pubmed">13212414</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1985 May-Jun;8(3):251-7</Citation><ArticleIdList><ArticleId IdType="pubmed">2862170</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2001 May;64(2-3):267-70</Citation><ArticleIdList><ArticleId IdType="pubmed">11313094</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 1970 Aug 15;2(7668):326-30</Citation><ArticleIdList><ArticleId IdType="pubmed">4194439</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1993 Apr;27(4):267-72</Citation><ArticleIdList><ArticleId IdType="pubmed">8099591</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2001 Apr;62(4):249-55</Citation><ArticleIdList><ArticleId IdType="pubmed">11379838</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 1997 Nov;96(5):367-72</Citation><ArticleIdList><ArticleId IdType="pubmed">9395155</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1991 Sep;48(9):851-5</Citation><ArticleIdList><ArticleId IdType="pubmed">1929776</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Rehabil Res. 1999 Dec;22(4):303-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10669980</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1990 Feb;18(2):113-9</Citation><ArticleIdList><ArticleId IdType="pubmed">2137468</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1994 Jul;165(1):113-6</Citation><ArticleIdList><ArticleId IdType="pubmed">7953013</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1999 Aug 1;46(3):432-6</Citation><ArticleIdList><ArticleId IdType="pubmed">10435211</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 1996 Oct;94(4):241-51</Citation><ArticleIdList><ArticleId IdType="pubmed">8911559</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 1975 Jul;52(1):1-6</Citation><ArticleIdList><ArticleId IdType="pubmed">1155198</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1988 Aug;153:198-204</Citation><ArticleIdList><ArticleId IdType="pubmed">3151275</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1997 Apr;43(2):151-61</Citation><ArticleIdList><ArticleId IdType="pubmed">9165384</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Med Psychol. 1959;32(1):50-5</Citation><ArticleIdList><ArticleId IdType="pubmed">13638508</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1978 Nov;133:429-35</Citation><ArticleIdList><ArticleId IdType="pubmed">728692</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 1976 Dec 6;236(23):2645-6</Citation><ArticleIdList><ArticleId IdType="pubmed">1036539</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 1995 Jul;92(1):69-74</Citation><ArticleIdList><ArticleId IdType="pubmed">7572251</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1997 Aug;171:113-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9337944</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2001 Jun;62(6):421-5</Citation><ArticleIdList><ArticleId IdType="pubmed">11465518</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1972 Feb;26(2):146-53</Citation><ArticleIdList><ArticleId IdType="pubmed">4551257</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2000 May;157(5):835-6</Citation><ArticleIdList><ArticleId IdType="pubmed">10784486</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 1996 Feb;93(2):119-24</Citation><ArticleIdList><ArticleId IdType="pubmed">8686481</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2000 Feb;57(2):187-90</Citation><ArticleIdList><ArticleId IdType="pubmed">10665622</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1998 Nov;155(11):1608-10</Citation><ArticleIdList><ArticleId IdType="pubmed">9812128</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1997 Jun 15;41(12):1165-73</Citation><ArticleIdList><ArticleId IdType="pubmed">9171907</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1994 Feb;151(2):169-76</Citation><ArticleIdList><ArticleId IdType="pubmed">8296883</ArticleId></ArticleIdList></Reference><Reference><Citation>Depress Anxiety. 1997;5(2):73-83</Citation><ArticleIdList><ArticleId IdType="pubmed">9262937</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhonghua Shen Jing Jing Shen Ke Za Zhi. 1991 Aug;24(4):200-2, 251</Citation><ArticleIdList><ArticleId IdType="pubmed">1954789</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1990 Dec;47(12):1093-9</Citation><ArticleIdList><ArticleId IdType="pubmed">2244793</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 1994 Mar 23-30;271(12):918-24</Citation><ArticleIdList><ArticleId IdType="pubmed">8120960</ArticleId></ArticleIdList></Reference><Reference><Citation>Compr Psychiatry. 1991 May-Jun;32(3):187-94</Citation><ArticleIdList><ArticleId IdType="pubmed">1884599</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2000 Sep;61(9):649-55</Citation><ArticleIdList><ArticleId IdType="pubmed">11030485</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Med Psychol (Paris). 1952 Mar;110(1 3):331-5</Citation><ArticleIdList><ArticleId IdType="pubmed">12976825</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Neuropharmacol. 1998 May-Jun;21(3):176-80</Citation><ArticleIdList><ArticleId IdType="pubmed">9617509</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1970 Mar;22(3):252-61</Citation><ArticleIdList><ArticleId IdType="pubmed">5413274</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1999 Jun 15;45(12):1580-4</Citation><ArticleIdList><ArticleId IdType="pubmed">10376118</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhonghua Shen Jing Jing Shen Ke Za Zhi. 1990 Oct;23(5):261-5, 318</Citation><ArticleIdList><ArticleId IdType="pubmed">2282877</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Psychiatry Clin Pract. 2000;4(3):171-93</Citation><ArticleIdList><ArticleId IdType="pubmed">24927452</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 1991 May;52 Suppl:28-34</Citation><ArticleIdList><ArticleId IdType="pubmed">1903134</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmatherapeutica. 1987;5(1):62-8</Citation><ArticleIdList><ArticleId IdType="pubmed">3602024</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nerv Ment Dis. 1993 Dec;181(12):718-24</Citation><ArticleIdList><ArticleId IdType="pubmed">8254322</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1988 Aug;45(8):727-32</Citation><ArticleIdList><ArticleId IdType="pubmed">2899425</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacopsychiatry. 1991 May;24(3):85-8</Citation><ArticleIdList><ArticleId IdType="pubmed">1909797</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1992 Oct;49(10):769-73</Citation><ArticleIdList><ArticleId IdType="pubmed">1417428</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Clin Psychiatry. 1999 Dec;11(4):217-22</Citation><ArticleIdList><ArticleId IdType="pubmed">10596736</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropharmacology. 1978 Jun;17(6):430-1</Citation><ArticleIdList><ArticleId IdType="pubmed">673161</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1969 Oct;21(4):486-96</Citation><ArticleIdList><ArticleId IdType="pubmed">4896983</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2000 Mar;157(3):463-5</Citation><ArticleIdList><ArticleId IdType="pubmed">10698828</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 1976 Jan;53(1):70-81</Citation><ArticleIdList><ArticleId IdType="pubmed">1251757</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 1992 Jan;85(1):65-9</Citation><ArticleIdList><ArticleId IdType="pubmed">1546552</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 1992 Feb;85(2):114-8</Citation><ArticleIdList><ArticleId IdType="pubmed">1543034</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychopharmacol. 1999 Aug;19(4):303-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10440456</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62</Citation><ArticleIdList><ArticleId IdType="pubmed">14399272</ArticleId></ArticleIdList></Reference><Reference><Citation>Can J Psychiatry. 1997 Aug;42 Suppl 2:79S-86S</Citation><ArticleIdList><ArticleId IdType="pubmed">9288440</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 1998 Jun;97(6):387-97</Citation><ArticleIdList><ArticleId IdType="pubmed">9669508</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychopharmacol. 2000 Feb;20(1 Suppl 1):1S-17S</Citation><ArticleIdList><ArticleId IdType="pubmed">10646685</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1987 Jun;150:863-4</Citation><ArticleIdList><ArticleId IdType="pubmed">3651744</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropsychiatr. 2000 Sep;12(3):115-9</Citation><ArticleIdList><ArticleId IdType="pubmed">26975267</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19473667</PMID><DateCompleted><Year>2009</Year><Month>11</Month><Day>23</Day></DateCompleted><DateRevised><Year>2009</Year><Month>09</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-1379</ISSN><JournalIssue CitedMedium="Internet"><Volume>43</Volume><Issue>14</Issue><PubDate><Year>2009</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Journal of psychiatric research</Title><ISOAbbreviation>J Psychiatr Res</ISOAbbreviation></Journal><ArticleTitle>Decreased brain-derived neurotrophic factor in medicated and drug-free bipolar patients.</ArticleTitle><Pagination><MedlinePgn>1171-4</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jpsychires.2009.04.002</ELocationID><Abstract><AbstractText>Bipolar disorder (BD) has been associated with abnormalities in neuroplasticity and previous studies suggest an important role for BDNF in the pathophysiology of BD. The confounding effect of the use of medication in these studies has been considered a limitation. Thus, studies with both drug-free and medicated patients are necessary to assess the role of medication in serum BDNF levels. Twenty-two manic and depressed drug-free and 22 medicated BD type I patients were matched to 22 controls according to sex and age in a cross-sectional study. BDNF serum levels were assessed using sandwich-ELISA. Serum BDNF levels in drug-free (0.23+/-0.09), and medicated (0.29+/-0.19) BD patients were decreased when compared to controls (0.40+/-0.12) - drug-free/medicated vs. control p&lt;0.001. The BDNF levels did not differ between medicated and drug-free BD patients. When analyzing patients according to mood states, serum BDNF levels were lower in BD patients during both manic (0.28+/-0.11) and depressive episodes (0.22+/-0.17), as compared with healthy controls (0.40+/-0.12) - manic/depressed patients vs. controls p&lt;0.001. Results suggest that the association of lower serum BDNF and BD mood episodes is kept even in medicated patients, which strengthens the notion that BDNF serum levels may be considered a biomarker of mood episodes in BD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>de Oliveira</LastName><ForeName>Gislaine S</ForeName><Initials>GS</Initials><AffiliationInfo><Affiliation>Bipolar Disorder Program, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ceresér</LastName><ForeName>Keila Maria</ForeName><Initials>KM</Initials></Author><Author ValidYN="Y"><LastName>Fernandes</LastName><ForeName>Brisa Simões</ForeName><Initials>BS</Initials></Author><Author ValidYN="Y"><LastName>Kauer-Sant'Anna</LastName><ForeName>Marcia</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Fries</LastName><ForeName>Gabriel Rodrigo</ForeName><Initials>GR</Initials></Author><Author ValidYN="Y"><LastName>Stertz</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Aguiar</LastName><ForeName>Bianca</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Pfaffenseller</LastName><ForeName>Bianca</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Kapczinski</LastName><ForeName>Flavio</ForeName><Initials>F</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>05</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Psychiatr Res</MedlineTA><NlmUniqueID>0376331</NlmUniqueID><ISSNLinking>0022-3956</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019208">Brain-Derived Neurotrophic Factor</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019208" MajorTopicYN="N">Brain-Derived Neurotrophic Factor</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>02</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2009</Year><Month>04</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>04</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>5</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>5</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19473667</ArticleId><ArticleId IdType="pii">S0022-3956(09)00082-X</ArticleId><ArticleId IdType="doi">10.1016/j.jpsychires.2009.04.002</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">28073041</PMID><DateCompleted><Year>2017</Year><Month>11</Month><Day>27</Day></DateCompleted><DateRevised><Year>2019</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>210</Volume><PubDate><Year>2017</Year><Month>Mar</Month><Day>01</Day></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Major depressive disorder with subthreshold hypomanic (mixed) features: A real-world assessment of treatment patterns and economic burden.</ArticleTitle><Pagination><MedlinePgn>332-337</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0165-0327(16)31424-0</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2016.12.033</ELocationID><Abstract><AbstractText Label="BACKGROUND">To compare outcomes for individuals with major depressive disorder (MDD) with or without subthreshold hypomania (mixed features) in naturalistic settings.</AbstractText><AbstractText Label="METHODS">Using the Optum Research Database (1/1/2009─10/31/2014), a retrospective analysis of individuals newly diagnosed with MDD was conducted. Continuous enrollment for 12-months before and after the initial MDD diagnosis was required. MDD with subthreshold hypomania (mixed features) (MDD-MF) was defined based on ≥1 hypomania diagnosis within 30 days after an MDD diagnosis during the one-year follow-up period, in the absence of bipolar I diagnoses. Psychiatric medication use, healthcare utilization, and costs during the one-year follow-up period were compared using multivariate logistic and gamma regressions, controlling for baseline differences.</AbstractText><AbstractText Label="RESULTS">Of 130,626 MDD individuals, 652 (0.5%) met the operational definition of MDD-MF. Compared to the MDD-only group, the MDD-MF group had more suicidality (2.0% vs. 0.5%), anxiety disorders (46.8% vs. 34.0%), and substance use disorders (15.5% vs. 6.1%, all P&lt;0.001). More individuals with MDD-MF were treated with antidepressants (83.6% vs. 71.6%), mood stabilizers (50.5% vs. 2.7%), atypical antipsychotics (39.0% vs. 5.5%), and polypharmacy with multiple drug classes (72.1% vs. 22.7%, all P&lt;0.001). Individuals with MDD-MF had higher hospitalizations rates (24.2% vs. 10.5%) and total healthcare costs (mean: $15,660 vs. $10,744, all P&lt;0.001).</AbstractText><AbstractText Label="LIMITATIONS">The commercial claims data used were not collected for research purposes and may over- or under-represent certain populations. No specific claims-based diagnostic code for MDD with mixed features exists.</AbstractText><AbstractText Label="CONCLUSIONS">Greater use of mood stabilizers, atypical antipsychotics, polypharmacy, and healthcare resources provides evidence of the complexity and severity of MDD-MF. Identifying optimal treatment regimens for this population represents a major unmet medical need.</AbstractText><CopyrightInformation>Copyright © 2016 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McIntyre</LastName><ForeName>Roger S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>University of Toronto, MDPU-BCDF, Toronto, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ng-Mak</LastName><ForeName>Daisy</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Sunovion Pharmaceuticals Inc., Marlborough, MA, USA. Electronic address: Daisy.Ng-Mak@Sunovion.Com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chuang</LastName><ForeName>Chien-Chia</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Vertex Pharmaceuticals Inc., Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Halpern</LastName><ForeName>Rachel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Optum, Prairie, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Pankaj A</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Kantar Health, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rajagopalan</LastName><ForeName>Krithika</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Sunovion Pharmaceuticals Inc., Marlborough, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loebel</LastName><ForeName>Antony</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Sunovion Pharmaceuticals Inc., Fort Lee, NY, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>12</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001008" MajorTopicYN="N">Anxiety Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017281" MajorTopicYN="N">Cost of Illness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017048" MajorTopicYN="N">Health Care Costs</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019966" MajorTopicYN="N">Substance-Related Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Drug utilization</Keyword><Keyword MajorTopicYN="Y">Health services research</Keyword><Keyword MajorTopicYN="Y">Healthcare administrative claims</Keyword><Keyword MajorTopicYN="Y">Major depressive disorder</Keyword><Keyword MajorTopicYN="Y">Major depressive disorder with mixed features</Keyword><Keyword MajorTopicYN="Y">Mood disorders</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>08</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>10</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>12</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>1</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>11</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>1</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28073041</ArticleId><ArticleId IdType="pii">S0165-0327(16)31424-0</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2016.12.033</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25379425</PMID><DateCompleted><Year>2015</Year><Month>07</Month><Day>20</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2213-1582</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><PubDate><Year>2014</Year></PubDate></JournalIssue><Title>NeuroImage. Clinical</Title><ISOAbbreviation>Neuroimage Clin</ISOAbbreviation></Journal><ArticleTitle>Multimodal assessments of the hippocampal formation in schizophrenia and bipolar disorder: evidences from neurobehavioral measures and functional and structural MRI.</ArticleTitle><Pagination><MedlinePgn>134-44</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.nicl.2014.08.015</ELocationID><Abstract><AbstractText>A potential clinical and etiological overlap between schizophrenia (SZ) and bipolar disorder (BD) has long been a subject of discussion. Imaging studies imply functional and structural alterations of the hippocampus in both diseases. Thus, imaging this core memory region could provide insight into the pathophysiology of these disorders and the associated cognitive deficits. To examine possible shared alterations in the hippocampus, we conducted a multi-modal assessment, including functional and structural imaging as well as neurobehavioral measures of memory performance in BD and SZ patients compared with healthy controls. We assessed episodic memory performance, using tests of verbal and visual learning (HVLT, BVMT) in three groups of participants: BD patients (n = 21), SZ patients (n = 21) and matched (age, gender, education) healthy control subjects (n = 21). In addition, we examined hippocampal resting state functional connectivity, hippocampal volume using voxel-based morphometry (VBM) and fibre integrity of hippocampal connections using diffusion tensor imaging (DTI). We found memory deficits, changes in functional connectivity within the hippocampal network as well as volumetric reductions and altered white matter fibre integrity across patient groups in comparison with controls. However, SZ patients when directly compared with BD patients were more severely affected in several of the assessed parameters (verbal learning, left hippocampal volumes, mean diffusivity of bilateral cingulum and right uncinated fasciculus). The results of our study suggest a graded expression of verbal learning deficits accompanied by structural alterations within the hippocampus in BD patients and SZ patients, with SZ patients being more strongly affected. Our findings imply that these two disorders may share some common pathophysiological mechanisms. The results could thus help to further advance and integrate current pathophysiological models of SZ and BD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Knöchel</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Laboratory of Neurophysiology and Neuroimaging, Dept. of Psychiatry, Psychosomatic Medicine and Psychotherapy, Goethe Univ., Frankfurt/Main, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stäblein</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Laboratory of Neurophysiology and Neuroimaging, Dept. of Psychiatry, Psychosomatic Medicine and Psychotherapy, Goethe Univ., Frankfurt/Main, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Storchak</LastName><ForeName>Helena</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Laboratory of Neurophysiology and Neuroimaging, Dept. of Psychiatry, Psychosomatic Medicine and Psychotherapy, Goethe Univ., Frankfurt/Main, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reinke</LastName><ForeName>Britta</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Laboratory of Neurophysiology and Neuroimaging, Dept. of Psychiatry, Psychosomatic Medicine and Psychotherapy, Goethe Univ., Frankfurt/Main, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jurcoane</LastName><ForeName>Alina</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute for Neuroradiology, Goethe Univ., Frankfurt/Main, Germany ; Center for Individual Development and Adaptive Education of Children at Risk, Frankfurt/Main, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prvulovic</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Laboratory of Neurophysiology and Neuroimaging, Dept. of Psychiatry, Psychosomatic Medicine and Psychotherapy, Goethe Univ., Frankfurt/Main, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Linden</LastName><ForeName>David E J</ForeName><Initials>DE</Initials><AffiliationInfo><Affiliation>MRC Centre for Neuropsychiatric Genetics and Genomics, Institute of Psychological Medicine and Clinical Neurosciences, School of Medicine, Cardiff University, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van de Ven</LastName><ForeName>Vincent</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Cognitive Neuroscience, Faculty of Psychology and Neuroscience, Maastricht University, Maastricht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghinea</LastName><ForeName>Denisa</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Laboratory of Neurophysiology and Neuroimaging, Dept. of Psychiatry, Psychosomatic Medicine and Psychotherapy, Goethe Univ., Frankfurt/Main, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wenzler</LastName><ForeName>Sofia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Laboratory of Neurophysiology and Neuroimaging, Dept. of Psychiatry, Psychosomatic Medicine and Psychotherapy, Goethe Univ., Frankfurt/Main, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alves</LastName><ForeName>Gilberto</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Center for Alzheimer's Disease and Related Disorders, Universidade Federal, do Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matura</LastName><ForeName>Silke</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Laboratory of Neurophysiology and Neuroimaging, Dept. of Psychiatry, Psychosomatic Medicine and Psychotherapy, Goethe Univ., Frankfurt/Main, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kröger</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Laboratory of Neurophysiology and Neuroimaging, Dept. of Psychiatry, Psychosomatic Medicine and Psychotherapy, Goethe Univ., Frankfurt/Main, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oertel-Knöchel</LastName><ForeName>Viola</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Laboratory of Neurophysiology and Neuroimaging, Dept. of Psychiatry, Psychosomatic Medicine and Psychotherapy, Goethe Univ., Frankfurt/Main, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MR/L010305/1</GrantID><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>08</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Neuroimage Clin</MedlineTA><NlmUniqueID>101597070</NlmUniqueID><ISSNLinking>2213-1582</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061212" MajorTopicYN="N">Memory, Episodic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="Y">Schizophrenic Psychology</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bipolar</Keyword><Keyword MajorTopicYN="N">DTI</Keyword><Keyword MajorTopicYN="N">Hippocampus</Keyword><Keyword MajorTopicYN="N">Resting state</Keyword><Keyword MajorTopicYN="N">Schizophrenia</Keyword><Keyword MajorTopicYN="N">VBM</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>05</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>07</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>08</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>11</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>11</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>7</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25379425</ArticleId><ArticleId IdType="doi">10.1016/j.nicl.2014.08.015</ArticleId><ArticleId IdType="pii">S2213-1582(14)00124-7</ArticleId><ArticleId IdType="pmc">PMC4215399</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Clin Psychiatry. 2003 Jun;64(6):663-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12823080</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2009 Sep;35(5):1022-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18495643</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Brain Mapp. 2006 May;27(5):392-401</Citation><ArticleIdList><ArticleId IdType="pubmed">16596654</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2005 Jan;10(1):105-16</Citation><ArticleIdList><ArticleId IdType="pubmed">15340357</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2011 Feb;13(1):1-15</Citation><ArticleIdList><ArticleId IdType="pubmed">21320248</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Hum Neurosci. 2012 Jun 21;6:184</Citation><ArticleIdList><ArticleId IdType="pubmed">22737116</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2007 Mar 15;61(6):776-81</Citation><ArticleIdList><ArticleId IdType="pubmed">17027928</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2013 Oct;150(1):42-50</Citation><ArticleIdList><ArticleId IdType="pubmed">23911259</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2003 Jun;60(6):601-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12796223</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2008 Jul;65(7):746-60</Citation><ArticleIdList><ArticleId IdType="pubmed">18606948</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2012 Jan 16;59(2):1420-8</Citation><ArticleIdList><ArticleId IdType="pubmed">21889994</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2010 Jul 30;183(1):59-68</Citation><ArticleIdList><ArticleId IdType="pubmed">20553873</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2009 Dec 30;174(3):195-201</Citation><ArticleIdList><ArticleId IdType="pubmed">19910166</ArticleId></ArticleIdList></Reference><Reference><Citation>Magn Reson Med. 2002 Jun;47(6):1202-10</Citation><ArticleIdList><ArticleId IdType="pubmed">12111967</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2005 Apr;30(4):765-74</Citation><ArticleIdList><ArticleId IdType="pubmed">15702141</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2010 Mar;117(1):21-30</Citation><ArticleIdList><ArticleId IdType="pubmed">20097544</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2003 Jul;19(3):1233-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12880848</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2002 Jan 1;53(1-2):31-44</Citation><ArticleIdList><ArticleId IdType="pubmed">11728836</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2012 Jun;14(4):375-410</Citation><ArticleIdList><ArticleId IdType="pubmed">22631621</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2010 Feb;196(2):92-5</Citation><ArticleIdList><ArticleId IdType="pubmed">20118450</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2012 Jan 12;73(1):8-22</Citation><ArticleIdList><ArticleId IdType="pubmed">22243743</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2004 Feb;21(2):757-67</Citation><ArticleIdList><ArticleId IdType="pubmed">14980579</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2011 Jun;13(4):334-42</Citation><ArticleIdList><ArticleId IdType="pubmed">21843273</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2013 Mar;39(2):358-65</Citation><ArticleIdList><ArticleId IdType="pubmed">22080493</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2009 Mar 31;171(3):189-98</Citation><ArticleIdList><ArticleId IdType="pubmed">19230623</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2006 Jul 15;31(4):1487-505</Citation><ArticleIdList><ArticleId IdType="pubmed">16624579</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Arch Psychiatry Clin Neurosci. 2008 Sep;258(6):345-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18347837</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2000 Jan;157(1):16-25</Citation><ArticleIdList><ArticleId IdType="pubmed">10618008</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2006 Jul 15;31(4):1536-48</Citation><ArticleIdList><ArticleId IdType="pubmed">16632379</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2005 May;186:364-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15863738</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2010 Jun 30;182(3):207-10</Citation><ArticleIdList><ArticleId IdType="pubmed">20493671</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet B Neuropsychiatr Genet. 2014 Jan;165B(1):9-18</Citation><ArticleIdList><ArticleId IdType="pubmed">24339136</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand Suppl. 1981;295:1-101</Citation><ArticleIdList><ArticleId IdType="pubmed">7044046</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2011 Dec 1;35(8):1820-6</Citation><ArticleIdList><ArticleId IdType="pubmed">21624424</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2011 Aug-Sep;13(5-6):545-55</Citation><ArticleIdList><ArticleId IdType="pubmed">22017223</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2008 Jan 1;39(1):336-47</Citation><ArticleIdList><ArticleId IdType="pubmed">17931890</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 1998 Mar 10;30(2):115-25</Citation><ArticleIdList><ArticleId IdType="pubmed">9549774</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2002 Apr;15(4):870-8</Citation><ArticleIdList><ArticleId IdType="pubmed">11906227</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2011 Nov 30;194(2):149-56</Citation><ArticleIdList><ArticleId IdType="pubmed">21924872</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2005 Apr;62(4):379-86</Citation><ArticleIdList><ArticleId IdType="pubmed">15809405</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2014 Feb;155:223-33</Citation><ArticleIdList><ArticleId IdType="pubmed">24295601</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2011 Sep;36(10):2009-17</Citation><ArticleIdList><ArticleId IdType="pubmed">21654735</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropsychiatr. 2009 Sep 23;21(6):228-238</Citation><ArticleIdList><ArticleId IdType="pubmed">20676360</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 1987;13(2):261-76</Citation><ArticleIdList><ArticleId IdType="pubmed">3616518</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2000 Sep;2(3 Pt 2):237-48</Citation><ArticleIdList><ArticleId IdType="pubmed">11249801</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2006 Feb;8(1):28-39</Citation><ArticleIdList><ArticleId IdType="pubmed">16411978</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2012 Mar 15;71(6):552-60</Citation><ArticleIdList><ArticleId IdType="pubmed">22281121</ArticleId></ArticleIdList></Reference><Reference><Citation>Magn Reson Med. 1995 Oct;34(4):537-41</Citation><ArticleIdList><ArticleId IdType="pubmed">8524021</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">14531760</PMID><DateCompleted><Year>2004</Year><Month>04</Month><Day>01</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0001-690X</ISSN><JournalIssue CitedMedium="Print"><Volume>108</Volume><Issue>5</Issue><PubDate><Year>2003</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Acta psychiatrica Scandinavica</Title><ISOAbbreviation>Acta Psychiatr Scand</ISOAbbreviation></Journal><ArticleTitle>No association between two polymorphisms at the 5HT2A gene and bipolar affective puerperal psychosis.</ArticleTitle><Pagination><MedlinePgn>387-91</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To examine whether variation at two common polymorphisms, T102C and -1438AG, of the serotonin 2A gene (5HT2A) are involved in the puerperal triggering mechanism of bipolar affective puerperal psychosis.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">A total of 242 parous women diagnosed with bipolar disorder were genotyped for the two polymorphisms. Of these, 165 women had experienced a manic or psychotic episode, according to DSM-IV criteria, within 6 weeks of childbirth (the puerperal psychosis group). The comparison group comprised of 77 parous women who had not experienced psychiatric disturbance following childbirth.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">No significant differences between genotype or allelic frequencies were found between the two groups for either polymorphism.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The results indicate that variation at two common polymorphisms of the 5HT2A gene does not appear to play a major role in the development of bipolar affective puerperal psychosis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Robertson</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Division of Neuroscience, Queen Elizabeth Psychiatric Hospital, University of Birmingham, Edgbaston, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>I</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Middle</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Moray</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Craddock</LastName><ForeName>N</ForeName><Initials>N</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>G9810900</GrantID><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Acta Psychiatr Scand</MedlineTA><NlmUniqueID>0370364</NlmUniqueID><ISSNLinking>0001-690X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D044402">Receptor, Serotonin, 5-HT2A</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005787" MajorTopicYN="N">Gene Frequency</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011110" MajorTopicYN="N">Polymorphism, Genetic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011644" MajorTopicYN="N">Puerperal Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044402" MajorTopicYN="N">Receptor, Serotonin, 5-HT2A</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012016" MajorTopicYN="N">Reference Values</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>10</Month><Day>9</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>4</Month><Day>2</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>10</Month><Day>9</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">14531760</ArticleId><ArticleId IdType="pii">167</ArticleId><ArticleId IdType="doi">10.1034/j.1600-0447.2003.00167.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21377212</PMID><DateCompleted><Year>2011</Year><Month>11</Month><Day>01</Day></DateCompleted><DateRevised><Year>2016</Year><Month>11</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>132</Volume><Issue>1-2</Issue><PubDate><Year>2011</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>The seasonality of bipolar affective disorder: comparison with a primary care sample using the Seasonal Pattern Assessment Questionnaire.</ArticleTitle><Pagination><MedlinePgn>289-92</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2011.02.015</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">In contrast with recurrent unipolar depression, relatively little is known about the seasonality of depressive episodes in bipolar affective disorder (BAD).</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">We compared responses on the Seasonal Pattern Assessment Questionnaire (SPAQ) between a cohort of 183 patients with BAD and a large sample of patients in primary care (N=4746). Comparisons were adjusted for age and gender.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">27% of the BAD patients fulfilled SPAQ criteria for Seasonal Affective Disorder (SAD. This gave an adjusted odds ratio of 3.73 (95% confidence intervals 2.64 to 5.27) in comparison with the rate among the primary care samples. Global seasonality scores were significantly higher among BAD patients (adjusted mean difference 1.73, 95% CI 0.97 to 2.49, p&lt;0.001).</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">The SPAQ was originally designed as a screening instrument rather than as a case-finding instrument.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Vigilance for seasonal symptom recurrence in BAD may be important with regard to management and relapse prevention.</AbstractText><CopyrightInformation>Copyright © 2011 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shand</LastName><ForeName>Allen J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Royal Cornhill Hospital, Aberdeen, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scott</LastName><ForeName>Neil W</ForeName><Initials>NW</Initials></Author><Author ValidYN="Y"><LastName>Anderson</LastName><ForeName>Seonaid M</ForeName><Initials>SM</Initials></Author><Author ValidYN="Y"><LastName>Eagles</LastName><ForeName>John M</ForeName><Initials>JM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>03</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008403" MajorTopicYN="N">Mass Screening</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011320" MajorTopicYN="N">Primary Health Care</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016574" MajorTopicYN="N">Seasonal Affective Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012621" MajorTopicYN="Y">Seasons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="Y">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006113" MajorTopicYN="N">United Kingdom</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>12</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2011</Year><Month>02</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>02</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>3</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>3</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>11</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21377212</ArticleId><ArticleId IdType="pii">S0165-0327(11)00069-3</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2011.02.015</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">2840887</PMID><DateCompleted><Year>1988</Year><Month>09</Month><Day>01</Day></DateCompleted><DateRevised><Year>2017</Year><Month>02</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0004-8674</ISSN><JournalIssue CitedMedium="Print"><Volume>22</Volume><Issue>2</Issue><PubDate><Year>1988</Year><Month>Jun</Month></PubDate></JournalIssue><Title>The Australian and New Zealand journal of psychiatry</Title><ISOAbbreviation>Aust N Z J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Mania associated with small cell carcinoma of the lung.</ArticleTitle><Pagination><MedlinePgn>207-9</MedlinePgn></Pagination><Abstract><AbstractText>This paper describes a case of small cell carcinoma of the lung with ectopic adrenocorticotropic hormone (ACTH) production which presented with mania. The association between manic syndromes and the various forms of glucocorticoid or ACTH excess is discussed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Collins</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Sunnyside Hospital, Christchurch, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oakley-Browne</LastName><ForeName>M</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Aust N Z J Psychiatry</MedlineTA><NlmUniqueID>0111052</NlmUniqueID><ISSNLinking>0004-8674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>J6292F8L3D</RegistryNumber><NameOfSubstance UI="D006220">Haloperidol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000182" MajorTopicYN="N">ACTH Syndrome, Ectopic</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018288" MajorTopicYN="N">Carcinoma, Small Cell</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006220" MajorTopicYN="N">Haloperidol</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019965" MajorTopicYN="N">Neurocognitive Disorders</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1988</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1988</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1988</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2840887</ArticleId><ArticleId IdType="doi">10.3109/00048678809158962</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8682975</PMID><DateCompleted><Year>1996</Year><Month>08</Month><Day>16</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0165-0327</ISSN><JournalIssue CitedMedium="Print"><Volume>37</Volume><Issue>1</Issue><PubDate><Year>1996</Year><Month>Feb</Month><Day>12</Day></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Mood-congruent versus mood-incongruent psychotic symptoms in first-admission patients with affective disorder.</ArticleTitle><Pagination><MedlinePgn>23-9</MedlinePgn></Pagination><Abstract><AbstractText>The distribution of mood-congruent and mood-incongruent symptoms in 49 first-admission DSM-III-R psychotic bipolar and 35 psychotic depressed patients is presented. Most patients had mood-incongruent symptoms (77.4%). 73% of mood-incongruent bipolars and 32% of incongruent depressives had a combination of mood-congruent and mood-incongruent symptoms. Demographic and clinical variables were unrelated to incongruence. The only 24-month clinical outcome predicted by mood incongruence was poorer GAF rating. 15 of the 16 patients whose diagnosis was changed at follow-up from affective to nonaffective psychosis had mood-incongruent features initially. The findings raise questions about the general prognostic utility of mood congruence.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fennig</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Science, State University of New York at Stony Brook 11794-8790, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bromet</LastName><ForeName>E J</ForeName><Initials>EJ</Initials></Author><Author ValidYN="Y"><LastName>Karant</LastName><ForeName>M T</ForeName><Initials>MT</Initials></Author><Author ValidYN="Y"><LastName>Ram</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Jandorf</LastName><ForeName>L</ForeName><Initials>L</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>44801</GrantID><Agency>PHS HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000341" MajorTopicYN="N">Affective Disorders, Psychotic</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010343" MajorTopicYN="N">Patient Admission</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="Y">Psychiatric Status Rating Scales</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="N">Schizophrenic Psychology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1996</Year><Month>2</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1996</Year><Month>2</Month><Day>12</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1996</Year><Month>2</Month><Day>12</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8682975</ArticleId><ArticleId IdType="pii">0165032795000739</ArticleId><ArticleId IdType="doi">10.1016/0165-0327(95)00073-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">32692124</PMID><DateCompleted><Year>2021</Year><Month>09</Month><Day>01</Day></DateCompleted><DateRevised><Year>2021</Year><Month>09</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-1145</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>4</Issue><PubDate><Year>2020</Year><Month>07</Month></PubDate></JournalIssue><Title>Journal of psychiatric practice</Title><ISOAbbreviation>J Psychiatr Pract</ISOAbbreviation></Journal><ArticleTitle>Cognitive Remediation for Outpatients With Recurrent Mood Disorders: A Feasibility Study.</ArticleTitle><Pagination><MedlinePgn>273-283</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/PRA.0000000000000487</ELocationID><Abstract><AbstractText>Current first-line treatments for mood disorders often improve mood symptoms but do little to reduce cognitive and functional impairment. This 10-week, uncontrolled, feasibility study evaluated a cognitive remediation (CR) intervention for individuals with recurrent mood disorders. Adults with recurrent major depressive disorder or bipolar disorder, who had recently been treated and discharged from specialized mental health services, were eligible for inclusion. Twenty patients completed the CR intervention, which involved weekly individual sessions with a therapist, as well as the practice of computerized CR exercises between sessions. The study assessed the acceptability of the assessment and treatment as well as outcomes in terms of mood symptoms, general functioning, and cognitive functioning. Patients reported that they were generally satisfied with the CR intervention and were close to reaching the recommended amount of practice between therapist-led sessions. The retention rate from baseline to posttreatment was 87%. When within-group effects were examined, large effect sizes over time (&gt;0.9) were seen for 2 cognitive variables that measured executive function: Category Switching-Total Words and Total Switching Score. Findings from the current feasibility study will inform the development of a large randomized controlled trial of an adapted version of the CR intervention for mood disorders assessed in this preliminary study, with the goal of translating the intervention into clinical practice.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Douglas</LastName><ForeName>Katie M</ForeName><Initials>KM</Initials></Author><Author ValidYN="Y"><LastName>Jordan</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Inder</LastName><ForeName>Maree L</ForeName><Initials>ML</Initials></Author><Author ValidYN="Y"><LastName>Crowe</LastName><ForeName>Marie T</ForeName><Initials>MT</Initials></Author><Author ValidYN="Y"><LastName>Mulder</LastName><ForeName>Roger</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Lacey</LastName><ForeName>Cameron</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Beaglehole</LastName><ForeName>Ben</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Bowie</LastName><ForeName>Christopher R</ForeName><Initials>CR</Initials></Author><Author ValidYN="Y"><LastName>Porter</LastName><ForeName>Richard J</ForeName><Initials>RJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Psychiatr Pract</MedlineTA><NlmUniqueID>100901141</NlmUniqueID><ISSNLinking>1527-4160</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072466" MajorTopicYN="Y">Cognitive Remediation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005240" MajorTopicYN="N">Feasibility Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010045" MajorTopicYN="N">Outpatients</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>7</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32692124</ArticleId><ArticleId IdType="doi">10.1097/PRA.0000000000000487</ArticleId><ArticleId IdType="pii">00131746-202007000-00003</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Douglas KM, Porter RJ, Knight RG, et al. Neuropsychological changes and treatment response in severe depression. Br J Psychiatry. 2011;198:115–122.</Citation></Reference><Reference><Citation>Robinson LJ, Thompson JM, Gallagher P, et al. A meta-analysis of cognitive deficits in euthymic patients with bipolar disorder. J Affect Disord. 2006;93:105–115.</Citation></Reference><Reference><Citation>Porter RJ, Bourke C, Gallagher P. Neuropsychological impairment in major depression: its nature, origin and clinical significance. Aust N Z J Psychiatry. 2007;41:115–128.</Citation></Reference><Reference><Citation>Porter RJ, Robinson LJ, Malhi GS, et al. The neurocognitive profile of mood disorders—a review of the evidence and methodological issues. Bipolar Disord. 2015;17(suppl 2):21–40.</Citation></Reference><Reference><Citation>Depp CA, Mausbach BT, Harmell AL, et al. Meta-analysis of the association between cognitive abilities and everyday functioning in bipolar disorder. Bipolar Disord. 2012;14:217–226.</Citation></Reference><Reference><Citation>Gupta M, Holshausen K, Best MW, et al. Relationships among neurocognition, symptoms, and functioning in treatment-resistant depression. Arch Clin Neuropsychol. 2013;28:272–281.</Citation></Reference><Reference><Citation>Baune BT, Malhi GS. A review on the impact of cognitive dysfunction on social, occupational, and general functional outcomes in bipolar disorder. Bipolar Disord. 2015;17(suppl 2):41–55.</Citation></Reference><Reference><Citation>Wagner S, Doering B, Helmreich I, et al. A meta-analysis of executive dysfunctions in unipolar major depressive disorder without psychotic symptoms and their changes during antidepressant treatment. Acta Psychiatr Scand. 2012;125:281–292.</Citation></Reference><Reference><Citation>Reppermund S, Ising M, Lucae S, et al. Cognitive impairment in unipolar depression is persistent and non-specific: further evidence for the final common pathway disorder hypothesis. Psychol Med. 2009;39:603–614.</Citation></Reference><Reference><Citation>Porter RJ, Bourke C, Carter JD, et al. No change in neuropsychological dysfunction or emotional processing during treatment of major depression with cognitive-behaviour therapy or schema therapy. Psychol Med. 2016;46:393–404.</Citation></Reference><Reference><Citation>Shilyansky C, Williams LM, Gyurak A, et al. Effect of antidepressant treatment on cognitive impairments associated with depression: a randomised longitudinal study. Lancet Psychiatry. 2016;3:425–435.</Citation></Reference><Reference><Citation>Thorsen AL, Johansson K, Loberg EM. Neurobiology of cognitive remediation therapy for schizophrenia: a systematic review. Front Psychiatry. 2014;5:103.</Citation></Reference><Reference><Citation>Wykes T, Huddy V, Cellard C, et al. A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes. Am J Psychiatry. 2011;168:472–485.</Citation></Reference><Reference><Citation>Porter RJ, Douglas K, Jordan J, et al. Psychological treatments for cognitive dysfunction in major depressive disorder: current evidence and perspectives. CNS Neurol Disord Drug Targets. 2014;13:1677–1692.</Citation></Reference><Reference><Citation>Douglas KM, Van Rheenen TE. Current treatment options for cognitive impairment in bipolar disorder: a review. Curr Treat Options Psychiatry. 2016;3:330–355.</Citation></Reference><Reference><Citation>Torrent C, Bonnin Cdel M, Martinez-Aran A, et al. Efficacy of functional remediation in bipolar disorder: a multicenter randomized controlled study. Am J Psychiatry. 2013;170:852–859.</Citation></Reference><Reference><Citation>Bonnin CM, Torrent C, Arango C, et al. Functional remediation in bipolar disorder: 1-year follow-up of neurocognitive and functional outcome. Br J Psychiatry. 2016;208:87–93.</Citation></Reference><Reference><Citation>Lewandowski KE, Sperry SH, Cohen BM, et al. Treatment to enhance cognition in bipolar disorder (TREC-BD): efficacy of a randomized controlled trial of cognitive remediation versus active control. J Clin Psychiatry. 2017;78:e1242–e1249.</Citation></Reference><Reference><Citation>Veeh J, Kopf J, Kittel-Schneider S, et al. Cognitive remediation for bipolar patients with objective cognitive impairment: a naturalistic study. Int J Bipolar Disord. 2017;5:8.</Citation></Reference><Reference><Citation>Demant KM, Vinberg M, Kessing LV, et al. Effects of short-term cognitive remediation on cognitive dysfunction in partially or fully remitted individuals with bipolar disorder: results of a randomised controlled trial. PLoS One. 2015;10:e0127955.</Citation></Reference><Reference><Citation>Bowie CR, Gupta M, Holshausen K, et al. Cognitive remediation for treatment-resistant depression: effects on cognition and functioning and the role of online homework. J Nerv Ment Dis. 2013;201:680–685.</Citation></Reference><Reference><Citation>Trapp W, Engel S, Hajak G, et al. Cognitive remediation for depressed inpatients: results of a pilot randomized controlled trial. Aust N Z J Psychiatry. 2016;50:46–55.</Citation></Reference><Reference><Citation>First MB, Williams JBW, Karg RS, et al. Structured Clinical Interview for DSM-5 Disorders, Clinician Version (SCID-5-CV). Arlington, VA: American Psychiatric Association; 2015.</Citation></Reference><Reference><Citation>Douglas KM, Gallagher P, Robinson LJ, et al. Prevalence of cognitive impairment in major depression and bipolar disorder. Bipolar Disord. 2018;20:260–274.</Citation></Reference><Reference><Citation>Miskowiak KW, Burdick KE, Martinez-Aran A, et al. Methodological recommendations for cognition trials in bipolar disorder by the International Society for Bipolar Disorders Targeting Cognition Task Force. Bipolar Disord. 2017;19:614–626.</Citation></Reference><Reference><Citation>Bowie CR, Grossman M, Gupta M, et al. Action-based cognitive remediation for individuals with serious mental illnesses: effects of real-world simulations and goal setting on functional and vocational outcomes. Psychiatr Rehabil J. 2017;40:53–60.</Citation></Reference><Reference><Citation>Douglas KM, Porter RJ. Longitudinal assessment of neuropsychological function in major depression. Aust N Z J Psychiatry. 2009;43:1105–1117.</Citation></Reference><Reference><Citation>Rey A. L’examen Clinique en Psychologie. Paris: Presses Universitaires de France; 1964.</Citation></Reference><Reference><Citation>Snyder PJ, Jackson CE, Piskulic D, et al. Spatial working memory and problem solving in schizophrenia: the effect of symptom stabilization with atypical antipsychotic medication. Psychiatry Res. 2008;160:316–326.</Citation></Reference><Reference><Citation>Benton AL, Hamsher K. Multilingual Aphasia Examination. Iowa City, IA: AJA Associates; 1989.</Citation></Reference><Reference><Citation>Delis DC, Kaplan E, Kramer JH. Delis-Kaplan Executive Function System (D-KEFS). San Antonio, TX: The Psychological Corporation; 2001.</Citation></Reference><Reference><Citation>Wechsler D. Wechsler Adult Intelligence Scale—Fourth Edition (WAIS-IV). San Antonio, TX: Pearson Education Inc; 2008.</Citation></Reference><Reference><Citation>Wechsler D. Wechsler Adult Intelligence Scale-III. San Antonio, TX: The Psychological Corporation; 1997.</Citation></Reference><Reference><Citation>Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003;54:573–583.</Citation></Reference><Reference><Citation>Young RC, Biggs JT, Ziegler VE, et al. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429–435.</Citation></Reference><Reference><Citation>Üstün TB, Kostanjsek N, Chatterji S, Rehm J, editors. Measuring Health and Disability: Manual for WHO Disability Assessment Scale WHODAS 20. Geneva: World Health Organisation; 2010.</Citation></Reference><Reference><Citation>Rosa AR, Sanchez-Moreno J, Martinez-Aran A, et al. Validity and reliability of the Functioning Assessment Short Test (FAST) in bipolar disorder. Clin Pract Epidemiol Ment Health. 2007;3:5.</Citation></Reference><Reference><Citation>Cacilhas AA, Magalhaes PV, Cereser KM, et al. Validity of a short functioning test (FAST) in Brazilian outpatients with bipolar disorder. Value Health. 2009;12:624–627.</Citation></Reference><Reference><Citation>Moro MF, Colom F, Floris F, et al. Validity and reliability of the Italian version of the Functioning Assessment Short Test (FAST) in bipolar disorder. Clin Pract Epidemiol Ment Health. 2012;8:67–73.</Citation></Reference><Reference><Citation>Schmid M, Hammar A. A follow-up study of first episode major depressive disorder. Impairment in inhibition and semantic fluency-potential predictors for relapse? Front Psychol. 2013;4:633.</Citation></Reference><Reference><Citation>Majer M, Ising M, Kunzel H, et al. Impaired divided attention predicts delayed response and risk to relapse in subjects with depressive disorders. Psychol Med. 2004;34:1453–1463.</Citation></Reference><Reference><Citation>Murphy FC, Michael A, Robbins TW, et al. Neuropsychological impairment in patients with major depressive disorder: the effects of feedback on task performance. Psychol Med. 2003;33:455–467.</Citation></Reference><Reference><Citation>Elliott R, Sahakian BJ, Herrod JJ, et al. Abnormal response to negative feedback in unipolar depression: evidence for a diagnosis specific impairment. J Neurol Neurosurg Psychiatry Res. 1997;63:74–82.</Citation></Reference><Reference><Citation>Bartels C, Wegrzyn M, Wiedl A, et al. Practice effects in healthy adults: a longitudinal study on frequent repetitive cognitive testing. BMC Neurosci. 2010;11:118.</Citation></Reference><Reference><Citation>Lezak M, Howieson, D, Loring D. Neuropsychological Assessment. New York, NY: Oxford University Press Inc; 2004.</Citation></Reference><Reference><Citation>Goldberg TE, Harvey PD, Wesnes KA, et al. Practice effects due to serial cognitive assessment: implications for preclinical Alzheimer’s disease randomized controlled trials. Alzheimers Dement (Amst). 2015;1:103–111.</Citation></Reference><Reference><Citation>Miskowiak KW, Rush AJ Jr, Gerds TA, et al. Targeting treatments to improve cognitive function in mood disorder: suggestions from trials using erythropoietin. J Clin Psychiatry. 2016;77:e1639–e1646.</Citation></Reference><Reference><Citation>Petersen JZ, Porter RJ, Miskowiak KW. Clinical characteristics associated with the discrepancy between subjective and objective cognitive impairment in depression. J Affect Disord. 2019;246:763–774.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12222080</PMID><DateCompleted><Year>2003</Year><Month>02</Month><Day>12</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>06</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1056-4993</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><Issue>3</Issue><PubDate><Year>2002</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Child and adolescent psychiatric clinics of North America</Title><ISOAbbreviation>Child Adolesc Psychiatr Clin N Am</ISOAbbreviation></Journal><ArticleTitle>Etiology and genetics of early-onset mood disorders.</ArticleTitle><Pagination><MedlinePgn>499-518</MedlinePgn></Pagination><Abstract><AbstractText>Most studies dealing with the familiality and genetics of mood disorders have been limited to adults, but several studies suggest that there is continuity between childhood- and adolescence-onset depression and mania and adult illness. More direct estimates of the heritability of depressive symptoms or episodes in children and adolescents indicate that the genetic contributions may be greater than 50%. A number of functional and structural imaging studies have identified particular circuitry as being involved in the generation of emotion and mood disorders. Imaging studies of twins have suggested that regional brain volume and characteristics of brain shape are heritable. A potentially important new avenue of research will be the correlation of the genetics of brain structure or function with the genetics of mood disorders. Preliminary studies of adolescent and young adult twins suggest a significant correspondence between the genetic contributions to some regional brain volumes and early-onset mood disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Todd</LastName><ForeName>Richard D</ForeName><Initials>RD</Initials><AffiliationInfo><Affiliation>Division of Child Psychiatry, Department of Psychiatry, Washington University School of Medicine, 660 South Euclid Avenue, Box 8134, St. Louis, MO 63110, USA. toddr@psychiatry.wustl.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Botteron</LastName><ForeName>Kelly N</ForeName><Initials>KN</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MH01292</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH52813</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Child Adolesc Psychiatr Clin N Am</MedlineTA><NlmUniqueID>9313451</NlmUniqueID><ISSNLinking>1056-4993</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000002" MajorTopicYN="N">abnormalities</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008032" MajorTopicYN="N">Limbic System</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019964" MajorTopicYN="N">Mood Disorders</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017397" MajorTopicYN="N">Prefrontal Cortex</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>126</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>9</Month><Day>12</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>2</Month><Day>14</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>9</Month><Day>12</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12222080</ArticleId><ArticleId IdType="pii">S1056-4993(02)00013-5</ArticleId><ArticleId IdType="doi">10.1016/s1056-4993(02)00013-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">29454164</PMID><DateCompleted><Year>2018</Year><Month>12</Month><Day>11</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-8384</ISSN><JournalIssue CitedMedium="Internet"><Volume>82</Volume><PubDate><Year>2018</Year><Month>04</Month></PubDate></JournalIssue><Title>Comprehensive psychiatry</Title><ISOAbbreviation>Compr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Self-reported inhibition predicts history of suicide attempts in bipolar disorder and major depression.</ArticleTitle><Pagination><MedlinePgn>89-94</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0010-440X(18)30023-3</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.comppsych.2018.01.011</ELocationID><Abstract><AbstractText Label="BACKGROUND">Studies have reliably identified an association between suicide attempts and executive functions such as decision making (DM) and inhibitory control (IC) in patients with mood disorders. As such, the present study aimed to investigate the association between inhibition, DM, impulsivity and the history of suicide attempts in individuals with bipolar (BD) or major depressive disorder (MDD), identifying which assessment instruments may be most strongly associated with suicide in clinical samples.</AbstractText><AbstractText Label="METHODS">The sample included 80 control subjects and two groups of patients with BD and MDD, matched by age and education (26 with a history of suicide attempts [MD+], and 26 with no such history [MD-]). Participants completed behavioral and self-report measures of DM and IC, which were compared between groups using ANCOVA, followed by logistic regression for patients with mood disorders only, and the presence or absence of a history of suicide as the outcome.</AbstractText><AbstractText Label="RESULTS">Cognitive performance did not differ between groups. The MD+ group showed significantly higher motor and attentional impulsivity on the BIS-11 than the MD- and control groups. A regression analysis containing these scores showed that motor impulsivity was the only significant predictor of a history of suicide (OR = 1.14; 95%CI 1.00-1.30).</AbstractText><AbstractText Label="CONCLUSIONS">Self-reported motor impulsivity was a significant predictor of suicide. These findings underscore the importance of self-report measures in neuropsychological assessment, and their contributions to the management and prognosis of patients with mood disorders. Lastly, they point to the role of impulsivity as a target for interventions and public policy on suicide prevention.</AbstractText><CopyrightInformation>Copyright © 2018 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ponsoni</LastName><ForeName>André</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Psychology, Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS), Av. Ipiranga, 6681, Building 11, Partenon, 90619-900 Porto Alegre, Rio Grande do Sul, Brazil. Electronic address: andreponsoni@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Branco</LastName><ForeName>Laura Damiani</ForeName><Initials>LD</Initials><AffiliationInfo><Affiliation>Department of Psychology, Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS), Av. Ipiranga, 6681, Building 11, Partenon, 90619-900 Porto Alegre, Rio Grande do Sul, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cotrena</LastName><ForeName>Charles</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Psychology, Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS), Av. Ipiranga, 6681, Building 11, Partenon, 90619-900 Porto Alegre, Rio Grande do Sul, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shansis</LastName><ForeName>Flávio Milman</ForeName><Initials>FM</Initials><AffiliationInfo><Affiliation>Programa de Ensino e Pesquisa em Transtornos do Humor (PROPESTH), Hospital Psiquiátrico São Pedro (HPSP), Avenida Bento Gonçalves, 2460, Partenon, 90650-001 Porto Alegre, Rio Grande do Sul, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grassi-Oliveira</LastName><ForeName>Rodrigo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Psychology, Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS), Av. Ipiranga, 6681, Building 11, Partenon, 90619-900 Porto Alegre, Rio Grande do Sul, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fonseca</LastName><ForeName>Rochele Paz</ForeName><Initials>RP</Initials><AffiliationInfo><Affiliation>Department of Psychology, Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS), Av. Ipiranga, 6681, Building 11, Partenon, 90619-900 Porto Alegre, Rio Grande do Sul, Brazil.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>02</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Compr Psychiatry</MedlineTA><NlmUniqueID>0372612</NlmUniqueID><ISSNLinking>0010-440X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007266" MajorTopicYN="Y">Inhibition, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057566" MajorTopicYN="Y">Self Report</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013406" MajorTopicYN="N">Suicide, Attempted</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Decision making</Keyword><Keyword MajorTopicYN="Y">Impulsivity</Keyword><Keyword MajorTopicYN="Y">Inhibitory control</Keyword><Keyword MajorTopicYN="Y">Mood disorder</Keyword><Keyword MajorTopicYN="Y">Self-report</Keyword><Keyword MajorTopicYN="Y">Suicide</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>10</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>01</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>01</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>2</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>12</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>2</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29454164</ArticleId><ArticleId IdType="pii">S0010-440X(18)30023-3</ArticleId><ArticleId IdType="doi">10.1016/j.comppsych.2018.01.011</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">7792565</PMID><DateCompleted><Year>1995</Year><Month>07</Month><Day>27</Day></DateCompleted><DateRevised><Year>2016</Year><Month>07</Month><Day>26</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0258-7661</ISSN><JournalIssue CitedMedium="Print"><Volume>146</Volume><Issue>1</Issue><PubDate><Year>1995</Year></PubDate></JournalIssue><Title>Schweizer Archiv fur Neurologie und Psychiatrie (Zurich, Switzerland : 1985)</Title><ISOAbbreviation>Schweiz Arch Neurol Psychiatr (1985)</ISOAbbreviation></Journal><ArticleTitle>Outcome of a clinical cohort of unipolar, bipolar and schizoaffective patients. Results of a prospective study from 1959 to 1985.</ArticleTitle><Pagination><MedlinePgn>17-23</MedlinePgn></Pagination><Abstract><AbstractText>In a prospective study, 186 unipolar depressives and 220 cases of bipolar disorder meeting DSM-III criteria for major depression or mania were followed up. Subjects were classified according to polarity and the presence or absence of schizophrenic symptoms, into four diagnostic subgroups: unipolar depression, bipolar disorder, unipolar schizoaffective disorder and bipolar schizoaffective disorder. At the last follow-up in 1985, 53% of the patients had deceased. Eleven percent of the sample (17% of all deaths) had committed suicide. The risk of suicide was associated with clinical severity and onset prior to the age of 60. However, there was no difference in suicide rates according to sex or diagnostic subgroup. Late onset of affective illness was associated with chronicity, which occurred in 10 to 19% of cases. Recovery was more frequent among unipolar than among bipolar patients. The 5-year remission rates (i.e. 26% in unipolars, 16% in bipolars) were independent of the number of episodes.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Angst</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Research Departement, Psychiatrie University Hospital Zürich.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Preisig</LastName><ForeName>M</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Schweiz Arch Neurol Psychiatr (1985)</MedlineTA><NlmUniqueID>8503709</NlmUniqueID><ISSNLinking>0258-7661</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002423" MajorTopicYN="N">Cause of Death</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019965" MajorTopicYN="N">Neurocognitive Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013405" MajorTopicYN="N">Suicide</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1995</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1995</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1995</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">7792565</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19215628</PMID><DateCompleted><Year>2009</Year><Month>09</Month><Day>28</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1469-8978</ISSN><JournalIssue CitedMedium="Internet"><Volume>39</Volume><Issue>8</Issue><PubDate><Year>2009</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Psychological medicine</Title><ISOAbbreviation>Psychol Med</ISOAbbreviation></Journal><ArticleTitle>Extracting a needle from a haystack: reanalysis of whole genome data reveals a readily translatable finding.</ArticleTitle><Pagination><MedlinePgn>1231-5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1017/S0033291708005084</ELocationID><Abstract><AbstractText>There is significant unmet need for more effective treatments for bipolar disorder. The drug discovery process is becoming prohibitively expensive. Hence, biomarker clues to assist or shortcut this process are now widely sought. Using the publicly available data from the whole genome association study conducted by the Wellcome Trust Case Control Consortium, we sought to identify groups of genetic markers (single nucleotide polymorphisms) in which each marker was independently associated with bipolar disorder, with a less stringent threshold than that set by the original investigators (p&lt; or =1 x 10(-4)). We identified a group of markers occurring within the CACNA1C gene (encoding the alpha subunit of the calcium channel Cav1.2). We then ascertained that this locus had been previously associated with the disorder in both a smaller and a whole genome study, and that a number of drugs blocking this channel (including verapamil and diltiazem) had been trialled in the treatment of bipolar disorder. The dihydropyridine-based blockers such as nimodipine that bind specifically to Cav1.2 and are more penetrant to the central nervous system have shown some promising early results; however, further trials are indicated. In addition, migraine is commonly seen in affective disorder, and calcium channel antagonists are successfully used in the treatment of migraine. One such agent, flunarizine, is structurally related to other first-generation derivatives of antihistamines such as antipsychotics. This implies that flunarizine could be useful in the treatment of bipolar disorder, and, furthermore, that other currently licensed drugs should be investigated for antagonism of Cav1.2.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Keers</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>MRC SGDP Centre, Institute of Psychiatry at King's College London, 16 De Crespigny Park, Denmark Hill, London, UK. robert.keers@iop.kcl.ac.uk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farmer</LastName><ForeName>A E</ForeName><Initials>AE</Initials></Author><Author ValidYN="Y"><LastName>Aitchison</LastName><ForeName>K J</ForeName><Initials>KJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>02</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Psychol Med</MedlineTA><NlmUniqueID>1254142</NlmUniqueID><ISSNLinking>0033-2917</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C079146">CACNA1C protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002121">Calcium Channel Blockers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020746">Calcium Channels, L-Type</NameOfSubstance></Chemical><Chemical><RegistryNumber>R7PLA2DM0J</RegistryNumber><NameOfSubstance UI="D005444">Flunarizine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Psychol Med. 2010 Apr;40(4):702; author reply 703-4</RefSource><PMID Version="1">20132581</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002121" MajorTopicYN="N">Calcium Channel Blockers</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020746" MajorTopicYN="N">Calcium Channels, L-Type</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005444" MajorTopicYN="N">Flunarizine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005787" MajorTopicYN="N">Gene Frequency</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015894" MajorTopicYN="N">Genome, Human</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>35</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>2</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>2</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>9</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19215628</ArticleId><ArticleId IdType="pii">S0033291708005084</ArticleId><ArticleId IdType="doi">10.1017/S0033291708005084</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28784391</PMID><DateCompleted><Year>2018</Year><Month>04</Month><Day>27</Day></DateCompleted><DateRevised><Year>2018</Year><Month>04</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1876-2026</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><PubDate><Year>2017</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Asian journal of psychiatry</Title><ISOAbbreviation>Asian J Psychiatr</ISOAbbreviation></Journal><ArticleTitle>Inhalant induced mania: An unexplored entity.</ArticleTitle><Pagination><MedlinePgn>32-33</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S1876-2018(17)30003-5</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ajp.2017.03.009</ELocationID><Abstract><AbstractText>Inhalant abuse is one of the common presentations in de-addiction clinic among children and adolescent age group. Psychiatric morbidity is high among inhalant users but there is very little evidence to consider it a direct result of it. We present a case of 17-year-old boy with symptoms of mania which had time event correlation with inhalant use. He was successfully treated with antipsychotic medications and is maintaining well. The case highlights the need of strong suspicion of inhalant abuse in young patients who present with acute onset of psychiatric symptoms.</AbstractText><CopyrightInformation>Copyright © 2017 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Joshi</LastName><ForeName>Sulochana</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Patan Academy of Health Sciences, Lalitpur, Nepal; Department of Psychiatry, BP Koirala Institute of Health Sciences, Dharan, Nepal; Department of Psychiatry, Patan Academy of Health Sciences, Lalitpur, Nepal. Electronic address: dr.sulochana@hotmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sapkota</LastName><ForeName>Nidesh</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Patan Academy of Health Sciences, Lalitpur, Nepal; Department of Psychiatry, BP Koirala Institute of Health Sciences, Dharan, Nepal; Department of Psychiatry, Patan Academy of Health Sciences, Lalitpur, Nepal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>Pawan</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Patan Academy of Health Sciences, Lalitpur, Nepal; Department of Psychiatry, BP Koirala Institute of Health Sciences, Dharan, Nepal; Department of Psychiatry, Patan Academy of Health Sciences, Lalitpur, Nepal.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>03</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Asian J Psychiatr</MedlineTA><NlmUniqueID>101517820</NlmUniqueID><ISSNLinking>1876-2018</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058545" MajorTopicYN="N">Inhalant Abuse</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adolescents</Keyword><Keyword MajorTopicYN="N">Inhalant dependence</Keyword><Keyword MajorTopicYN="N">Inhalant induced mania</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>01</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>03</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>03</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>8</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>8</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>4</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28784391</ArticleId><ArticleId IdType="pii">S1876-2018(17)30003-5</ArticleId><ArticleId IdType="doi">10.1016/j.ajp.2017.03.009</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16160638</PMID><DateCompleted><Year>2005</Year><Month>11</Month><Day>30</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0271-0749</ISSN><JournalIssue CitedMedium="Print"><Volume>25</Volume><Issue>5</Issue><PubDate><Year>2005</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Journal of clinical psychopharmacology</Title><ISOAbbreviation>J Clin Psychopharmacol</ISOAbbreviation></Journal><ArticleTitle>Double-blind, placebo-controlled pilot study of mexiletine for acute mania or hypomania.</ArticleTitle><Pagination><MedlinePgn>507-8</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schaffer</LastName><ForeName>Ayal</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Levitt</LastName><ForeName>Anthony J</ForeName><Initials>AJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016422">Letter</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychopharmacol</MedlineTA><NlmUniqueID>8109496</NlmUniqueID><ISSNLinking>0271-0749</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000889">Anti-Arrhythmia Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>1U511HHV4Z</RegistryNumber><NameOfSubstance UI="D008801">Mexiletine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000889" MajorTopicYN="N">Anti-Arrhythmia Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008801" MajorTopicYN="N">Mexiletine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>9</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>12</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>9</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16160638</ArticleId><ArticleId IdType="pii">00004714-200510000-00026</ArticleId><ArticleId IdType="doi">10.1097/01.jcp.0000177852.08287.08</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10082332</PMID><DateCompleted><Year>1999</Year><Month>07</Month><Day>13</Day></DateCompleted><DateRevised><Year>2007</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0894-878X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>1</Issue><PubDate><Year>1999</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Neuropsychiatry, neuropsychology, and behavioral neurology</Title><ISOAbbreviation>Neuropsychiatry Neuropsychol Behav Neurol</ISOAbbreviation></Journal><ArticleTitle>Mania, pseudomania, depression, and pseudodepression resulting from focal unilateral cortical lesions.</ArticleTitle><Pagination><MedlinePgn>35-51</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This consecutive multiple case study was designed to determine whether cortical lesion sites can predict occurrence of mood or psychomotor disorders in adults and children.</AbstractText><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Most of a large body of research supports the contention that left hemisphere lesions result more often than right ones in depression, and that the inverse occurs in mania. However, it is not clear how psychomotor status fits into this picture, nor whether children respond to the same lesions in a similar manner.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Published (n = 88) and unpublished (n = 31) cases of school-aged child and adult patients with focal unilateral cortical lesions and psychomotor agitation or lethargy with or without corresponding mania or depression were reviewed systematically to determine whether lesion location relates systematically to any of those psychiatric conditions. No patients had symptoms prior to detection of their lesion. Manic-depressives and agitated depressives were also excluded.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Patients with mania and/or psychomotor agitation had predominantly right hemisphere lesions. Postlesion hyperactivity (without mania) in children was common but was not more related to lesions in one or the other hemisphere. Adult and child patients with depression and/or psychomotor lethargy had predominantly left hemisphere lesions. The intrahemispherical site of the lesion did not significantly predict the type of mood or psychomotor disorder. Nevertheless, the nonsignificant trend was for right posterorolandic lesions to predict mania or agitation and for left frontal lesions to predict depression or psychomotor lethargy.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These findings support the neuropsychiatric approach to mood and psychomotor disorder in children and adults.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Braun</LastName><ForeName>C M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Laboratoire de Neuroscience de la Cognition, Université du Québec à Montréal, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Larocque</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Daigneault</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Montour-Proulx</LastName><ForeName>I</ForeName><Initials>I</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuropsychiatry Neuropsychol Behav Neurol</MedlineTA><NlmUniqueID>8811108</NlmUniqueID><ISSNLinking>0894-878X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001927" MajorTopicYN="N">Brain Diseases</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019992" MajorTopicYN="N">Databases as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007839" MajorTopicYN="N">Functional Laterality</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011596" MajorTopicYN="N">Psychomotor Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>163</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1999</Year><Month>3</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1999</Year><Month>3</Month><Day>19</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1999</Year><Month>3</Month><Day>19</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10082332</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">14744163</PMID><DateCompleted><Year>2004</Year><Month>03</Month><Day>02</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0160-6689</ISSN><JournalIssue CitedMedium="Print"><Volume>65</Volume><Issue>1</Issue><PubDate><Year>2004</Year><Month>Jan</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Glycogen synthase kinase-3: a target for novel bipolar disorder treatments.</ArticleTitle><Pagination><MedlinePgn>10-21</MedlinePgn></Pagination><Abstract><AbstractText>The enzyme glycogen synthase kinase-3 (GSK-3) is a direct target of lithium. While originally recognized as an important molecule in a limited number of cellular processes, with unclear significance for the treatment of bipolar disorder, recent evidence suggests it has critically important cellular functions in the adult brain. GSK-3 has an essential role in a number of signaling pathways and regulates the function of a diverse number of proteins, notably transcription factors and cytoskeletal elements. The most important functions of the enzyme in regard to bipolar disorder may be critical effects on cellular resilience and neuronal plasticity. There is tremendous interest in GSK-3 inhibitors as novel therapeutic agents, and selective, small-molecule compounds are rapidly being developed for a broad range of other maladies including diabetes, Alzheimer's disease, stroke, and inflammatory conditions. In this perspectives article, we provide an overview of the molecular targets of lithium, focusing on GSK-3-regulated signaling pathways and the important functions of GSK-3 that may have relevance for the treatment of bipolar disorder. We conclude with a discussion of the GSK-3 inhibitors furthest in development and the clinical trials that may emerge.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gould</LastName><ForeName>Todd D</ForeName><Initials>TD</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular Pathophysiology, National Institute of Mental Health, NIH, Bethesda, MD 20892, USA. gouldt@intra.nimh.nih.gov</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zarate</LastName><ForeName>Carlos A</ForeName><Initials>CA</Initials></Author><Author ValidYN="Y"><LastName>Manji</LastName><ForeName>Husseini K</ForeName><Initials>HK</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>2BMD2GNA4V</RegistryNumber><NameOfSubstance UI="D016651">Lithium Carbonate</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.26</RegistryNumber><NameOfSubstance UI="D038362">Glycogen Synthase Kinase 3</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D038362" MajorTopicYN="N">Glycogen Synthase Kinase 3</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016651" MajorTopicYN="N">Lithium Carbonate</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009473" MajorTopicYN="N">Neuronal Plasticity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014157" MajorTopicYN="N">Transcription Factors</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>153</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>1</Month><Day>28</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>3</Month><Day>3</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>1</Month><Day>28</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">14744163</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12971015</PMID><DateCompleted><Year>2004</Year><Month>01</Month><Day>15</Day></DateCompleted><DateRevised><Year>2017</Year><Month>02</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0706-7437</ISSN><JournalIssue CitedMedium="Print"><Volume>48</Volume><Issue>7</Issue><PubDate><Year>2003</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Canadian journal of psychiatry. Revue canadienne de psychiatrie</Title><ISOAbbreviation>Can J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Clinical features of bipolar disorder with and without comorbid diabetes mellitus.</ArticleTitle><Pagination><MedlinePgn>458-61</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Several papers have reported higher prevalence of diabetes mellitus (DM) type 2 in patients suffering from bipolar disorder (BD). The possible links between these 2 disorders include treatment, lifestyle, alterations in signal transduction, and possibly, a genetic link. To study this relation more closely, we investigated whether there are any differences in the clinical characteristics of BD patients with and without DM.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">We compared the clinical data of 26 diabetic and 196 nondiabetic subjects from The Maritime Bipolar Registry. Subjects were aged 15 to 82 years, with psychiatric diagnoses of BD I (n = 151), BD II (n = 65), and BD not otherwise specified (n = 6). The registry included basic demographic data and details on the clinical course of bipolar illness, its treatment, and physical comorbidity. In a subsequent analysis using logistic regression, we examined the variables showing differences between groups, with diabetes as an outcome variable.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The prevalence of DM in our sample was 11.7% (n = 26). Diabetic patients were significantly older than nondiabetic patients (P &lt; 0.001), had higher rates of rapid cycling (P = 0.02) and chronic course of BD (P = 0.006), scored lower on the Global Assessment of Functioning Scale (P = 0.01), were more often on disability for BD (P &lt; 0.001), and had higher body mass index (P &lt; 0.001) and increased frequency of hypertension (P = 0.003). Lifetime history of treatment with antipsychotics was not significantly associated with an elevated risk of diabetes (P = 0.16); however, the data showed a trend toward more frequent use of antipsychotic medication among diabetic subjects.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our findings suggest that the diagnosis of DM in BD patients is relevant for their prognosis and outcome.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ruzickova</LastName><ForeName>Martina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Dalhousie University, 5909 Jubilee Road, Halifax, NS B3H 2E2. mruzicko@dal.ca</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Slaney</LastName><ForeName>Claire</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Garnham</LastName><ForeName>Julie</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Alda</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Can J Psychiatry</MedlineTA><NlmUniqueID>7904187</NlmUniqueID><ISSNLinking>0706-7437</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002170" MajorTopicYN="N" Type="Geographic">Canada</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="N">Registries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012044" MajorTopicYN="N">Regression Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>9</Month><Day>16</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>1</Month><Day>16</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>9</Month><Day>16</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12971015</ArticleId><ArticleId IdType="doi">10.1177/070674370304800705</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27668941</PMID><DateCompleted><Year>2018</Year><Month>06</Month><Day>04</Day></DateCompleted><DateRevised><Year>2018</Year><Month>06</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1533-4112</ISSN><JournalIssue CitedMedium="Internet"><Volume>33</Volume><Issue>2</Issue><PubDate><Year>2017</Year><Month>06</Month></PubDate></JournalIssue><Title>The journal of ECT</Title><ISOAbbreviation>J ECT</ISOAbbreviation></Journal><ArticleTitle>A Camptocormia Case Treated With Electroconvulsive Therapy.</ArticleTitle><Pagination><MedlinePgn>e17</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/YCT.0000000000000355</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bayazit</LastName><ForeName>Huseyin</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Psychiatry Siverek State Hospital Harran University Sanliurfa, Turkey drbayazit@yahoo.com Department of Child and Adolescent Psychiatry Harran University Sanliurfa, Turkey Department of Psychiatry Harran University Sanliurfa, Turkey Department of Child and Adolescent Psychiatry Harran University Sanliurfa, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kilicaslan</LastName><ForeName>Fethiye</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Guler</LastName><ForeName>Kadir</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Karababa</LastName><ForeName>I Fatih</ForeName><Initials>IF</Initials></Author><Author ValidYN="Y"><LastName>Kandemir</LastName><ForeName>Hasan</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J ECT</MedlineTA><NlmUniqueID>9808943</NlmUniqueID><ISSNLinking>1095-0680</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C537968">Camptocormia</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004565" MajorTopicYN="N">Electroconvulsive Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009134" MajorTopicYN="N">Muscular Atrophy, Spinal</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013121" MajorTopicYN="N">Spinal Curvatures</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27668941</ArticleId><ArticleId IdType="doi">10.1097/YCT.0000000000000355</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">7485629</PMID><DateCompleted><Year>1995</Year><Month>12</Month><Day>06</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-953X</ISSN><JournalIssue CitedMedium="Print"><Volume>152</Volume><Issue>11</Issue><PubDate><Year>1995</Year><Month>Nov</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Comorbid Tourette's disorder and bipolar disorder: an etiologic perspective.</ArticleTitle><Pagination><MedlinePgn>1646-51</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Using an epidemiologic approach, the authors attempt to elucidate relationships between Tourette's disorder and bipolar disorder.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Of 205 patients with Tourette's disorder in the North Dakota Longitudinal Tourette Syndrome Surveillance Project, 15 had comorbid bipolar disorder. A subset of the patients with Tourette's disorder had been included in earlier population-based prevalence studies of Tourette's disorder in children, adolescents, and adults. Minimal risk ratios were calculated for the patients with Tourette's disorder plus bipolar disorder by age group (children/adolescents and adults). This information was used to estimate genetic risk indicators for comorbid Tourette's disorder and bipolar disorder.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The estimated risk of developing bipolar disorder among the study group of children, adolescents, and adults with Tourette's disorder was more than four times higher than the level expected by chance, but this finding did not reach statistical significance. It was indicative of trends, however.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Comorbidity between Tourette's disorder and bipolar disorder does not appear to be due to chance co-occurrence of the two disorders. Although a genetic mechanism may play a causal role, in the absence of family studies an explanatory model involving the concept of canalization of basal-ganglia-mediated dysfunctions is offered. In such a construct, Tourette's disorder would be a likely accompaniment to other conditions, including bipolar disorder, whose pathogenic determinants might channel through neural pathways involving the basal ganglia. The presence of significant developmental disabilities may further enhance factors culminating in comorbid Tourette's disorder and bipolar disorder.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kerbeshian</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, University of North Dakota School of Medicine, Grand Forks, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burd</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Klug</LastName><ForeName>M G</ForeName><Initials>MG</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001479" MajorTopicYN="N">Basal Ganglia</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008959" MajorTopicYN="N">Models, Neurological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009658" MajorTopicYN="N" Type="Geographic">North Dakota</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005879" MajorTopicYN="N">Tourette Syndrome</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1995</Year><Month>11</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1995</Year><Month>11</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1995</Year><Month>11</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">7485629</ArticleId><ArticleId IdType="doi">10.1176/ajp.152.11.1646</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">2380693</PMID><DateCompleted><Year>1990</Year><Month>09</Month><Day>10</Day></DateCompleted><DateRevised><Year>2007</Year><Month>11</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-3018</ISSN><JournalIssue CitedMedium="Print"><Volume>178</Volume><Issue>8</Issue><PubDate><Year>1990</Year><Month>Aug</Month></PubDate></JournalIssue><Title>The Journal of nervous and mental disease</Title><ISOAbbreviation>J Nerv Ment Dis</ISOAbbreviation></Journal><ArticleTitle>Linguistic and cognitive failures in schizophrenia. A multivariate analysis.</ArticleTitle><Pagination><MedlinePgn>487-93</MedlinePgn></Pagination><Abstract><AbstractText>Schizophrenic (N = 38), manic (N = 30), and normal (N = 25) subjects were examined with laboratory tasks measuring serial recall and encoding, distractibility, and reality monitoring. In addition, the psychiatric patients were examined with three measures of verbal communication disorder, including positive thought disorder, negative thought disorder, and frequency of reference failures. It was found that positive thought disorder and reference failures in schizophrenics were best predicted by measures of distractibility and reality monitoring, with communication disorder in mania, although common and severe, not predicted by these cognitive performance measures. Furthermore, negative thought disorder in schizophrenics was not predicted by the cognitive measures. These results are discussed in terms of their implications regarding the differences in potential determinants of positive and negative thought disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Harvey</LastName><ForeName>P D</ForeName><Initials>PD</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Mt. Sinai Medical School, New York, NY 10029.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Serper</LastName><ForeName>M R</ForeName><Initials>MR</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MH 38431</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Nerv Ment Dis</MedlineTA><NlmUniqueID>0375402</NlmUniqueID><ISSNLinking>0022-3018</ISSNLinking></MedlineJournalInfo><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001288" MajorTopicYN="N">Attention</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001307" MajorTopicYN="N">Auditory Perception</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015999" MajorTopicYN="N">Multivariate Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012564" MajorTopicYN="Y">Schizophrenic Language</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="Y">Schizophrenic Psychology</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1990</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1990</Year><Month>8</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1990</Year><Month>8</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2380693</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">29754705</PMID><DateCompleted><Year>2018</Year><Month>10</Month><Day>11</Day></DateCompleted><DateRevised><Year>2021</Year><Month>05</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2530-3120</ISSN><JournalIssue CitedMedium="Internet"><Volume>47</Volume><Issue>2</Issue><PubDate><MedlineDate>2018 Apr - Jun</MedlineDate></PubDate></JournalIssue><Title>Revista Colombiana de psiquiatria (English ed.)</Title><ISOAbbreviation>Rev Colomb Psiquiatr (Engl Ed)</ISOAbbreviation></Journal><ArticleTitle>Inflammatory Markers in the Staging of Bipolar Disorder: A Systematic Review of the Literature.</ArticleTitle><Pagination><MedlinePgn>119-128</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0034-7450(17)30019-7</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.rcp.2017.01.004</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Previous studies suggest that inflammatory molecules play an important role in the pathophysiology of Bipolar Disorder (BD). The evidence suggests that BD may present a progressive course. Therefore there are theories that postulate the relationship between progression and stages of the disease with distinct peripheral biomarkers.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The aim of this study was to carry out a systematic review of the literature of studies about the association between peripheral inflammatory markers and clinical variables related with staging in BD patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a systematic review using electronic databases: PubMed, SciELO, LiLACS and PsycINFO. Keywords were divided into inflammatory markers and, BD and staging. Studies involving euthymic BD patients, studies evaluating peripheral biomarkers and studies correlating these with clinical variables related to neuroprogression or stage of BD were included.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We present and discuss the methods and findings of ten articles. The inflammatory markers were measured with different techniques and show some contradictories results. The TNF superfamily and inflammatory cytokines may have a relationship with the neuroprogression of the disease.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This study suggests that TNF and ILs could play a role in neuroprogression. However, longitudinal studies are needed to clarify the relationship between factors associated with neuroprogression.</AbstractText><CopyrightInformation>Copyright © 2017 Asociación Colombiana de Psiquiatría. Publicado por Elsevier España. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Castaño-Ramírez</LastName><ForeName>Oscar Mauricio</ForeName><Initials>OM</Initials><AffiliationInfo><Affiliation>Grupo de Investigación en Salud Mental y Comportamiento Humano, Departamento de Psiquiatría, Universidad de Caldas, Manizales, Caldas, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sepúlveda-Arias</LastName><ForeName>Juan C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Grupo de Investigacion en Infección e Inmunidad, Facultad de Ciencias de la Salud, Universidad Tecnológica de Pereira, Pereira, Risaralda, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duica</LastName><ForeName>Kelly</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Grupo de Investigación en Psiquiatría GIPSI, Departamento de Psiquiatría, Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Díaz Zuluaga</LastName><ForeName>Ana M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Grupo de Investigación en Psiquiatría GIPSI, Departamento de Psiquiatría, Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vargas</LastName><ForeName>Cristian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Grupo de Investigación en Psiquiatría GIPSI, Departamento de Psiquiatría, Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>López-Jaramillo</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Grupo de Investigación en Psiquiatría GIPSI, Departamento de Psiquiatría, Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia. Electronic address: carloslopezjaramillo@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><Language>spa</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>02</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><MedlineTA>Rev Colomb Psiquiatr (Engl Ed)</MedlineTA><NlmUniqueID>101778593</NlmUniqueID><ISSNLinking>2530-3120</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Biomarcadores inflamatorios</Keyword><Keyword MajorTopicYN="N">Bipolar disorders</Keyword><Keyword MajorTopicYN="N">Estadificación de la enfermedad</Keyword><Keyword MajorTopicYN="N">Inflammatory biomarkers</Keyword><Keyword MajorTopicYN="N">Revisión sistemática</Keyword><Keyword MajorTopicYN="N">Staging illness</Keyword><Keyword MajorTopicYN="N">Systematic review</Keyword><Keyword MajorTopicYN="N">Trastorno bipolar</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>08</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>12</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>01</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>5</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>5</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29754705</ArticleId><ArticleId IdType="pii">S0034-7450(17)30019-7</ArticleId><ArticleId IdType="doi">10.1016/j.rcp.2017.01.004</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">27138833</PMID><DateCompleted><Year>2017</Year><Month>02</Month><Day>14</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-7123</ISSN><JournalIssue CitedMedium="Internet"><Volume>240</Volume><PubDate><Year>2016</Year><Month>06</Month><Day>30</Day></PubDate></JournalIssue><Title>Psychiatry research</Title><ISOAbbreviation>Psychiatry Res</ISOAbbreviation></Journal><ArticleTitle>Electrophysiological correlates of bilateral and unilateral repetitive transcranial magnetic stimulation in patients with bipolar depression.</ArticleTitle><Pagination><MedlinePgn>364-375</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0165-1781(16)30678-3</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.psychres.2016.04.061</ELocationID><Abstract><AbstractText>Repetitive transcranial magnetic stimulation (rTMS) has been demonstrated to have efficacy in the treatment of unipolar depression but limited research has explored the efficacy of rTMS in bipolar depression. Therefore, we conducted a comparative clinical trial evaluating clinical responses to prefrontal bilateral and unilateral rTMS in patients suffering from bipolar depression. We hypothesized that, 1) the response to the treatment would be associated with a decrease in the frequency of beta waves, 2) bilateral stimulation of the cortex would bring about more extensive changes in brain activity than unilateral stimulation, and 3) bilateral stimulation is more effective than unilateral. Thirty patients with bipolar depression were divided into two groups. Bilateral Group (n=15) who received rTMS in the left DLPFC (10Hz) and right DLPFC (1-Hz), and unilateral group (n=15) who received the stimulation only in the right DLPFC (1-Hz) during 20 treatment sessions. The proportion of responders in the bilateral stimulation group was significantly higher than that in the unilateral group [80% versus 47%]. The remission rate was 40% in the bilateral group and 40% in the unilateral group (not significant). In the responders to bilateral rTMS treatment, a significant reduction of alpha1-2, beta 1-3, and gamma frequencies were observed in medial and superior frontal and cingulate gyrus . Responders to the unilateral treatment showed decrease of gamma frequency in postcentral gyrus, precuneus, superior and inferior parietal lobule, Cuneus and angular gyrus. In conclusion, we found that bilateral stimulation was more effective than the unilateral stimulation and evidence that beta frequency activity could possibly be used as a marker for response to rTMS.</AbstractText><CopyrightInformation>Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kazemi</LastName><ForeName>Reza</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Atieh Clinical Neuroscience Center, Tehran, Iran. Electronic address: rezakazemi@ut.ac.ir.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rostami</LastName><ForeName>Reza</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Atieh Clinical Neuroscience Center, Tehran, Iran; Psychology Department, Faculty of Psychology and Educational Science, Tehran University, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khomami</LastName><ForeName>Sanaz</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Atieh Clinical Neuroscience Center, Tehran, Iran; Psychology Department, Faculty of Psychology and Educational Science, Shahid Chamran University of Ahvaz, Ahvaz, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Horacek</LastName><ForeName>Jiri</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>National Institute of Mental Health, Klecany, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brunovsky</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>National Institute of Mental Health, Klecany, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Novak</LastName><ForeName>Tomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>National Institute of Mental Health, Klecany, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fitzgerald</LastName><ForeName>Paul B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Monash Alfred Psychiatry Research Centre, Monash University Central Clinical School and The Alfred, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>04</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Psychiatry Res</MedlineTA><NlmUniqueID>7911385</NlmUniqueID><ISSNLinking>0165-1781</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007839" MajorTopicYN="N">Functional Laterality</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050781" MajorTopicYN="Y">Transcranial Magnetic Stimulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Biomarker</Keyword><Keyword MajorTopicYN="N">Bipolar disorder</Keyword><Keyword MajorTopicYN="N">Electroencephalography</Keyword><Keyword MajorTopicYN="N">Transcranial magnetic stimulation</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>10</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>03</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>04</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>5</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>5</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>2</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27138833</ArticleId><ArticleId IdType="pii">S0165-1781(16)30678-3</ArticleId><ArticleId IdType="doi">10.1016/j.psychres.2016.04.061</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28000158</PMID><DateCompleted><Year>2017</Year><Month>10</Month><Day>30</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1179-2027</ISSN><JournalIssue CitedMedium="Internet"><Volume>35</Volume><Issue>3</Issue><PubDate><Year>2017</Year><Month>03</Month></PubDate></JournalIssue><Title>PharmacoEconomics</Title><ISOAbbreviation>Pharmacoeconomics</ISOAbbreviation></Journal><ArticleTitle>A Systematic Review and Critical Appraisal of Economic Evaluations of Pharmacological Interventions for People with Bipolar Disorder.</ArticleTitle><Pagination><MedlinePgn>271-296</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40273-016-0473-1</ELocationID><Abstract><AbstractText Label="BACKGROUND">Bipolar disorder (BD) is a chronic mood disorder that causes substantial psychological and financial burden. Various pharmacological treatments are effective in the management and prevention of acute episodes of BD. In an era of tighter healthcare budgets and a need for more efficient use of resources, several economic evaluations have evaluated the cost effectiveness of treatments for BD.</AbstractText><AbstractText Label="OBJECTIVE">The aim of this study was to systematically review and appraise published economic evaluations of pharmacological interventions for BD.</AbstractText><AbstractText Label="METHODS">A systematic search combining search terms specific to BD with a health economics search filter was conducted on six bibliographic databases (EMBASE, MEDLINE, PsycINFO, HTA, NHS EED, CENTRAL) in order to identify trial- or model-based full economic evaluations of pharmacological treatments of any phase of the disorder that were published between 1 January 1990 and 18 December 2015. Studies that met the inclusion criteria were critically appraised using the Quality of Health Economic Studies (QHES) checklist, and synthesised in a narrative way.</AbstractText><AbstractText Label="RESULTS">The review included 19 economic studies, which varied with regard to the type and number of interventions assessed, the study design, the phase of treatment (acute or maintenance), the source of efficacy data and the method for evidence synthesis, the outcome measures, the time horizon and the countries/settings in which the studies were conducted. The study quality was variable but the majority of studies were of high or fair quality.</AbstractText><AbstractText Label="CONCLUSION">Pharmacological interventions are cost effective, compared with no treatment, in the management of BD, both in the acute and maintenance phases. However, it is difficult to draw safe conclusions on the relative cost effectiveness between drugs due to differences across studies and limitations characterising many of them. Future economic evaluations need to consider the whole range of treatment options available for the management of BD and adopt appropriate methods for evidence synthesis and economic modelling, to explore more robustly the relative cost effectiveness of pharmacological interventions for people with BD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mavranezouli</LastName><ForeName>Ifigeneia</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0001-9095-3566</Identifier><AffiliationInfo><Affiliation>National Guideline Alliance (NGA), Centre for Outcomes Research and Effectiveness (CORE), Research Department of Clinical, Educational and Health Psychology, University College London, 1-19 Torrington Place, London, WC1E 7HB, UK. i.mavranezouli@ucl.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lokkerbol</LastName><ForeName>Joran</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Centre of Economic Evaluation, Trimbos Institute (The Netherlands Institute of Mental Health and Addiction), Utrecht, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Rob Giel Research Centre, University Medical Centre Groningen, Groningen, The Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Pharmacoeconomics</MedlineTA><NlmUniqueID>9212404</NlmUniqueID><ISSNLinking>1170-7690</ISSNLinking></MedlineJournalInfo><CitationSubset>T</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003362" MajorTopicYN="N">Cost-Benefit Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018803" MajorTopicYN="Y">Models, Economic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017063" MajorTopicYN="N">Outcome Assessment, Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012107" MajorTopicYN="N">Research Design</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>12</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>10</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>12</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28000158</ArticleId><ArticleId IdType="doi">10.1007/s40273-016-0473-1</ArticleId><ArticleId IdType="pii">10.1007/s40273-016-0473-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Pharmacoeconomics. 2010;28(9):751-64</Citation><ArticleIdList><ArticleId IdType="pubmed">20623994</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2011 Apr 11;342:d1766</Citation><ArticleIdList><ArticleId IdType="pubmed">21482590</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2005 Aug;87(2-3):203-10</Citation><ArticleIdList><ArticleId IdType="pubmed">16005983</ArticleId></ArticleIdList></Reference><Reference><Citation>CNS Drugs. 2003;17(7):491-511</Citation><ArticleIdList><ArticleId IdType="pubmed">12751919</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2005 Dec;187:559-67</Citation><ArticleIdList><ArticleId IdType="pubmed">16319409</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2004 May;109(5):339-44</Citation><ArticleIdList><ArticleId IdType="pubmed">15049770</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2003 Mar;64(3):288-94</Citation><ArticleIdList><ArticleId IdType="pubmed">12716270</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Health Econ. 2009 Oct;10(4):357-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19618224</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Intern Med. 2005 Jun 21;142(12 Pt 2):1073-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15968032</ArticleId></ArticleIdList></Reference><Reference><Citation>J Health Econ. 2002 Mar;21(2):271-92</Citation><ArticleIdList><ArticleId IdType="pubmed">11939242</ArticleId></ArticleIdList></Reference><Reference><Citation>Health Technol Assess. 2007 Oct;11(39):iii-iv, ix-206</Citation><ArticleIdList><ArticleId IdType="pubmed">17903393</ArticleId></ArticleIdList></Reference><Reference><Citation>Appl Health Econ Health Policy. 2014 Aug;12(4):359-72</Citation><ArticleIdList><ArticleId IdType="pubmed">24838515</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2007 Mar;98 (3):247-52</Citation><ArticleIdList><ArticleId IdType="pubmed">16970993</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2006 Jul;67(7):1055-61</Citation><ArticleIdList><ArticleId IdType="pubmed">16889448</ArticleId></ArticleIdList></Reference><Reference><Citation>Qual Life Res. 2006 Sep;15(7):1271-80</Citation><ArticleIdList><ArticleId IdType="pubmed">16972160</ArticleId></ArticleIdList></Reference><Reference><Citation>Value Health. 2008 Dec;11(7):1007-21</Citation><ArticleIdList><ArticleId IdType="pubmed">18489517</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2005 Oct 15;331(7521):897-900</Citation><ArticleIdList><ArticleId IdType="pubmed">16223826</ArticleId></ArticleIdList></Reference><Reference><Citation>J Manag Care Pharm. 2003 Jan-Feb;9(1):53-61</Citation><ArticleIdList><ArticleId IdType="pubmed">14613362</ArticleId></ArticleIdList></Reference><Reference><Citation>Adv Ther. 2014 Aug;31(8):873-90</Citation><ArticleIdList><ArticleId IdType="pubmed">25055791</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2002 May;69(1-3):109-18</Citation><ArticleIdList><ArticleId IdType="pubmed">12103458</ArticleId></ArticleIdList></Reference><Reference><Citation>Health Econ. 2001 Dec;10(8):779-87</Citation><ArticleIdList><ArticleId IdType="pubmed">11747057</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoeconomics. 2013 Nov;31(11):981-90</Citation><ArticleIdList><ArticleId IdType="pubmed">24092620</ArticleId></ArticleIdList></Reference><Reference><Citation>J Health Serv Res Policy. 2004 Apr;9(2):110-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15099459</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2004 Nov;110(5):383-92</Citation><ArticleIdList><ArticleId IdType="pubmed">15458562</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2012 Mar 02;344:e609</Citation><ArticleIdList><ArticleId IdType="pubmed">22389339</ArticleId></ArticleIdList></Reference><Reference><Citation>Value Health. 2007 Mar-Apr;10(2):153-60</Citation><ArticleIdList><ArticleId IdType="pubmed">17391424</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Econ. 2014 Jul;17 (7):508-19</Citation><ArticleIdList><ArticleId IdType="pubmed">24720805</ArticleId></ArticleIdList></Reference><Reference><Citation>Health Econ. 2004 Sep;13(9):873-84</Citation><ArticleIdList><ArticleId IdType="pubmed">15362179</ArticleId></ArticleIdList></Reference><Reference><Citation>Health Econ. 2004 May;13(5):405-15</Citation><ArticleIdList><ArticleId IdType="pubmed">15127421</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Econ. 2015;18(10):821-7</Citation><ArticleIdList><ArticleId IdType="pubmed">25985265</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2009 Jul 21;339:b2700</Citation><ArticleIdList><ArticleId IdType="pubmed">19622552</ArticleId></ArticleIdList></Reference><Reference><Citation>Value Health. 2010 Aug;13(5):519-27</Citation><ArticleIdList><ArticleId IdType="pubmed">20712601</ArticleId></ArticleIdList></Reference><Reference><Citation>Qual Life Res. 2010 Sep;19(7):943-54</Citation><ArticleIdList><ArticleId IdType="pubmed">20454863</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2002;4 Suppl 1:21-5</Citation><ArticleIdList><ArticleId IdType="pubmed">12479671</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Ther. 2009 Jun;31 Pt 1:1456-68</Citation><ArticleIdList><ArticleId IdType="pubmed">19698903</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Clin Psychiatry. 2008 Jan-Mar;20(1):21-31</Citation><ArticleIdList><ArticleId IdType="pubmed">18297583</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2012 Dec 15;380(9859):2197-223</Citation><ArticleIdList><ArticleId IdType="pubmed">23245608</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2000 Dec 2;321(7273):1362-3</Citation><ArticleIdList><ArticleId IdType="pubmed">11099268</ArticleId></ArticleIdList></Reference><Reference><Citation>Evid Based Ment Health. 2015 May;18(2):40-6</Citation><ArticleIdList><ArticleId IdType="pubmed">25908686</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Care. 1997 Nov;35(11):1095-108</Citation><ArticleIdList><ArticleId IdType="pubmed">9366889</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2001 Sep;58(9):844-50</Citation><ArticleIdList><ArticleId IdType="pubmed">11545667</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2007;68 Suppl 4:8-13</Citation><ArticleIdList><ArticleId IdType="pubmed">17539694</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2012 Feb 25;379(9817):721-8</Citation><ArticleIdList><ArticleId IdType="pubmed">22265699</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Ophthalmol. 2010 Sep;94(9):1118-26</Citation><ArticleIdList><ArticleId IdType="pubmed">20813751</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Decis Making. 1993 Oct-Dec;13(4):322-38</Citation><ArticleIdList><ArticleId IdType="pubmed">8246705</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychopharmacol. 2007 Aug;21(6):588-96</Citation><ArticleIdList><ArticleId IdType="pubmed">17050661</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Rev Pharmacoecon Outcomes Res. 2007 Oct;7(5):459-67</Citation><ArticleIdList><ArticleId IdType="pubmed">20528391</ArticleId></ArticleIdList></Reference><Reference><Citation>Health Technol Assess. 2014 May;18(34):vii-viii, xiii-xxv, 1-188</Citation><ArticleIdList><ArticleId IdType="pubmed">24857402</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2011 Mar;129(1-3):79-83</Citation><ArticleIdList><ArticleId IdType="pubmed">20888048</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2005 Jun;86(2-3):183-93</Citation><ArticleIdList><ArticleId IdType="pubmed">15935238</ArticleId></ArticleIdList></Reference><Reference><Citation>J Manag Care Pharm. 2006 May;12 (4):322-30</Citation><ArticleIdList><ArticleId IdType="pubmed">16792438</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoeconomics. 1998 May;13(5 Pt 1):487-97</Citation><ArticleIdList><ArticleId IdType="pubmed">10180748</ArticleId></ArticleIdList></Reference><Reference><Citation>Gastroenterology. 2004 Aug;127(2):403-11</Citation><ArticleIdList><ArticleId IdType="pubmed">15300571</ArticleId></ArticleIdList></Reference><Reference><Citation>Health Qual Life Outcomes. 2008 Nov 28;6:105</Citation><ArticleIdList><ArticleId IdType="pubmed">19040721</ArticleId></ArticleIdList></Reference><Reference><Citation>Nervenarzt. 2004 Sep;75(9):896-903</Citation><ArticleIdList><ArticleId IdType="pubmed">14999464</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoeconomics. 2014 Dec;32(12):1157-70</Citation><ArticleIdList><ArticleId IdType="pubmed">25069632</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2013 Jun 27;346:f3646</Citation><ArticleIdList><ArticleId IdType="pubmed">23814104</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ Open. 2015 Nov 13;5(11):e008998</Citation><ArticleIdList><ArticleId IdType="pubmed">26567255</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoeconomics. 2005;23(4):323-32</Citation><ArticleIdList><ArticleId IdType="pubmed">15853433</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Care. 2003 Jan;41(1):32-44</Citation><ArticleIdList><ArticleId IdType="pubmed">12544542</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoeconomics. 2012 Jun 1;30(6):513-30</Citation><ArticleIdList><ArticleId IdType="pubmed">22591130</ArticleId></ArticleIdList></Reference><Reference><Citation>Health Technol Assess. 2004 May;8(19):iii-iv, 1-187</Citation><ArticleIdList><ArticleId IdType="pubmed">15147609</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Econ. 2009;12(4):259-68</Citation><ArticleIdList><ArticleId IdType="pubmed">19769548</ArticleId></ArticleIdList></Reference><Reference><Citation>Health Econ. 2006 Nov;15(11):1229-36</Citation><ArticleIdList><ArticleId IdType="pubmed">16625671</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22142324</PMID><DateCompleted><Year>2012</Year><Month>09</Month><Day>04</Day></DateCompleted><DateRevised><Year>2012</Year><Month>05</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1360-0567</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>2</Issue><PubDate><Year>2012</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Journal of mental health (Abingdon, England)</Title><ISOAbbreviation>J Ment Health</ISOAbbreviation></Journal><ArticleTitle>"Recovery" in bipolar disorder: how can service users be supported through a self-management intervention? A qualitative focus group study.</ArticleTitle><Pagination><MedlinePgn>114-26</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3109/09638237.2011.621471</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Bipolar disorder (BD) is a chronic and recurrent affective disorder. Recovery is defined as the process by which people can live fulfilling lives despite experiencing symptoms.</AbstractText><AbstractText Label="AIMS" NlmCategory="OBJECTIVE">To explore how an opportunistically recruited group of service users with BD experience recovery and self-management to understand more about how a service users' recovery may be supported.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Twelve service users with BD took part in a series of focus groups. Service users' responses to questions about their personal experiences of self-management and recovery were analysed. Focus groups were transcribed verbatim and thematic analysis ([ Braun, V., &amp; Clarke, V. (2006). Using thematic analysis in psychology. Qualitative Research in Psychology, 3(2), 77-101]) was employed to identify common themes in the data.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Four key themes were identified: (1) Recovery is not about being symptom free; (2) Recovery requires taking responsibility for your own wellness; (3) Self-management: building on existing techniques; (4) Overcoming barriers to recovery: negativity, stigma and taboo.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Service users with BD have provided further support for the concept of recovery and have suggested a number of ways recovery can be supported. A self-management approach informed by the recovery literature has been proposed as a way to support service users' recovery.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Todd</LastName><ForeName>Nicholas J</ForeName><Initials>NJ</Initials><AffiliationInfo><Affiliation>Spectrum Centre for Mental Health Research, Department of Health Research, Faculty of Health and Medicine, Lancaster University, Lancaster, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Steven H</ForeName><Initials>SH</Initials></Author><Author ValidYN="Y"><LastName>Lobban</LastName><ForeName>Fiona A</ForeName><Initials>FA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>12</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Ment Health</MedlineTA><NlmUniqueID>9212352</NlmUniqueID><ISSNLinking>0963-8237</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000223" MajorTopicYN="Y">Adaptation, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000534" MajorTopicYN="Y">rehabilitation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004739" MajorTopicYN="N" Type="Geographic">England</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017144" MajorTopicYN="N">Focus Groups</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007389" MajorTopicYN="N">Internal-External Control</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020407" MajorTopicYN="Y">Internet</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036301" MajorTopicYN="N">Qualitative Research</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012648" MajorTopicYN="N">Self Care</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012657" MajorTopicYN="Y">Self-Help Groups</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057545" MajorTopicYN="N">Social Stigma</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>12</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>12</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>9</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22142324</ArticleId><ArticleId IdType="doi">10.3109/09638237.2011.621471</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">6747615</PMID><DateCompleted><Year>1984</Year><Month>09</Month><Day>11</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-3018</ISSN><JournalIssue CitedMedium="Print"><Volume>172</Volume><Issue>8</Issue><PubDate><Year>1984</Year><Month>Aug</Month></PubDate></JournalIssue><Title>The Journal of nervous and mental disease</Title><ISOAbbreviation>J Nerv Ment Dis</ISOAbbreviation></Journal><ArticleTitle>The consistency of thought disorder in mania and schizophrenia. An assessment of acute psychotics.</ArticleTitle><Pagination><MedlinePgn>458-63</MedlinePgn></Pagination><Abstract><AbstractText>This report presents an assessment of 20 manic and 20 schizophrenic patients using a clinical rating instrument: the Scale for Assessment of Thought, Language, and Communication (TLC). These 40 patients were assessed three times within a 10-day period at the outset of an acute psychotic episode with open-ended interviews which were then evaluated with the TLC. It was found that clinically rated speech disorders were relatively consistent within these patients at the outset of a psychotic episode. Furthermore, it was found that composite ratings of positive and negative speech disorders, as defined by the TLC, were stable discriminators of the manic and schizophrenic patients, while global thought disorder was not useful as a discriminator. The results provide evidence that thought disorder in psychosis may be a stable trait of patients during acute episodes and that positive and negative disorder is a useful construct.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Harvey</LastName><ForeName>P D</ForeName><Initials>PD</Initials></Author><Author ValidYN="Y"><LastName>Earle-Boyer</LastName><ForeName>E A</ForeName><Initials>EA</Initials></Author><Author ValidYN="Y"><LastName>Wielgus</LastName><ForeName>M S</ForeName><Initials>MS</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>SO7RR07149-09</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Nerv Ment Dis</MedlineTA><NlmUniqueID>0375402</NlmUniqueID><ISSNLinking>0022-3018</ISSNLinking></MedlineJournalInfo><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="Y">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="Y">Schizophrenic Psychology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013060" MajorTopicYN="N">Speech</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1984</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1984</Year><Month>8</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1984</Year><Month>8</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">6747615</ArticleId><ArticleId IdType="doi">10.1097/00005053-198408000-00003</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23968965</PMID><DateCompleted><Year>2014</Year><Month>06</Month><Day>17</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-7862</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>11</Issue><PubDate><Year>2013</Year><Month>Nov</Month></PubDate></JournalIssue><Title>European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology</Title><ISOAbbreviation>Eur Neuropsychopharmacol</ISOAbbreviation></Journal><ArticleTitle>A systematic review and meta-analysis of proton magnetic resonance spectroscopy and mismatch negativity in bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>1348-63</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.euroneuro.2013.07.007</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0924-977X(13)00207-1</ELocationID><Abstract><AbstractText>Aberrant glutamate neurotransmission has been implicated in the pathophysiology of bipolar disorder with accumulating evidence from imaging, post-mortem and pathology studies. Studies investigating in vivo changes to the glutamatergic system have not been as consistent and warrant clarification. Studies utilizing proton-magnetic resonance spectroscopy ((1)H-MRS) have reported increased levels of combined glutamate and glutamine ("Glx"), which have been linked to impairments in N-methyl-d-aspartate (NMDA) receptor function. Similarly, neurophysiological studies utilising mismatch negativity (MMN) as an index of NMDA receptor function, have reported impairments in bipolar disorder. Here, we provide a systematic review of the literature in regards to the concentration of Glx and the magnitude of MMN in bipolar disorder. Separate meta-analyses revealed that bipolar disorder was associated with increased Glx concentration and decreased MMN-both measured frontally. The current findings corroborate previous evidence indicating that bipolar disorder is characterized by a perturbed frontal glutamate system. These observed changes in bipolar disorder might manifest as impairments in neuronal-glial interactions that lead to disrupted neuronal output and ultimately result in the characteristic neurocognitive sequelae associated with this disorder. </AbstractText><CopyrightInformation>© 2013 Published by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chitty</LastName><ForeName>Kate M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Clinical Research Unit, Brain and Mind Research Institute, University of Sydney, 94 Mallett Street, Camperdown, NSW 2050, Australia. Electronic address: kate.chitty@sydney.edu.au.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lagopoulos</LastName><ForeName>Jim</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Rico S C</ForeName><Initials>RS</Initials></Author><Author ValidYN="Y"><LastName>Hickie</LastName><ForeName>Ian B</ForeName><Initials>IB</Initials></Author><Author ValidYN="Y"><LastName>Hermens</LastName><ForeName>Daniel F</ForeName><Initials>DF</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>08</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Eur Neuropsychopharmacol</MedlineTA><NlmUniqueID>9111390</NlmUniqueID><ISSNLinking>0924-977X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011522">Protons</NameOfSubstance></Chemical><Chemical><RegistryNumber>0RH81L854J</RegistryNumber><NameOfSubstance UI="D005973">Glutamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>3KX376GY7L</RegistryNumber><NameOfSubstance UI="D018698">Glutamic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005071" MajorTopicYN="N">Evoked Potentials</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005625" MajorTopicYN="N">Frontal Lobe</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018698" MajorTopicYN="N">Glutamic Acid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005973" MajorTopicYN="N">Glutamine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009682" MajorTopicYN="Y">Magnetic Resonance Spectroscopy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011522" MajorTopicYN="Y">Protons</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Anterior cingulate cortex</Keyword><Keyword MajorTopicYN="N">Bipolar disorder</Keyword><Keyword MajorTopicYN="N">Frontal lobe</Keyword><Keyword MajorTopicYN="N">Glutamate</Keyword><Keyword MajorTopicYN="N">Magnetic resonance spectroscopy</Keyword><Keyword MajorTopicYN="N">Meta-analysis</Keyword><Keyword MajorTopicYN="N">Mismatch negativity</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>02</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2013</Year><Month>07</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>07</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>8</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>8</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>6</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23968965</ArticleId><ArticleId IdType="pii">S0924-977X(13)00207-1</ArticleId><ArticleId IdType="doi">10.1016/j.euroneuro.2013.07.007</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11097977</PMID><DateCompleted><Year>2001</Year><Month>02</Month><Day>01</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-953X</ISSN><JournalIssue CitedMedium="Print"><Volume>157</Volume><Issue>12</Issue><PubDate><Year>2000</Year><Month>Dec</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Attempted suicide and alcoholism in bipolar disorder: clinical and familial relationships.</ArticleTitle><Pagination><MedlinePgn>2048-50</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This study examined the clinical and familial relationships between comorbid alcoholism and attempted suicide in affectively ill relatives of probands with bipolar I disorder.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">In 71 families ascertained for a genetic linkage study, 337 subjects with major affective disorder were assessed by using the Schedule for Affective Disorders and Schizophrenia-Lifetime Version.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Subjects with bipolar disorder and alcoholism had a 38.4% lifetime rate of attempted suicide, whereas those without alcoholism had a 21.7% rate. Attempted suicide among subjects with bipolar disorder and alcoholism clustered in a subset of seven families. Families with alcoholic and suicidal probands had a 40.7% rate of attempted suicide in first-degree relatives with bipolar disorder, whereas other families had a 19.0% rate.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Comorbid alcoholism was associated with a higher rate of attempted suicide among family members with bipolar disorder. Attempted suicide and alcoholism clustered in a subset of families. These relationships may have a genetic origin and may be mediated by intoxication, mixed states, and/or temperamental instability.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Potash</LastName><ForeName>J B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine, Baltimore, MD, USA. jpotash@jhmi.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kane</LastName><ForeName>H S</ForeName><Initials>HS</Initials></Author><Author ValidYN="Y"><LastName>Chiu</LastName><ForeName>Y F</ForeName><Initials>YF</Initials></Author><Author ValidYN="Y"><LastName>Simpson</LastName><ForeName>S G</ForeName><Initials>SG</Initials></Author><Author ValidYN="Y"><LastName>MacKinnon</LastName><ForeName>D F</ForeName><Initials>DF</Initials></Author><Author ValidYN="Y"><LastName>McInnis</LastName><ForeName>M G</ForeName><Initials>MG</Initials></Author><Author ValidYN="Y"><LastName>McMahon</LastName><ForeName>F J</ForeName><Initials>FJ</Initials></Author><Author ValidYN="Y"><LastName>DePaulo</LastName><ForeName>J R</ForeName><Initials>JR</Initials><Suffix>Jr</Suffix></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000435" MajorTopicYN="N">Alcoholic Intoxication</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000437" MajorTopicYN="N">Alcoholism</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005190" MajorTopicYN="Y">Family</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007175" MajorTopicYN="N">Impulsive Behavior</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016017" MajorTopicYN="N">Odds Ratio</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013406" MajorTopicYN="N">Suicide, Attempted</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013694" MajorTopicYN="N">Temperament</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>12</Month><Day>1</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>2</Month><Day>28</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>12</Month><Day>1</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11097977</ArticleId><ArticleId IdType="doi">10.1176/appi.ajp.157.12.2048</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22164915</PMID><DateCompleted><Year>2011</Year><Month>12</Month><Day>22</Day></DateCompleted><DateRevised><Year>2011</Year><Month>12</Month><Day>12</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0017-7768</ISSN><JournalIssue CitedMedium="Print"><Volume>150</Volume><Issue>4</Issue><PubDate><Year>2011</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Harefuah</Title><ISOAbbreviation>Harefuah</ISOAbbreviation></Journal><ArticleTitle>[Borderline personality disorder and bipolar II disorder--similarities and differences].</ArticleTitle><Pagination><MedlinePgn>349-52, 419</MedlinePgn></Pagination><Abstract><AbstractText>Since both borderline personality disorder (BPD) and bipolar II disorder (BP-II) are common psychiatric diagnoses due to their co-morbidity and similar characteristics, some researchers suggested they coexist along a spectrum of cyclical affective disorders. As part of the ongoing debate regarding these central diagnoses, a few studies were recently conducted. The results showed that patients with BPD reported higher Levels of impulsiveness and hostility across Axis I diagnostic groups. Furthermore, refining the impulsivity scale revealed different types of impulsivity in the two disorders. This should be carefully considered as impulsivity is known to predict suicidal behavior in both disorders. Subjective reported depression differed across groups, with BPD patients reporting higher Levels of cognitive and anxiety-related symptoms, supporting the notion that BPD patients show increased sensitivity to negative emotional states. Thus, providing further evidence that BP-II and BPD are distinct diagnostic entities. On the other hand, recent studies didn't attain statistically significant differences between bipolar disorder and BPD, although BPD patients displayed higher scores than unipolar patients in mood and cognition depressive subdomains. Further research is still needed to clarify this diagnostic and clinical question.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Massler</LastName><ForeName>Anda</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Child and Adolescent Division, Geha Mental Health Center and Sackler Faculty of Medicine, Tel Aviv University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zatsman</LastName><ForeName>Gil</ForeName><Initials>G</Initials></Author></AuthorList><Language>heb</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Israel</Country><MedlineTA>Harefuah</MedlineTA><NlmUniqueID>0034351</NlmUniqueID><ISSNLinking>0017-7768</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000339" MajorTopicYN="N">Affect</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001883" MajorTopicYN="N">Borderline Personality Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006791" MajorTopicYN="N">Hostility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007175" MajorTopicYN="N">Impulsive Behavior</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>12</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22164915</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16511725</PMID><DateCompleted><Year>2006</Year><Month>07</Month><Day>06</Day></DateCompleted><DateRevised><Year>2014</Year><Month>11</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0303-4259</ISSN><JournalIssue CitedMedium="Print"><Volume>33 Suppl 1</Volume><PubDate><Year>2006</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Psychiatrische Praxis</Title><ISOAbbreviation>Psychiatr Prax</ISOAbbreviation></Journal><ArticleTitle>[Needs of patients with bipolar disorder during hospitalisation for an acute episode].</ArticleTitle><Pagination><MedlinePgn>S7-11</MedlinePgn></Pagination><Abstract><AbstractText>The needs and expectations of patients with bipolar disorder who require hospitalisation are not known to most professionals. A high degree of patient satisfaction, however, is known to improve outcome and adherence to a medication or psychotherapy regimen. In this article, bipolar patients' needs and expectations with respect to hospital treatment are presented. It will become obvious, that the gap between wishful thinking and reality is still wide. Possible improvement strategies to narrow this gap are discussed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kahlert</LastName><ForeName>Armin</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>armin-kahlert@bipolar-netzwerk.de</Affiliation></AffiliationInfo></Author></AuthorList><Language>ger</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Bedürfnisse von Patienten mit einer bipolaren Erkrankung während des stationären Aufenthaltes.</VernacularTitle></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Psychiatr Prax</MedlineTA><NlmUniqueID>0423204</NlmUniqueID><ISSNLinking>0303-4259</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006301" MajorTopicYN="Y">Health Services Needs and Demand</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="Y">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010349" MajorTopicYN="N">Patient Compliance</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017060" MajorTopicYN="N">Patient Satisfaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011613" MajorTopicYN="N">Psychotherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055502" MajorTopicYN="N">Secondary Prevention</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>3</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>7</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>3</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16511725</ArticleId><ArticleId IdType="doi">10.1055/s-2005-867018</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15465580</PMID><DateCompleted><Year>2005</Year><Month>02</Month><Day>07</Day></DateCompleted><DateRevised><Year>2009</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0165-0327</ISSN><JournalIssue CitedMedium="Print"><Volume>82</Volume><Issue>1</Issue><PubDate><Year>2004</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Prefrontal hemodynamic response to verbal-fluency task and hyperventilation in bipolar disorder measured by multi-channel near-infrared spectroscopy.</ArticleTitle><Pagination><MedlinePgn>85-92</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Many neuroimaging studies of patients with bipolar disorder have demonstrated functional hypofrontality (reduced activation of the frontal cortex), although this finding is still controversial. We previously found hypoactivation of the left prefrontal region in remitted subjects with bipolar disorder measured by one-channel near-infrared spectroscopy (NIRS). The aim of the present study was to clarify whether or not this finding was due to altered cerebral lateralization or caused by reduced cerebrovascular reactivity.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We enrolled nine remitted patients with bipolar disorder and nine normal controls. Hemodynamic responses in the prefrontal cortex during the verbal-fluency and hyperventilation tasks were monitored by 24-channel NIRS, which can measure oxygenated hemoglobin (OxyHb), deoxygenated hemoglobin, and total hemoglobin (TotalHb).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The increases of OxyHb and TotalHb in the bipolar group were significantly smaller than that in the controls during the verbal-fluency task. The response of TotalHb during hyperventilation in the bipolar group was weaker than that in the controls.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">The sample size was small.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These findings suggest that the bilateral hypofrontality to a cognitive task is seen in remitted subjects with bipolar disorder, which may be related to vascular function as measured by the response to hyperventilation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Matsuo</LastName><ForeName>Koji</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neuropsychiatry, Graduate School of Medicine, University of Tokyo, Tokyo, Japan. matsuo-tky@umin.ac.jp &lt;matsuo-tky@umin.ac.jp&gt;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Watanabe</LastName><ForeName>Akira</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Onodera</LastName><ForeName>Yoichi</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Kato</LastName><ForeName>Nobumasa</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Kato</LastName><ForeName>Tadafumi</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006454">Hemoglobins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006439" MajorTopicYN="N">Hemodynamics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006454" MajorTopicYN="N">Hemoglobins</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006985" MajorTopicYN="Y">Hyperventilation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017397" MajorTopicYN="N">Prefrontal Cortex</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="Y">blood supply</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012039" MajorTopicYN="N">Regional Blood Flow</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019265" MajorTopicYN="N">Spectroscopy, Near-Infrared</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013060" MajorTopicYN="Y">Speech</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013647" MajorTopicYN="N">Task Performance and Analysis</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2002</Year><Month>12</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2003</Year><Month>10</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>10</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>2</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>10</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15465580</ArticleId><ArticleId IdType="pii">S0165032703002659</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2003.10.004</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">27128359</PMID><DateCompleted><Year>2017</Year><Month>11</Month><Day>20</Day></DateCompleted><DateRevised><Year>2019</Year><Month>10</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>200</Volume><PubDate><Year>2016</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Differential endorsement of suicidal ideation and attempt in bipolar versus unipolar depression: a testlet response theory analysis.</ArticleTitle><Pagination><MedlinePgn>67-73</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2016.04.034</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0165-0327(16)30281-6</ELocationID><Abstract><AbstractText Label="BACKGROUND">Published data concerning differences in suicide risk across the mood disorders spectrum remain mixed. The current study used testlet response theory methods to evaluate differences in the endorsement of suicidal ideation and attempt in an epidemiological sample of individuals with bipolar and unipolar depression.</AbstractText><AbstractText Label="METHOD">Participants with lifetime history of bipolar I (n=1154), bipolar II (n=494), and unipolar (n=5695) depression were drawn from the National Epidemiologic Survey on Alcohol and Related Conditions, which included 4 structured queries concerning suicidal ideation/attempt. We estimated differential item functioning between groups with a 2-pl parametric item response model.</AbstractText><AbstractText Label="RESULTS">Endorsement of suicide items increased as a function of underlying depression severity. Equating for severity, endorsement of suicidal ideation and attempt was generally more frequent in bipolar versus unipolar depression, and in bipolar I versus bipolar II depression. Yet findings were not consistent across all suicide items, and differences were small in magnitude.</AbstractText><AbstractText Label="LIMITATIONS">The NESARC relied upon lifetime endorsement of suicide items, and suicide risk was only evaluated within the context of a major depressive episode. Thus, this study could not evaluate endorsement of suicide items within the context of (hypo)manic or mixed states.</AbstractText><AbstractText Label="CONCLUSION">Although there were some group differences, patterns of item endorsement were more similar than different. These data support a transdiagnostic model of suicide that emphasizes underlying depression severity over mood disorder class.</AbstractText><CopyrightInformation>Copyright © 2016 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Weinstock</LastName><ForeName>Lauren M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Alpert Medical School of Brown University, Department of Psychiatry &amp; Human Behavior, Providence, RI, USA; Butler Hospital, Psychosocial Research Program, Providence, RI, USA. Electronic address: Lauren_Weinstock@brown.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strong</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>University of California, San Diego, Department of Family Medicine and Public Health, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uebelacker</LastName><ForeName>Lisa A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Alpert Medical School of Brown University, Department of Psychiatry &amp; Human Behavior, Providence, RI, USA; Butler Hospital, Psychosocial Research Program, Providence, RI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Ivan W</ForeName><Initials>IW</Initials><AffiliationInfo><Affiliation>Alpert Medical School of Brown University, Department of Psychiatry &amp; Human Behavior, Providence, RI, USA; Butler Hospital, Psychosocial Research Program, Providence, RI, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K23 MH079907</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AA008159</GrantID><Acronym>AA</Acronym><Agency>NIAAA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>04</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008960" MajorTopicYN="N">Models, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059020" MajorTopicYN="Y">Suicidal Ideation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013406" MajorTopicYN="N">Suicide, Attempted</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Bipolar disorder</Keyword><Keyword MajorTopicYN="Y">Major depressive disorder</Keyword><Keyword MajorTopicYN="Y">Suicide</Keyword><Keyword MajorTopicYN="Y">Testlet response theory</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>02</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>04</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>04</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>4</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>4</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>11</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27128359</ArticleId><ArticleId IdType="pii">S0165-0327(16)30281-6</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2016.04.034</ArticleId><ArticleId IdType="pmc">PMC4898479</ArticleId><ArticleId IdType="mid">NIHMS782220</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Drug Alcohol Depend. 2003 Jul 20;71(1):7-16</Citation><ArticleIdList><ArticleId IdType="pubmed">12821201</ArticleId></ArticleIdList></Reference><Reference><Citation>CNS Drugs. 2003;17(7):491-511</Citation><ArticleIdList><ArticleId IdType="pubmed">12751919</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2005 Jun;62(6):593-602</Citation><ArticleIdList><ArticleId IdType="pubmed">15939837</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2006 Oct;8(5 Pt 2):558-65</Citation><ArticleIdList><ArticleId IdType="pubmed">17042829</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2014 Sep;16(6):652-61</Citation><ArticleIdList><ArticleId IdType="pubmed">24636453</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2007 Dec;116(6):419-28</Citation><ArticleIdList><ArticleId IdType="pubmed">17997721</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1993 Feb;27(2):117-21</Citation><ArticleIdList><ArticleId IdType="pubmed">8440807</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1996 May 15;39(10):896-9</Citation><ArticleIdList><ArticleId IdType="pubmed">8860192</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2004 Nov 1;82(3):437-42</Citation><ArticleIdList><ArticleId IdType="pubmed">15555695</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2005 Jun;62(6):617-27</Citation><ArticleIdList><ArticleId IdType="pubmed">15939839</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2010 Oct;44(14):979-85</Citation><ArticleIdList><ArticleId IdType="pubmed">20398907</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Arch Psychiatry Clin Neurosci. 2000;250(5):257-61</Citation><ArticleIdList><ArticleId IdType="pubmed">11097169</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Med. 2013 May 14;11:126</Citation><ArticleIdList><ArticleId IdType="pubmed">23672542</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2002;4 Suppl 1:21-5</Citation><ArticleIdList><ArticleId IdType="pubmed">12479671</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1992 Oct;26(2):127-40</Citation><ArticleIdList><ArticleId IdType="pubmed">1447430</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 1999;60 Suppl 2:63-9; discussion 75-6, 113-6</Citation><ArticleIdList><ArticleId IdType="pubmed">10073390</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2006 Oct;95(1-3):141-4</Citation><ArticleIdList><ArticleId IdType="pubmed">16777233</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nerv Ment Dis. 1997 Jun;185(6):407-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9205428</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2002 Apr;68(2-3):167-81</Citation><ArticleIdList><ArticleId IdType="pubmed">12063145</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2004 Apr;61(4):361-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15066894</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1987 Mar;144(3):309-15</Citation><ArticleIdList><ArticleId IdType="pubmed">3826429</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2005 Oct;66(10):1205-15</Citation><ArticleIdList><ArticleId IdType="pubmed">16259532</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2012 May;14(3):271-82</Citation><ArticleIdList><ArticleId IdType="pubmed">22548900</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2009 May;39(5):763-71</Citation><ArticleIdList><ArticleId IdType="pubmed">18667100</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2005 Oct;162(10):1977-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16199851</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Intern Med. 2004 May 18;140(10):822-35</Citation><ArticleIdList><ArticleId IdType="pubmed">15148072</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1985 Jan-Feb;8(1):17-28</Citation><ArticleIdList><ArticleId IdType="pubmed">3156908</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pers Assess. 2010 Nov;92(6):544-59</Citation><ArticleIdList><ArticleId IdType="pubmed">20954056</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2013 Feb;15(1):110-1</Citation><ArticleIdList><ArticleId IdType="pubmed">23231053</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2009 May;11(3):289-97</Citation><ArticleIdList><ArticleId IdType="pubmed">19419386</ArticleId></ArticleIdList></Reference><Reference><Citation>Suicide Life Threat Behav. 2010 Dec;40(6):620-7</Citation><ArticleIdList><ArticleId IdType="pubmed">21198331</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2005 Aug;87(2-3):231-41</Citation><ArticleIdList><ArticleId IdType="pubmed">16009430</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Methods. 2006 Dec;11(4):402-15</Citation><ArticleIdList><ArticleId IdType="pubmed">17154754</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">22954812</PMID><DateCompleted><Year>2013</Year><Month>08</Month><Day>13</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>142</Volume><Issue>1-3</Issue><PubDate><Year>2012</Year><Month>Dec</Month><Day>15</Day></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Are bipolar disorders underdiagnosed in patients with depressive episodes? Results of the multicenter BRIDGE screening study in Germany.</ArticleTitle><Pagination><MedlinePgn>45-52</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2012.03.042</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0165-0327(12)00243-1</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Recent reports indicate that the prevalence of bipolar disorder (BD) in patients with an acute major depressive episode might be higher than previously thought. We aimed to study systematically all patients who sought therapy for major depressive episode (MDE) within the BRIDGE study in Germany, reporting on an increased number (increased from 2 in the international BRIDGE report to 5) of different diagnostic algorithms.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A total of 252 patients with acute MDE (DSM-IV confirmed) were examined for the existence of BD (a) according to DSM-IV criteria, (b) according to modified DSM-IV criteria (without the exclusion criterion of 'mania not induced by substances/antidepressants'), (c) according to a Bipolarity Specifier Algorithm which expands the DSM-IV criteria, (d) according to HCL-32R (Hypomania-Checklist-32R), and (e) according to a criteria-free physician's diagnosis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The five different diagnostic approaches yielded immensely variable prevalences for BD: (a) 11.6; (b) 24.8%; (c) 40.6%; (d) 58.7; e) 18.4% with only partial overlap between diagnoses according to the physician's diagnosis or HCL-32R with diagnoses according to the three DSM-based algorithms.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The diagnosis of BD in patients with MDE depends strongly on the method and criteria employed. The considerable difference between criteria-free physician's diagnosis and the remaining algorithms indicate the usefulness of criteria lists within the everyday clinical setting.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">Diagnoses based on DSM were only made with checklists. The diagnoses of (hypo-) manic episodes in the patient history were not systematically verifiable by indirect anamnesis.</AbstractText><CopyrightInformation>Copyright © 2012 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bschor</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Schlosspark-Clinic, Department of Psychiatry, Berlin, Germany; Technical University of Dresden, University Hospital Dresden, Germany. bschor@mailbox.tu-dresden.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Angst</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Azorin</LastName><ForeName>J M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Bowden</LastName><ForeName>C L</ForeName><Initials>CL</Initials></Author><Author ValidYN="Y"><LastName>Perugi</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Vieta</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Young</LastName><ForeName>A H</ForeName><Initials>AH</Initials></Author><Author ValidYN="Y"><LastName>Krüger</LastName><ForeName>S</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>09</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000465" MajorTopicYN="N">Algorithms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057189" MajorTopicYN="N">Checklist</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003951" MajorTopicYN="N">Diagnostic Errors</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N">Germany</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>01</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2012</Year><Month>03</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>03</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>9</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>9</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>8</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22954812</ArticleId><ArticleId IdType="pii">S0165-0327(12)00243-1</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2012.03.042</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17042830</PMID><DateCompleted><Year>2007</Year><Month>02</Month><Day>20</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1398-5647</ISSN><JournalIssue CitedMedium="Print"><Volume>8</Volume><Issue>5 Pt 2</Issue><PubDate><Year>2006</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Prospective predictors of suicide and suicide attempts in 1,556 patients with bipolar disorders followed for up to 2 years.</ArticleTitle><Pagination><MedlinePgn>566-75</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Bipolar disorders are associated with high rates of suicide attempts (SAs) and completions. Several factors have been reported to be associated with suicide in persons with bipolar disorder, but most studies to date have been retrospective and have not utilized multivariate statistics to account for the redundant prediction among variables submitted for analysis.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This study examined the association between baseline clinical and demographic variables and subsequent SAs and completions through 2 years of follow-up of participants in the Systematic Treatment Enhancement Program for Bipolar Disorder using a pattern-mixture model.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the sample with complete data (n = 1,556), 57 patients (3.66%) experienced an SA or completion (CS). Several variables predicted suicidality (SA + CS) in this data set when considered alone, but after controlling for redundant prediction from other baseline characteristics, only history of suicide [odds ratio (OR) = 4.52, p &lt; 0.0001] and percent days depressed in the past year (OR = 1.16, p = 0.036) were significantly associated with SAs and completions. A secondary analysis included a greater number of variables but a smaller sample size (n = 1,014). In the secondary analyses, only prior SAs predicted prospective suicidality (OR = 3.87, p = 0.0029).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These results indicate that patients with bipolar disorder who present with a history of SAs are over four times as likely to have a subsequent SA or completion. Further studies are needed to evaluate and prevent future attempts in this high-risk cohort.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Marangell</LastName><ForeName>Lauren B</ForeName><Initials>LB</Initials><AffiliationInfo><Affiliation>Mood Disorders Center, Menninger Department of Psychiatry, Baylor College of Medicine and the Department of Veterans Affairs, VISN 16 MIRECC, Houston, TX 77030, USA. laurenm@bcm.tmc.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bauer</LastName><ForeName>Mark S</ForeName><Initials>MS</Initials></Author><Author ValidYN="Y"><LastName>Dennehy</LastName><ForeName>Ellen B</ForeName><Initials>EB</Initials></Author><Author ValidYN="Y"><LastName>Wisniewski</LastName><ForeName>Stephen R</ForeName><Initials>SR</Initials></Author><Author ValidYN="Y"><LastName>Allen</LastName><ForeName>Michael H</ForeName><Initials>MH</Initials></Author><Author ValidYN="Y"><LastName>Miklowitz</LastName><ForeName>David J</ForeName><Initials>DJ</Initials></Author><Author ValidYN="Y"><LastName>Oquendo</LastName><ForeName>Maria A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Frank</LastName><ForeName>Ellen</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Perlis</LastName><ForeName>Roy H</ForeName><Initials>RH</Initials></Author><Author ValidYN="Y"><LastName>Martinez</LastName><ForeName>James M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Fagiolini</LastName><ForeName>Andrea</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Otto</LastName><ForeName>Michael W</ForeName><Initials>MW</Initials></Author><Author ValidYN="Y"><LastName>Chessick</LastName><ForeName>Cheryl A</ForeName><Initials>CA</Initials></Author><Author ValidYN="Y"><LastName>Zboyan</LastName><ForeName>Holly A</ForeName><Initials>HA</Initials></Author><Author ValidYN="Y"><LastName>Miyahara</LastName><ForeName>Sachiko</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Sachs</LastName><ForeName>Gary</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Thase</LastName><ForeName>Michael E</ForeName><Initials>ME</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>N01MH80001</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003710" MajorTopicYN="N">Demography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013405" MajorTopicYN="N">Suicide</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013406" MajorTopicYN="N">Suicide, Attempted</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>10</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>2</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>10</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17042830</ArticleId><ArticleId IdType="pii">BDI369</ArticleId><ArticleId IdType="doi">10.1111/j.1399-5618.2006.00369.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">3715419</PMID><DateCompleted><Year>1986</Year><Month>07</Month><Day>24</Day></DateCompleted><DateRevised><Year>2019</Year><Month>05</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0586-7614</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>2</Issue><PubDate><Year>1986</Year></PubDate></JournalIssue><Title>Schizophrenia bulletin</Title><ISOAbbreviation>Schizophr Bull</ISOAbbreviation></Journal><ArticleTitle>Encoding, memory, and thought disorder in schizophrenia and mania.</ArticleTitle><Pagination><MedlinePgn>252-61</MedlinePgn></Pagination><Abstract><AbstractText>Schizophrenic (n = 24) and manic (n = 20) inpatients were compared with a normal comparison sample (n = 10) on memory and encoding performance for both self- and other-generated speech. It was found that the level of encoding, as indexed by the level of organization present in the recalled speech, predicted memory performance for both schizophrenic and normal samples. Schizophrenics were less effective at encoding than normals, although the relationship between level of encoding and memory performance was similar for both samples. For the manic patients, however, clinically rated thought disorder predicted memory performance better than encoding performance. It appeared that thought disorder specifically disrupted recall performance, with less of an effect on encoding. These relationships, as well as the lack of a significant relationship between thought disorder and task performance in the schizophrenics, are discussed in terms of their implications for later research in the area of information processing in psychotic patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Harvey</LastName><ForeName>P D</ForeName><Initials>PD</Initials></Author><Author ValidYN="Y"><LastName>Earle-Boyer</LastName><ForeName>E A</ForeName><Initials>EA</Initials></Author><Author ValidYN="Y"><LastName>Weilgus</LastName><ForeName>M S</ForeName><Initials>MS</Initials></Author><Author ValidYN="Y"><LastName>Levinson</LastName><ForeName>J C</ForeName><Initials>JC</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>S07RR07149-09</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Schizophr Bull</MedlineTA><NlmUniqueID>0236760</NlmUniqueID><ISSNLinking>0586-7614</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="Y">Memory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011939" MajorTopicYN="N">Mental Recall</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="Y">Schizophrenic Psychology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013850" MajorTopicYN="N">Thinking</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1986</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1986</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1986</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">3715419</ArticleId><ArticleId IdType="doi">10.1093/schbul/12.2.252</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21131056</PMID><DateCompleted><Year>2011</Year><Month>07</Month><Day>12</Day></DateCompleted><DateRevised><Year>2011</Year><Month>05</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0165-1781</ISSN><JournalIssue CitedMedium="Print"><Volume>188</Volume><Issue>1</Issue><PubDate><Year>2011</Year><Month>Jun</Month><Day>30</Day></PubDate></JournalIssue><Title>Psychiatry research</Title><ISOAbbreviation>Psychiatry Res</ISOAbbreviation></Journal><ArticleTitle>An admixture analysis of the age at index episodes in bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>34-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.psychres.2010.10.033</ELocationID><Abstract><AbstractText>The interaction between polarity at onset (PAO) and age at onset (AAO) appears to be important for interpreting results of previous analyses of AAO in bipolar disorder (BD). Using an admixture analysis, we examined independently the distributions of age at first depressive and hypomanic/manic episodes in 379 BD I and II patients. Subsequently, we examined the association of PAO and AAO with specific clinical variables, using parametric and nonparametric analyses. Both depressive and manic onsets showed bimodal distributions. For depressive episodes, the means were: 18.5±4.1 (early onset) and 33.6±10.4 (late onset) years; and for manic episodes 18.9±3.3 (early onset) and 34.8±10.9 (late onset) years. For the overall AAO the best fit was for a mixture of three lognormal distributions (mean±S.D.): 15.5±2.0, 22.8±4.6, and 36.1±10.1years. Overall, an early onset was significantly associated with a chronic course of the disorder, a stronger family history of affective disorder, higher rates of rapid cycling, suicidal behavior, psychotic symptoms, and co-morbid anxiety disorders. Early onset depressive episodes were associated with higher rates of suicidal behavior and anxiety disorders, whereas early onset manic episodes were associated with psychotic symptoms and rapid cycling. Our results suggest the presence of a bimodal distribution of age at onset in BD according to the polarity of the index episode, and denote that an early onset BD, irrespective of polarity, may be a more serious subtype of the disorder.</AbstractText><CopyrightInformation>Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ortiz</LastName><ForeName>Abigail</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Dalhousie University, Halifax, NS, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bradler</LastName><ForeName>Kamil</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Slaney</LastName><ForeName>Claire</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Garnham</LastName><ForeName>Julie</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Ruzickova</LastName><ForeName>Martina</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>O'Donovan</LastName><ForeName>Claire</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Hajek</LastName><ForeName>Tomas</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Alda</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>12</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Psychiatry Res</MedlineTA><NlmUniqueID>7911385</NlmUniqueID><ISSNLinking>0165-1781</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017677" MajorTopicYN="N">Age Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="Y">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016009" MajorTopicYN="N">Chi-Square Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011336" MajorTopicYN="N">Probability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>12</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2010</Year><Month>07</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>10</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>12</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>12</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>7</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21131056</ArticleId><ArticleId IdType="pii">S0165-1781(10)00688-8</ArticleId><ArticleId IdType="doi">10.1016/j.psychres.2010.10.033</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20679588</PMID><DateCompleted><Year>2010</Year><Month>08</Month><Day>17</Day></DateCompleted><DateRevised><Year>2010</Year><Month>08</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3636</ISSN><JournalIssue CitedMedium="Internet"><Volume>67</Volume><Issue>8</Issue><PubDate><Year>2010</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Archives of general psychiatry</Title><ISOAbbreviation>Arch Gen Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Brain function in carriers of a genome-wide supported bipolar disorder variant.</ArticleTitle><Pagination><MedlinePgn>803-11</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/archgenpsychiatry.2010.94</ELocationID><Abstract><AbstractText Label="CONTEXT" NlmCategory="BACKGROUND">The neural abnormalities underlying genetic risk for bipolar disorder, a severe, common, and highly heritable psychiatric condition, are largely unknown. An opportunity to define these mechanisms is provided by the recent discovery, through genome-wide association, of a single-nucleotide polymorphism (rs1006737) strongly associated with bipolar disorder within the CACNA1C gene, encoding the alpha subunit of the L-type voltage-dependent calcium channel Ca(v)1.2.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine whether the genetic risk associated with rs1006737 is mediated through hippocampal function.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Functional magnetic resonance imaging study.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">University hospital.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">A total of 110 healthy volunteers of both sexes and of German descent in the Hardy-Weinberg equilibrium for rs1006737.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Blood oxygen level-dependent signal during an episodic memory task and behavioral and psychopathological measures.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Using an intermediate phenotype approach, we show that healthy carriers of the CACNA1C risk variant exhibit a pronounced reduction of bilateral hippocampal activation during episodic memory recall and diminished functional coupling between left and right hippocampal regions. Furthermore, risk allele carriers exhibit activation deficits of the subgenual anterior cingulate cortex, a region repeatedly associated with affective disorders and the mediation of adaptive stress-related responses. The relevance of these findings for affective disorders is supported by significantly higher psychopathology scores for depression, anxiety, obsessive-compulsive thoughts, interpersonal sensitivity, and neuroticism in risk allele carriers, correlating negatively with the observed regional brain activation.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our data demonstrate that rs1006737 or genetic variants in linkage disequilibrium with it are functional in the human brain and provide a neurogenetic risk mechanism for bipolar disorder backed by genome-wide evidence.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Erk</LastName><ForeName>Susanne</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Medical Psychology, University of Bonn, Bonn, Germany. susanne.erk@charite.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meyer-Lindenberg</LastName><ForeName>Andreas</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Schnell</LastName><ForeName>Knut</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Opitz von Boberfeld</LastName><ForeName>Carola</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Esslinger</LastName><ForeName>Christine</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Kirsch</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Grimm</LastName><ForeName>Oliver</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Arnold</LastName><ForeName>Claudia</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Haddad</LastName><ForeName>Leila</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Witt</LastName><ForeName>Stephanie H</ForeName><Initials>SH</Initials></Author><Author ValidYN="Y"><LastName>Cichon</LastName><ForeName>Sven</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Nöthen</LastName><ForeName>Markus M</ForeName><Initials>MM</Initials></Author><Author ValidYN="Y"><LastName>Rietschel</LastName><ForeName>Marcella</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Walter</LastName><ForeName>Henrik</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Gen Psychiatry</MedlineTA><NlmUniqueID>0372435</NlmUniqueID><ISSNLinking>0003-990X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C425903">CACNA2D1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015220">Calcium Channels</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="N">Brain Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015220" MajorTopicYN="N">Calcium Channels</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002881" MajorTopicYN="N">Chromosomes, Human, Pair 12</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006579" MajorTopicYN="Y">Heterozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015810" MajorTopicYN="N">Linkage Disequilibrium</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>8</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>8</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>8</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20679588</ArticleId><ArticleId IdType="pii">67/8/803</ArticleId><ArticleId IdType="doi">10.1001/archgenpsychiatry.2010.94</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>